epitope_epitope id,epitope_description,epitope_starting position,epitope_ending position,epitope_antigen name,epitope_parent protein,related object_epitope relationship,related object_description,related object_parent protein,mhc_allele name,mhc_allele evidence code,assay_method/technique,agg_label,total_count,percentage_pos
155,AAGIGILTV,27.0,35.0,Melanoma antigen recognized by T-cells 1,Melanoma antigen recognized by T-cells 1,,,,HLA-A*02:01,MHC binding assay,ELISA,1,14,0.9285714285714286
1397578,AAIAASRSV,,,,,neo-epitope,AAIAASRSA,Uncharacterized protein C1orf198,HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
1397579,AAKAALEDF,,,,,neo-epitope,AAKAALEEF,SWI/SNF complex subunit SMARCC1,HLA-C*16:01,MHC binding prediction,ELISPOT,0,1,0.0
1398206,AAPAHSHAG,184.0,192.0,Mediator of RNA polymerase II transcription subunit 22,Mediator of RNA polymerase II transcription subunit 22,,,,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1398207,AAPAHSHAV,,,,,neo-epitope,AAPAHSHAG,Mediator of RNA polymerase II transcription subunit 22,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1860939,AAQARLQPV,,,,,neo-epitope,IAMARLQPV,Transmembrane protein 8B,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1397583,AASRSVVM,,,,,neo-epitope,AASRSAVM,Uncharacterized protein C1orf198,HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
1312103,AAYQRLTSEK,,,,,neo-epitope,AAYQQLTSEK,Golgin subfamily A member 2,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
785,ADVEFCLSL,316.0,324.0,Tyrosinase precursor,Tyrosinase,,,,HLA-B*44:03,MHC binding prediction,ELISPOT,1,2,0.5
1397584,AEAERLDVKAI,,,,,neo-epitope,AEAERLDVKAM,Eukaryotic translation initiation factor 5,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1397585,AEETPPFSNY,,,,,neo-epitope,AEETPPYSNY,T-lymphoma invasion and metastasis-inducing protein 1,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1309173,AEHSLQVAY,,,,,neo-epitope,AEHSLQVAH,Vesicle-trafficking protein SEC22c (Fragment),HLA-B*44:03,T cell assay -Mismatched MHC molecules,ELISA,1,2,1.0
1860956,AEPPFYVGF,,,,,neo-epitope,AEPPFYVGS,Double-stranded RNA-specific editase 1,HLA-B*47:01,MHC binding prediction,ELISPOT,0,1,0.0
1397586,AERLDVKAI,,,,,neo-epitope,AERLDVKAM,Eukaryotic translation initiation factor 5,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1852488,AEVDQDGVVM,,,,,neo-epitope,AEVDEDGVVM,Neurogenic locus notch homolog protein 4,HLA-B*44:03,Cited reference,ELISA,0,2,0.0
1334550,AEVPENVFL,,,,,neo-epitope,AEVPESVFL,Tumor necrosis factor alpha-induced protein 2,HLA-B*40:01,MHC binding prediction,ELISPOT,0,1,0.0
1397587,AEWRNGSTSSL,,,,,neo-epitope,PEWRNGSTSSL,Protein mono-ADP-ribosyltransferase PARP14 (Fragment),HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
1391811,AFFAQLQLDEETGQFLPIQPAQHIQSE,,,,,neo-epitope,AFFAQLQLDEETGEFLPIQPAQHIQSE,Nuclear factor erythroid 2-related factor 2,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1594803,AGQHIAKSLF,,,,,neo-epitope,AGQHIAKSPF,Filamin-A,HLA-B*44:02,MHC binding prediction,ELISPOT,1,2,0.5
1310262,AIDAALTFV,,,,,neo-epitope,AIDAALTSV,Nuclear pore membrane glycoprotein 210,HLA-A*02:01,MHC binding assay,ELISA,1,2,0.5
866005,AIDAALTSV,420.0,428.0,nuclear pore membrane glycoprotein 210 isoform X1 [Homo sapiens],Nuclear pore membrane glycoprotein 210,,,,HLA-A*02:01,MHC binding assay,ELISA,0,1,0.0
953238,AIGIGAYLV,1935.0,1943.0,Acetyl-CoA carboxylase 2,Acetyl-CoA carboxylase 2,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
1852506,AIKESPKANK,,,,,neo-epitope,AIKELREATSPKANK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISPOT,1,3,0.6666666666666666
1312125,AIKTSPKANK,,,,,neo-epitope,AIKELREATSPKANK,Epidermal growth factor receptor,HLA-A*03:01,Cited reference,ELISA,1,4,0.75
1089142,AILALLPAL,105.0,113.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0
1852507,AILLGAEEK,,,,,neo-epitope,AKLLGAEEK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,0,2,0.0
1087455,AIMPSSPPL,513.0,521.0,Transcription factor COE4,Transcription factor COE4,,,,HLA-B*15:01,MHC binding prediction,ELISPOT,1,2,0.5
1852513,AITSPKANK,,,,,neo-epitope,AIKELREATSPKANK,Epidermal growth factor receptor,HLA-A*11:02,Cited reference,ELISA,0,2,0.0
2469,ALDGGNKHFL,224.0,233.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1336354,ALDGYNGTV,,,,,neo-epitope,ALDGYNGTI,Kinesin-like protein KIF9,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1069080,ALDPHSGHFV,,,,,neo-epitope,ARDPHSGHFV,Cyclin-dependent kinase 4,HLA-A*02:01,Single allele present,ELISPOT,1,2,0.5
2489,ALDVYNGLL,299.0,307.0,Prostatic acid phosphatase precursor,Prostatic acid phosphatase,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
530809,ALEPGPVTA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,Cited reference,ELISA,1,2,0.5
1860990,ALFASRPRF,,,,,neo-epitope,VLFASRPRF,Rho guanine nucleotide exchange factor 15,HLA-B*15:01,MHC binding prediction,ELISPOT,0,1,0.0
442279,ALFDIESKV,711.0,719.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0
1312150,ALFTWTNL,,,,,neo-epitope,AVFTWTNL,Disco-interacting protein 2 homolog B,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1312151,ALFTWTNLL,,,,,neo-epitope,AVFTWTNLL,Disco-interacting protein 2 homolog B,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1312152,ALFTWTNLLV,,,,,neo-epitope,AVFTWTNLLV,Disco-interacting protein 2 homolog B,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1312153,ALFTWTNLLVV,,,,,neo-epitope,AVFTWTNLLVV,Disco-interacting protein 2 homolog B,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1561890,ALGAAALAVVKSTLEWAPKFQLQLF,,,,,neo-epitope,ALGAAALAVVKSALEWAPKFQLQLF,TBC1 domain family member 20,HLA-A*32:01,MHC binding prediction,ELISPOT,0,1,0.0
953250,ALGIGAVPI,12.0,20.0,Full-length cDNA clone CS0DI011YN22 of Placenta of Homo sapiens (human),Legumain,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
953251,ALGIGIYSL,,,"phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit",,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
953252,ALGIGVYPV,990.0,998.0,Membrane-associated phosphatidylinositol transfer protein 1,Membrane-associated phosphatidylinositol transfer protein 1,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
2630,ALIHHNTHL,466.0,474.0,Receptor tyrosine-protein kinase erbB-2 precursor,Receptor tyrosine-protein kinase erbB-2,,,,HLA-A*02:01,Single allele present,ELISA,0,1,0.0
858753,ALIHHNTYL,,,,,neo-epitope,ALIHHNTHL,Receptor tyrosine-protein kinase erbB-2,HLA-A*02:01,Single allele present,ELISA,1,8,1.0
1338250,ALIRALQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338251,ALIRCLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338252,ALIRDLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338253,ALIRELQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338254,ALIRFLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1338255,ALIRGLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338256,ALIRHLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
2644,ALIRILQQL,59.0,67.0,Protein Vpr,Protein Vpr,,,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1338257,ALIRKLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338258,ALIRLLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338259,ALIRMLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1338260,ALIRNLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338261,ALIRPLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338262,ALIRQLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338263,ALIRRLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338264,ALIRSLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338265,ALIRTLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338266,ALIRVLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338267,ALIRWLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1338268,ALIRYLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
2683,ALLAGLVSL,444.0,452.0,Fibroblast growth factor receptor 4,Fibroblast growth factor receptor 4,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
2684,ALLAGLVSLL,490.0,499.0,Tyrosinase precursor,Tyrosinase,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1862834,ALLALLPAL,,,Epidermal growth factor receptor,Epidermal growth factor receptor,,,,HLA-A*02:01,Single allele present,ELISA,0,1,0.0
2688,ALLAVGATK,17.0,25.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A3,Not determined,ELISPOT,1,1,1.0
562076,ALLERASATL,371.0,380.0,Melanoma antigen preferentially expressed in tumors,Melanoma antigen preferentially expressed in tumors,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1861000,ALLMAGLAL,7.0,15.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,5,0.8
1861001,ALLPALGLL,108.0,116.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
1862836,ALLPALGLLL,99.0,108.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,2,0.5
1391814,ALMAPLPVFI,156.0,165.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,0,1,0.0
2747,ALMDKSLHV,56.0,64.0,Melanoma antigen recognized by T-cells 1,Melanoma antigen recognized by T-cells 1,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
2779,ALNFPGSQK,87.0,95.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*11:01,MHC binding prediction,ELISPOT,1,2,1.0
1312161,ALNSEALSV,,,,,neo-epitope,ALNS,Transmembrane protease serine 2 (Fragment),HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1312162,ALNSEALSVV,,,,,neo-epitope,ALNS,Transmembrane protease serine 2 (Fragment),HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1312163,ALNSGSPPAI,2.0,11.0,Transmembrane protease serine 2,Transmembrane protease serine 2 (Fragment),,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1861004,ALPQSILLF,,,,,neo-epitope,ALPRSILLF,Fidgetin,HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
1861006,ALQPAAAIL,99.0,107.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1861007,ALQPGTALL,5.0,13.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,3,0.6666666666666666
1861008,ALQSQSISL,,,,,neo-epitope,VLQSQSISL,Serine-rich coiled-coil domain-containing protein 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1861009,ALQSQSISLV,,,,,neo-epitope,VLQSQSISLV,Serine-rich coiled-coil domain-containing protein 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1861010,ALRGLPGFV,,,Cysteine rich with EGF like domains 2,,,,,HLA-A*02:02,MHC binding prediction,ELISPOT,0,1,0.0
1861014,ALSPDGSIRK,,,,,neo-epitope,APSPDGSIRK,Potassium voltage-gated channel subfamily C member 3,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1861015,ALSPGLTRT,,,,,neo-epitope,ALSPGSTRT,Syntaxin-5,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1334552,ALSYLVSFQR,,,,,neo-epitope,ALSYLVSFQT,,HLA-A*11:02,Single allele present,ELISPOT,1,2,1.0
1334553,ALSYLVSFQT,207.0,216.0,Zinc finger protein 878,,,,,HLA-A*11:02,Single allele present,ELISPOT,1,1,1.0
1312173,ALTASTVPL,,,,,neo-epitope,ALTASPVPL,Metal transporter CNNM2,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1712130,ALVEFEDVL,140.0,148.0,Heterogeneous nuclear ribonucleoprotein L,Heterogeneous nuclear ribonucleoprotein L (Fragment),,,,HLA-A2,Cited reference,ELISA,1,7,0.7142857142857143
1861023,ALVVPVFEI,,,,,neo-epitope,ALVVPAFEI,"Beta-1,4-glucuronyltransferase 1",HLA-A*02:02,MHC binding prediction,ELISPOT,0,1,0.0
1870854,ALYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
858762,ALYGFVPVL,,,,,neo-epitope,ALYGSVPVL,Neutral alpha-glucosidase AB,HLA-A*02:01,Single allele present,ELISA,1,3,1.0
614093,ALYGSVPVL,294.0,302.0,Neutral alpha-glucosidase AB,Neutral alpha-glucosidase AB,,,,HLA-A*02:01,Single allele present,ELISA,0,1,0.0
225231,ALYVDSLFFL,300.0,309.0,Melanoma antigen preferentially expressed in tumors,Melanoma antigen preferentially expressed in tumors,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1628151,AMAKIQAKV,,,,,neo-epitope,AMAKIQAKI,Reticulon,HLA-A2,MHC binding assay,ELISA,1,1,1.0
1309664,AMAVLYLAL,,,,,neo-epitope,AVAVLYLAL,Cyclin-Q,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
3146,AMLDLLKSV,664.0,672.0,Proto-oncogene DBL,Proto-oncogene DBL,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
3147,AMLGTHTMEV,177.0,186.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1861025,AMLSKVVIL,,,,,neo-epitope,AMPSKVVIL,Citron Rho-interacting kinase,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1336387,AMPFSIFYPM,,,,,neo-epitope,AMPFSIFYRM,Proton channel OTOP1,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1645316,AMYQRAKLK,,,,,neo-epitope,AMYQRAKSK,Neutral ceramidase,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
742497,APARLERRHSA,,,,,neo-epitope,ALARLERRHSA,Kinesin-like protein KIF16B,HLA-B*07:02,MHC binding prediction,ELISA,1,2,1.0
1397613,APFPLGDSAL,,,,,neo-epitope,APFPHGDSAL,Ran-binding protein 9,HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
1861035,APGPLPRSL,,,,,neo-epitope,GPGPLPRSL,Dystrophia myotonica WD repeat-containing protein,HLA-B*07:02,MHC binding prediction,ELISPOT,0,1,0.0
1397614,APKKKSIKL,,,,,neo-epitope,APKKKSIKS,Liprin-alpha-3,HLA-B*07:02,MHC binding prediction,ELISPOT,0,1,0.0
1377773,APRERLIDAKTGLTVKTDITPGPSRLC,,,,,neo-epitope,APRERLIDAKTGLPVKTDITPGPSRLC,Aryl hydrocarbon receptor nuclear translocator-like protein 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
753317,APRGPHGGAASGL,60.0,72.0,Cancer/testis antigen 1,Cancer/testis antigen 1,,,,HLA-B*07:02,Cited reference,ELISPOT,1,3,1.0
144206,APSNLRFLATTPNSL,1996.0,2010.0,Fibronectin,Fibronectin,,,,HLA-B*07:02,MHC binding prediction,ELISPOT,1,2,0.5
1861038,APSPGQPPAL,,,,,neo-epitope,APSPGQPPAP,Zinc finger MIZ domain-containing protein 2,HLA-B*35:01,MHC binding prediction,ELISPOT,0,1,0.0
1398835,AQCPDVLV,,,,,neo-epitope,AQCPDVVV,Gem-associated protein 2,HLA-A*02:06,MHC binding prediction,ELISPOT,1,1,1.0
1397616,AQFAGKDQTY,,,,,neo-epitope,AQFAGKEQTY,SHC-transforming protein 3,HLA-A*32:01,MHC binding prediction,ELISPOT,0,1,0.0
1852603,AQPAVQSAF,,,,,neo-epitope,AQAAVQSAF,Cyclin-dependent kinase 13,HLA-A*02:06,Cited reference,ELISA,0,2,0.0
581960,ARAEIRARM,495.0,503.0,Melanoma-associated antigen D2,Melanoma-associated antigen D2,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1645909,ARFAVNLRL,,,,,neo-epitope,AGFAVNLRL,Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1861048,ARIQAGAEAK,529.0,538.0,Melanoma-associated antigen D2,Melanoma-associated antigen D2,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1645954,ARLFLGLAI,,,,,neo-epitope,ARLFPGLAI,Kinesin-like protein KIF2C,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1852610,ARLPVGAYEV,,,,,neo-epitope,ALLPVGAYEV,Aquaporin-12B,HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1852613,ARRASKARL,,,,,neo-epitope,ARRASKALL,Aquaporin-12B,HLA-C*07:02,Cited reference,ELISA,0,2,0.0
570817,ARSRFPQTF,742.0,750.0,Melanoma-associated antigen D1,Melanoma-associated antigen D1,,,,HLA-C*07:01,MHC binding prediction,ELISPOT,0,1,0.0
1861054,ARVSFTRGL,,,,,neo-epitope,ARVPFTRGL,Zinc finger SWIM domain-containing protein 4,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1861055,ARWKHKTRK,,,,,neo-epitope,ARWEHKTRK,Phosphatidylethanolamine N-methyltransferase,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1646037,ARWTAFFGV,,,,,neo-epitope,ARWTASFGV,Transmembrane protease serine 11E,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1397617,ASADGTVKLW,,,,,neo-epitope,ASADGTIKLW,Transducin beta-like protein 3,HLA-B*57:01,MHC binding prediction,ELISPOT,0,1,0.0
1397619,ASGNHHVW,,,,,neo-epitope,ASGNHYVW,Oxysterol-binding protein (Fragment),HLA-C*16:01,MHC binding prediction,ELISPOT,0,1,0.0
1309667,ASILAYLVV,38.0,46.0,P2X5a,P2X purinoceptor,,,,HLA-C*15:02,MHC binding prediction,ELISPOT,1,1,1.0
1712179,ASLDSDPWV,82.0,90.0,Negative elongation factor A,Negative elongation factor A,,,,HLA-A11,Cited reference,ELISPOT,1,12,0.5
1087463,ASMPSSPPL,,,,,neo-epitope,AIMPSSPPL,Transcription factor COE4,HLA-B*15:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666
1075197,ASSIMSTESITGSLGPLLDG,441.0,460.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0
1334554,ASSYISPEK,272.0,280.0,Melanoma antigen preferentially expressed in tumors,Melanoma antigen preferentially expressed in tumors,,,,HLA-A*25:01,MHC binding prediction,ELISPOT,1,2,0.5
1334555,ATHPIICFR,,,,,neo-epitope,THPIICFR,Cilia- and flagella-associated protein 65,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1397630,ATIVPELNEI,,,,,neo-epitope,ATIDPELNEI,Muskelin,HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
1312229,ATNAKDSSSR,,,,,neo-epitope,ATNARDSSSR,Contactin-associated protein-like 2,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1397632,ATPSLHTSV,,,,,neo-epitope,ATPSLHTSD,E3 ubiquitin-protein ligase RNF213,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1090906,ATPSRATVAPR,,,,,neo-epitope,serine/threonine-protein kinase STK11 [Homo sapiens],,HLA-A*31:01,MHC binding prediction,ELISPOT,0,1,0.0
1392644,ATRINPWVEKE28,,,,,neo-epitope,AIRINPWVEK,Nuclear pore complex-interacting protein family member B15,HLA-A*11:01,MHC binding prediction,ELISA,0,1,0.0
1334556,ATSPASASK,,,,,neo-epitope,ATSPASAS,Nuclear receptor subfamily 4 group A member 1,HLA-A*11:01,MHC binding prediction,ELISPOT,1,1,1.0
1861080,AVAGIIPPSV,,,,,neo-epitope,AVAGKIPPSV,14-3-3 protein eta,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1725684,AVEEVSLRK,290.0,298.0,nucleophosmin,Nucleophosmin,,,,HLA-A*11:01,MHC binding assay,ELISA,1,5,0.6
5316,AVFDRKSDAK,399.0,408.0,Epstein-Barr nuclear antigen 4,Epstein-Barr nuclear antigen 4,,,,HLA-A11,Cited reference,ELISPOT,1,1,1.0
1334557,AVIKIRFFK,240.0,248.0,G-protein coupled receptor 143,G-protein coupled receptor 143,,,,HLA-A*25:01,MHC binding prediction,ELISPOT,1,2,0.5
1861090,AVLDGLDVLL,99.0,108.0,Melanoma antigen preferentially expressed in tumors,Melanoma antigen preferentially expressed in tumors,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1076140,AVMRWGMPL,,,,,neo-epitope,AVMRWGMPP,Chromodomain-helicase-DNA-binding protein 3,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1076141,AVMRWGMPP,1423.0,1431.0,Chromodomain-helicase-DNA-binding protein 3,Chromodomain-helicase-DNA-binding protein 3,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1397635,AVSKPGLDYEL,,,,,neo-epitope,AVSKPGMDYEL,Probable E3 ubiquitin-protein ligase IRF2BPL,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1336446,AVYHEIHIGYL,,,,,neo-epitope,AVYHEILIGYL,CREB-binding protein,HLA-A*02:05,MHC binding prediction,ELISPOT,1,1,1.0
77841,AYDFLYNYL,161.0,169.0,Dermatan-sulfate epimerase precursor,Dermatan-sulfate epimerase,,,,HLA-A24,Cited reference,ELISA,1,6,0.8333333333333334
77842,AYIDFEMKI,333.0,341.0,Squamous cell carcinoma antigen recognized by T-cells 3,Squamous cell carcinoma antigen recognized by T-cells 3,,,,HLA-A*24:02,Cited reference,ELISA,1,6,0.6666666666666666
1852184,AYINADSSI,448.0,456.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,1.0
1334731,AYLEAIHDF,,,,,neo-epitope,AYLEAIHNF,AP-2 complex subunit sigma,HLA-A*24:02,MHC binding assay,ELISPOT,1,1,1.0
1334734,AYLEAIHKF,,,,,neo-epitope,AYLEAIHNF,AP-2 complex subunit sigma,HLA-A*24:02,MHC binding assay,ELISPOT,1,1,1.0
436735,AYLEAIHNF,79.0,87.0,AP-2 complex subunit sigma,AP complex subunit sigma,,,,HLA-A*24:02,MHC binding assay,ELISPOT,1,1,1.0
1334737,AYLEAIHYF,,,,,neo-epitope,AYLEAIHNF,AP-2 complex subunit sigma,HLA-A*24:02,MHC binding assay,ELISPOT,1,1,1.0
956331,AYRDLQTRK,,,,,neo-epitope,AYRDLQTRE,Protein NipSnap homolog 2,HLA-A*30:01,Single allele present,ELISA,1,1,1.0
1391819,CFTCSNCKQVIGTVSFFPKGEDFYCVT,,,,,neo-epitope,CFTCSNCKQVIGTGSFFPKGEDFYCVT,Four and a half LIM domains protein 1,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1125043,CISSCNPNL,,,,,neo-epitope,CISSCNPNP,Transcription factor HIVEP2,HLA-A*02:01,MHC binding prediction,ELISA,1,1,1.0
1125040,CISSCNPNL + AIB(C1),,,,,neo-epitope,CISSCNPNP,Transcription factor HIVEP2,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1125041,"CISSCNPNL + AIB(C1, C5)",,,,,neo-epitope,CISSCNPNP,Transcription factor HIVEP2,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1125042,CISSCNPNL + AIB(C5),,,,,neo-epitope,CISSCNPNP,Transcription factor HIVEP2,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1338286,CLAVEEVSL,288.0,296.0,nucleophosmin [Homo sapiens],Nucleophosmin,neo-epitope,Nucleophosmin,,HLA-A*02:01,MHC binding assay,ELISA,1,6,1.0
1727015,CLAVEEVSL + CYSTL(C1),288.0,296.0,nucleophosmin [Homo sapiens],Nucleophosmin,neo-epitope,Nucleophosmin,,HLA-A*02:01,Single allele present,ELISA,1,2,1.0
1648275,CLFFGIPWK,,,,,neo-epitope,CLFFGIPWE,Protocadherin gamma-A10,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1074867,CLGQLSNA,,,,,neo-epitope,CLGQLSNV,Mothers against decapentaplegic homolog 4,HLA-A*02:01,Single allele present,ELISPOT,1,1,1.0
1391820,CLHQDVMKL,181.0,189.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1870863,CLISAVLMV,,,Thyroglobulin precursor,Thyroglobulin,,,,HLA-A*02:01,Cited reference,ELISA,0,1,0.0
1392651,CLMHHLAQA,,,,,neo-epitope,CLMRHLAQA,Taste receptor type 1 member 1,HLA-A*02:03,MHC binding prediction,ELISA,0,1,0.0
1861104,CLPPRNVTL,404.0,412.0,Melanoma-associated antigen D4,Melanoma-associated antigen D4,,,,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1066644,CLWGRLWQL,,,,,analog,CQWGRLWQL,WD repeat-containing protein 46,HLA-A*02:01,T cell assay -Mismatched MHC molecules,ELISA,1,6,1.0
1870864,CLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1391821,CMGGMNRRPILTIFTLEDSSGNLLGRN,,,,,neo-epitope,CMGGMNRRPILTIITLEDSSGNLLGRN,Cellular tumor antigen p53,HLA-B*81:01,MHC binding prediction,ELISPOT,0,1,0.0
1083942,CMLGTYTQDF,91.0,100.0,calcitonin isoform CT preproprotein [Homo sapiens],Calcitonin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0
1391822,CMLSGIDILI,66.0,75.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,0,1,0.0
1852679,CMSCTVNLL,,,,,neo-epitope,RMSCTVNLL,Dedicator of cytokinesis protein 2,HLA-A*02:07,Cited reference,ELISA,0,2,0.0
6671,CMTWNQMNL,235.0,243.0,Wilms tumor protein,Wilms tumor protein,,,,HLA-A*24:02,Cited reference,ELISPOT,1,1,1.0
858793,CMWGRLWQL,,,,,analog,CQWGRLWQL,WD repeat-containing protein 46,HLA-A*02:01,T cell assay -Mismatched MHC molecules,ELISA,1,7,1.0
1091409,CNGSEDGALAY,,,,,neo-epitope,RNGSEDGALAY,Protein patched homolog 2,HLA-B*35:01,MHC binding prediction,ELISPOT,0,1,0.0
858794,CQWGRLWQL,,,WD repeat-containing protein BING4,WD repeat-containing protein 46,,,,HLA-A*02:01,T cell assay -Mismatched MHC molecules,ELISA,1,5,1.0
1391823,CSHICIAKGDGTPLCSCPVHLVLLQNL,,,,,neo-epitope,CSHICIAKGDGTPRCSCPVHLVLLQNL,Low-density lipoprotein receptor-related protein 5,HLA-B*81:01,MHC binding prediction,ELISPOT,0,1,0.0
1861108,CTECGRLFY,,,,,neo-epitope,CTECGRSFY,,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1861109,CTFSEVAAHY,,,,,neo-epitope,CTSSEVAAHY,ATP-binding cassette sub-family A member 3,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1125052,CTIAVVNFL,,,,,neo-epitope,CTNAVVNFL,Enoyl-CoA delta isomerase 2,HLA-A*68:02,Cited reference,ELISA,1,1,1.0
1125051,CTIAVVNFL + AIB(C1),,,,,neo-epitope,CTNAVVNFL,Enoyl-CoA delta isomerase 2,HLA-A*68:02,Cited reference,ELISA,1,1,1.0
1862858,CVDDSQDYYV,61.0,70.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,2,1.0
1391824,CVFILAIIGILHWLEKKADDREKRQEA,,,,,neo-epitope,CVFILAIIGILHWQEKKADDREKRQEA,T-cell immunomodulatory protein,HLA-A*02:07,MHC binding prediction,ELISPOT,0,1,0.0
1399225,CVRVSGQGL,,,,,neo-epitope,RVRVSGQGL,Filamin-A,HLA-B*07:02,MHC binding prediction,ELISPOT,1,1,1.0
1852699,CVVTEVFLL,,,,,neo-epitope,CGVTEVFLL,Olfactory receptor 5L2,HLA-A*02:06,Cited reference,ELISA,0,2,0.0
1860817,CYASGWGSI,152.0,160.0,Prostate-specific antigen precursor,Prostate-specific antigen,,,,HLA-A24,Cited reference,ELISA,1,4,0.75
1130596,CYMEALAL,20.0,27.0,Inactive hydroxysteroid dehydrogenase-like protein 1,Inactive hydroxysteroid dehydrogenase-like protein 1,,,,HLA-C*14:03,MHC binding prediction,ELISPOT,1,2,0.5
1130597,CYMEAVAL,,,,,neo-epitope,CYMEALAL,Inactive hydroxysteroid dehydrogenase-like protein 1,HLA-C*14:03,MHC binding prediction,ELISPOT,1,6,0.8333333333333334
1312275,CYMEAVALV,,,,,neo-epitope,CYMEALALV,Inactive hydroxysteroid dehydrogenase-like protein 1,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
7497,DAEKSDICTDEY,,,,,,,,HLA-A1,Not determined,ELISPOT,1,1,1.0
1063259,DANSFLQSV,,,,,neo-epitope,DANPFLQSV,Mediator of RNA polymerase II transcription subunit 15,HLA-B*51:01,T cell assay -Biological process measured,ELISA,1,1,1.0
1334559,DDIYPIDFH,55.0,63.0,Intraflagellar transport protein 80 homolog,Intraflagellar transport protein 80 homolog,,,,HLA-A*25:01,Single allele present,ELISPOT,0,1,0.0
1334560,DDIYPIDFY,,,,,neo-epitope,DDIYPIDFH,Intraflagellar transport protein 80 homolog,HLA-A*25:01,Single allele present,ELISPOT,1,2,0.5
1397638,DEERIPVL,,,,,neo-epitope,DEERIPML,E3 ubiquitin-protein ligase RNF216,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1397639,DENITTIQF,,,,,neo-epitope,DENITTIQC,Adhesion G protein-coupled receptor A3,HLA-B*18:01,MHC binding prediction,ELISPOT,1,1,1.0
1861119,DEQIESMTY,,,,,neo-epitope,DEQMESMTY,ATP-binding cassette sub-family B member 5,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1852721,DEVFGSSRL,,,,,neo-epitope,DEVFRFFEA,SH3 and PX domain-containing protein 2A,HLA-B*40:01,Cited reference,ELISA,1,2,0.5
1397640,DFATPSLHTSV,,,,,neo-epitope,DFATPSLHTSD,E3 ubiquitin-protein ligase RNF213,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1852199,DFEVFFQRL,520.0,528.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5
77848,DFMIQGGDF,99.0,107.0,Peptidyl-prolyl cis-trans isomerase B,Peptidyl-prolyl cis-trans isomerase B,,,,HLA-A*24:02,Cited reference,ELISA,1,2,0.5
1397641,DGVGKSAL,,,,,neo-epitope,GGVGKSAL,Ras-related protein Rap-2b,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1397642,DHFETIIKY,,,,,neo-epitope,DHFETIMKY,Bifunctional glutamate/proline--tRNA ligase,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1334563,DHYAYSYYL,,,,,neo-epitope,DHYAYSYYP,Receptor-type tyrosine-protein phosphatase U,HLA-C*06:02,Single allele present,ELISPOT,1,4,0.5
1334564,DHYAYSYYP,775.0,783.0,Receptor-type tyrosine-protein phosphatase U,Receptor-type tyrosine-protein phosphatase U,,,,HLA-B*51:01,Single allele present,ELISPOT,1,2,1.0
953446,DIAGIGLKTV,90.0,99.0,CAND2 protein,Cullin-associated NEDD8-dissociated protein 2,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
1397643,DIFQVVKAI,,,,,neo-epitope,DIFQVVKAL,Receptor-type tyrosine-protein phosphatase C,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1397644,DISEYRVEHL,,,,,neo-epitope,DISQYRVEHL,Epidermal growth factor receptor kinase substrate 8,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1397646,DLAGGTFDV,,,,,neo-epitope,DLGGGTFDV,Heat shock cognate 71 kDa protein,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1397647,DLAGGTFDVS,,,,,neo-epitope,DLGGGTFDVS,Heat shock cognate 71 kDa protein,HLA-A*32:01,MHC binding prediction,ELISPOT,0,1,0.0
1334758,DLDLKGPKV,4788.0,4796.0,neuroblast differentiation-associated protein AHNAK isoform X1 [Homo sapiens],Neuroblast differentiation-associated protein AHNAK,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0
1861147,DLHVISNDV,175.0,183.0,Prostate-specific antigen precursor,Prostate-specific antigen,,,,HLA-A2,MHC binding assay,ELISA,1,2,0.5
1711651,DLLSHAFFA,442.0,450.0,Serine/threonine-protein kinase WNK2,Serine/threonine-protein kinase WNK2,,,,HLA-A2,Cited reference,ELISA,1,6,0.6666666666666666
1852747,DLLSHAFFAI,,,Serine/threonine-protein kinase WNK2C,,,,,HLA-A2,Cited reference,ELISA,1,4,0.75
1378832,DLRALRALHLDGNQLTSLGEGQLRGLV,,,,,neo-epitope,DLRALRALHLDGNRLTSLGEGQLRGLV,Leucine-rich repeat and fibronectin type-III domain-containing protein 3,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1870866,DLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1596609,DMKARQKAL,,,,,neo-epitope,DMKARQEAL,Protein FAM50B,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1861152,DMKARQKALV,,,,,neo-epitope,DMKARQEALV,Protein FAM50B,HLA-B*08:01,MHC binding prediction,ELISPOT,1,1,1.0
1397649,DPEEVLVTV,,,,,neo-epitope,DPEEVSVTV,Clathrin heavy chain 1,HLA-B*51:01,MHC binding prediction,ELISPOT,0,1,0.0
1397651,DSPDGSNGL,,,,,neo-epitope,DSPDGSSGL,Oxidative stress-responsive serine-rich protein 1,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1397652,DTSPVAVAL,,,,,neo-epitope,DTLPVAVAL,F-BAR domain only protein 2,HLA-A*26:01,MHC binding prediction,ELISPOT,0,1,0.0
1397653,DTVEYPYTSF,,,,,neo-epitope,DTVEDPYTSF,Cofilin-2,HLA-A*26:01,MHC binding prediction,ELISPOT,1,1,1.0
1397655,DVKAIGPLV,,,,,neo-epitope,DVKAMGPLV,Eukaryotic translation initiation factor 5,HLA-A*26:01,MHC binding prediction,ELISPOT,0,1,0.0
1852773,DVSDNEPDLYR,,,,,neo-epitope,DVSDNEPDHYR,"Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN",HLA-A*33:01,Cited reference,ELISA,0,2,0.0
1397656,DVSVQVER,,,,,neo-epitope,DVSVQVEM,Ankyrin repeat domain-containing protein 20B,HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
1712502,DVWSFGILL,422.0,430.0,Tyrosine-protein kinase Lck,Tyrosine-protein kinase Lck,,,,HLA-A2,Cited reference,ELISA,1,4,1.0
606644,DVYPEIIER,315.0,323.0,Melanoma-associated antigen D2,Melanoma-associated antigen D2,,,,HLA-C*06:02,MHC binding prediction,ELISPOT,0,1,0.0
1711652,DYLRSVLEDF,488.0,497.0,Tyrosine-protein kinase Lck,Tyrosine-protein kinase Lck,,,,HLA-A*24:02,Cited reference,ELISA,1,13,0.5384615384615384
1087493,DYMIHIIEKW,,,,,neo-epitope,DYMSHIIEKW,Heparan-sulfate 6-O-sulfotransferase 1,HLA-B*27:05,MHC binding prediction,ELISPOT,1,2,0.5
1087494,DYMSHIIEKW,402.0,411.0,Heparan-sulfate 6-O-sulfotransferase 1,Heparan-sulfate 6-O-sulfotransferase 1,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1711653,DYSARWNEI,93.0,101.0,Dermatan-sulfate epimerase,DUF4962 domain-containing protein (Fragment),,,,HLA-A*24:02,Cited reference,ELISA,1,8,0.625
1712568,DYVREHKDNI,800.0,809.0,Epidermal growth factor receptor precursor,Epidermal growth factor receptor,,,,HLA-A24,Cited reference,ELISPOT,1,3,0.6666666666666666
1861199,DYVSALHPV,,,,,neo-epitope,DHVSALHPV,Protein CASC1,HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
1862872,DYYVGKKNI,67.0,75.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*24:02,MHC binding prediction,ELISA,1,1,1.0
1861200,EAAAPLLPM,,,,,neo-epitope,GAAAPLLPM,Phosphatidate phosphatase LPIN1,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
10987,EAAGIGILTV,26.0,35.0,melanoma antigen recognized by T-cells 1,Melanoma antigen recognized by T-cells 1,,,,HLA-A*02:01,MHC binding assay,ELISA,1,14,0.8571428571428571
1863981,EAAPPSTSM,,,,,neo-epitope,macrophage colony-stimulating factor 1 receptor precursor,,HLA-C*03:04,MHC binding prediction,ELISA,0,2,0.0
1391829,EADLFDKLEAVARGVRQQNKPFGGIQL,,,,,neo-epitope,EADLFDKLEAVARAVRQQNKPFGGIQL,ATP-dependent DNA helicase PIF1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
11010,EADPTGHSY,161.0,169.0,Melanoma-associated antigen 1,Melanoma-associated antigen 1,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,1,2,1.0
1397658,EAGNNSRVPR,,,,,neo-epitope,EAGNNSRGPR,Methylcytosine dioxygenase TET3,HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
1852786,EASGITYEY,,,,,neo-epitope,EASGITYED,Interleukin-6 receptor subunit beta,HLA-A*01:01,Cited reference,ELISA,0,2,0.0
1075245,EEAAGIGIL,25.0,33.0,Melanoma antigen recognized by T-cells 1,Melanoma antigen recognized by T-cells 1,,,,HLA-B*18:01,Single allele present,ELISPOT,1,2,1.0
1397659,EEADFLLAY,,,,,neo-epitope,EEADFPLAY,"N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase",HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1852801,EECLWMAVL,,,,,neo-epitope,EECLGMAVL,Tyrosine-protein kinase JAK2,HLA-B*40:02,Cited reference,ELISA,0,2,0.0
1861211,EEFWLVDLL,,,,,neo-epitope,EEFRLVDLL,Tenascin-R,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1861212,EEFWLVDLLP,,,,,neo-epitope,EEFRLVDLLP,Tenascin-R,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1312350,EEHAQNVSCAS,,,,,neo-epitope,EGHAQNVSCAS,Coatomer subunit beta',HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1312351,EEKAASSLVSY,,,,,neo-epitope,EQKAASSLVSY,Protein FAM234B,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1861215,EELSATVPS,,,,,neo-epitope,EEPSATVPS,Activating transcription factor 7-interacting protein 1,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1861216,EELSATVPSQ,,,,,neo-epitope,EEPSATVPSQ,Activating transcription factor 7-interacting protein 1,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1556302,EEMEPLPVM,,,,,neo-epitope,EEMEPPPVM,Interleukin-27 receptor subunit alpha,HLA-B*44:03,MHC binding prediction,ELISPOT,1,1,1.0
1312352,EENANFYKIF,,,,,neo-epitope,EENANFNKIF,C-X-C chemokine receptor type 4,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1861218,EESGGAVAFF,,,,,neo-epitope,EESGGAVAFS,Regulatory-associated protein of mTOR,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1397660,EETPPFSNY,,,,,neo-epitope,EETPPYSNY,T-lymphoma invasion and metastasis-inducing protein 1,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1397661,EEVTPILAI,,,,,neo-epitope,EEVTPISAI,Band 4.1-like protein 3,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1075251,EFTVSGNIL,125.0,133.0,Cancer/testis antigen 1,Cancer/testis antigen 1,,,,HLA-B*40:01,Single allele present,ELISPOT,1,2,1.0
1397662,EGSLGISHTR,,,,,neo-epitope,EGSWGISHTR,GPI ethanolamine phosphate transferase 1,HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
1397663,EHIPESAGF,,,,,neo-epitope,EQIPESAGF,Protein disulfide isomerase CRELD1,HLA-B*38:01,MHC binding prediction,ELISPOT,0,1,0.0
1861231,EISDRFIGI,,,,,neo-epitope,EISDRLIGI,Structural maintenance of chromosomes protein 4,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
1861232,EISDRFIGIY,,,,,neo-epitope,EISDRLIGIY,Structural maintenance of chromosomes protein 4,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
1379660,EIVPSPPSPPPLPHIYKPCFVCQDKSS,,,,,neo-epitope,EIVPSPPSPPPLPRIYKPCFVCQDKSS,Retinoic acid receptor alpha,HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0
1852827,EKTSSGLYVFR,,,,,neo-epitope,EKTSSGLYIFR,Breast cancer type 2 susceptibility protein,HLA-A*31:01,Cited reference,ELISA,1,2,0.5
12941,ELAGIGILTV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A2,Cited reference,ELISA,1,25,1.0
1397665,ELDPDIQLEY,,,,,neo-epitope,ELDPDIQLED,Katanin p60 ATPase-containing subunit A-like 1,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1397667,ELNARRCSF,,,,,neo-epitope,ELNARRRSF,Solute carrier family 66 member 2,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1870874,ELYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1397679,EMDMHLSDY,,,,,neo-epitope,EMDMHISDY,Ciliogenesis and planar polarity effector 1,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1861246,EMKRVFGFPV,,,,,neo-epitope,EMERVFGFPV,DNA (cytosine-5)-methyltransferase 3A,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1391833,EMPKLTEQLAGPLCQMQECAKRIAKVS,,,,,neo-epitope,EMPKLTEQLAGPLRQMQECAKRIAKVS,Exosome RNA helicase MTR4,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1397682,ENITTIQFY,,,,,neo-epitope,ENITTIQCY,Adhesion G protein-coupled receptor A3,HLA-A*26:01,MHC binding prediction,ELISPOT,0,1,0.0
1852854,EPLSYSLLQR,,,,,neo-epitope,EPLSYSRLQR,ALK tyrosine kinase receptor,HLA-A*33:01,Cited reference,ELISA,0,2,0.0
1397683,EQNFVSTSDIK,,,,,neo-epitope,EQNFVSKSDIK,"3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial",HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
1334567,ERIPLPPHLC,566.0,575.0,Prickle-like protein 3,Prickle planar cell polarity protein 3,,,,HLA-C*06:02,Single allele present,ELISPOT,1,1,1.0
1391834,ERMGSGIQYGDAAFRQLRSPRRAQAPN,,,,,neo-epitope,ERMGSGIQYGDAALRQLRSPRRAQAPN,GTP-binding protein GEM,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1861265,ERWSLPMLPR,46.0,55.0,S100 calcium binding protein B isoform 2,Protein S100-B,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1861266,ESDLNSWPV,,,,,neo-epitope,ESDLDSWPV,T-box transcription factor TBX10,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1861269,ESGGAVAFF,,,,,neo-epitope,ESGGAVAFS,Regulatory-associated protein of mTOR,HLA-A*25:01,MHC binding prediction,ELISPOT,0,1,0.0
1861272,ESIKEITNF,,,,,neo-epitope,ESIKEITNL,Early endosome antigen 1,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
1861273,ESIKEITNFK,,,,,neo-epitope,ESIKEITNLK,Early endosome antigen 1,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
1075267,ESITGSLGPLL,448.0,458.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-B*40:01,Single allele present,ELISPOT,1,2,1.0
14195,ESLFRAVITK,95.0,104.0,Melanoma-associated antigen 1,Melanoma-associated antigen 1,,,,HLA-A*11:01,MHC binding prediction,ELISPOT,1,2,0.5
1861277,ETDESLIYSF,,,,,neo-epitope,GTDESLIYSF,Probable E3 ubiquitin-protein ligase TRIML1,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1397687,ETPPFSNYNTL,,,,,neo-epitope,ETPPYSNYNTL,T-lymphoma invasion and metastasis-inducing protein 1,HLA-A*26:01,MHC binding prediction,ELISPOT,0,1,0.0
1397688,ETTEEMKYVL,,,,,neo-epitope,GTTEEMKYVL,Dual specificity protein kinase TTK,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1861281,ETVTLSEAPV,,,,,neo-epitope,ETVTPSEAPV,Thioredoxin domain-containing protein 5,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
1397689,EVADAATLTM,,,,,neo-epitope,EVADAAKLTM,Zinc finger FYVE domain-containing protein 9,HLA-A*26:01,MHC binding prediction,ELISPOT,1,1,1.0
14672,EVDPIGHLY,168.0,176.0,Melanoma-associated antigen 3,Melanoma-associated antigen 3,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666
1569330,EVLEQEKGALSDGEIVSLSIEFYEG,,,,,neo-epitope,EVLEQEKGALSDDEIVSLSIEFYEG,Polycomb group RING finger protein 2,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1391835,EVLLSASSSENEALDDESYISDVSDNI,,,,,neo-epitope,EVLLSASSSENEASDDESYISDVSDNI,Oxysterol-binding protein-related protein 6,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1309203,EVLPFFLFF,,,,,neo-epitope,EALPFFLFF,Kynurenine formamidase (Fragment),HLA-A*29:02,T cell assay -Mismatched MHC molecules,ELISA,1,2,0.5
1397691,EVTPILAIR,,,,,neo-epitope,EVTPISAIR,Band 4.1-like protein 3,HLA-A*26:01,MHC binding prediction,ELISPOT,0,1,0.0
1852887,EVVRHCPHHER,,,,,neo-epitope,EVVRRCPHHER,Cellular tumor antigen p53,HLA-A*33:03,Cited reference,ELISA,0,2,0.0
858879,EVYEGVWKK,255.0,263.0,Proto-oncogene tyrosine-protein kinase ABL1,Tyrosine-protein kinase ABL1,,,,HLA-A*03:01,MHC binding assay,ELISPOT,0,2,0.0
1074746,EYCKFSFLF,,,,,neo-epitope,EYCKFPFLF,72 kDa type IV collagenase,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1852892,EYCLKFTKL,188.0,196.0,STAGA complex 65 subunit gamma,STAGA complex 65 subunit gamma,,,,HLA-A*24:02,Cited reference,ELISA,1,4,0.75
735825,EYILSLEEL,298.0,306.0,glypican 3,Glypican-3,,,,HLA-A*24:02,Cited reference,ELISPOT,1,2,1.0
1861294,EYPVIFKSI,,,,,neo-epitope,EYPVISKSI,T-box transcription factor TBX4,HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
1870783,EYRGFTQDF,690.0,698.0,U4/U6.U5 tri-snRNP-associated protein 1,Hom s 1,,,,HLA-A24,Cited reference,ELISA,0,2,0.0
606702,EYYSKNLNSF,,,,,neo-epitope,EYYSKNLNSS,Protein MMS22-like,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0
1397693,FAFDAVSKPGL,,,,,neo-epitope,FAFDAVSKPGM,Probable E3 ubiquitin-protein ligase IRF2BPL,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1311332,FAIADTAYV,,,,,neo-epitope,FASADTAYV,Brefeldin A-inhibited guanine nucleotide-exchange protein 2,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1852898,FAKNPHLHY,,,,,neo-epitope,FAKNPHLRY,NT-3 growth factor receptor,HLA-B*15:27,Cited reference,ELISA,0,2,0.0
1852899,FAKNPHLHYI,,,,,neo-epitope,FAKNPHLRYI,NT-3 growth factor receptor,HLA-A*02:06,Cited reference,ELISA,0,2,0.0
1309710,FARAHALMF,,,,,neo-epitope,FARAHPLMF,Semaphorin-3G,HLA-B*15:01,MHC binding prediction,ELISPOT,1,1,1.0
1309711,FARAHPLMF,407.0,415.0,Semaphorin-3G,Semaphorin-3G,,,,HLA-B*15:01,MHC binding prediction,ELISPOT,1,1,1.0
1392780,FASDIPRIL,,,,,neo-epitope,FAADIPRIL,AP-2 complex subunit alpha-1,HLA-C*03:03,MHC binding prediction,ELISA,0,1,0.0
175795,FATGIGIITV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,MHC binding assay,ELISA,1,11,0.8181818181818182
1397695,FATPSLHTSV,,,,,neo-epitope,FATPSLHTSD,E3 ubiquitin-protein ligase RNF213,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1861309,FEAEFTQVA,,,,,neo-epitope,FGAEFTQVA,Rho GTPase-activating protein 29,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1066332,FEDKSVAYT,,,,,neo-epitope,FEDKTVAYT,Protein disulfide-isomerase A3,HLA-C*05:01,MHC binding prediction,ELISPOT,1,1,1.0
1312408,FEFCEDDLW,,,,,neo-epitope,FEFCEDDLR,"NACHT, LRR and PYD domains-containing protein 4",HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1852911,FEIRARTAA,,,,,neo-epitope,FQIRARTAA,Ephrin type-A receptor 5,HLA-B*40:02,Cited reference,ELISA,0,2,0.0
1312412,FFCDVQQVIKL,,,,,neo-epitope,FFCDVRQVIKL,Olfactory receptor,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1309205,FFYLLDFTF,,,,,neo-epitope,FFYPLDFTF,"Thioredoxin-dependent peroxide reductase, mitochondrial",HLA-A*29:02,T cell assay -Mismatched MHC molecules,ELISA,1,1,1.0
1556306,FGLLGNILLVI,,,,,neo-epitope,FGLLGNILVVI,C-C chemokine receptor type 6,HLA-A*02:24,MHC binding prediction,ELISPOT,1,1,1.0
1312425,FGRAKLLGA,,,,,neo-epitope,FGLAKLLGA,Epidermal growth factor receptor,HLA-B*54:01,Cited reference,ELISA,0,2,0.0
1397696,FHATNPLNL,,,,,neo-epitope,FDATNPLNL,Serine/threonine-protein kinase Nek9,HLA-B*38:01,MHC binding prediction,ELISPOT,0,1,0.0
1312429,FHGESTQVQL,,,,,neo-epitope,FHDESTQVQL,AP-2 complex subunit beta (Fragment),HLA-C*03:03,MHC binding prediction,ELISPOT,0,1,0.0
1852915,FHLKGHEDL,,,,,neo-epitope,FLLKGHEDL,Serine/threonine-protein kinase mTOR,HLA-B*39:01,Cited reference,ELISA,0,2,0.0
1087511,FICAIIVVV,,,,,neo-epitope,FIGAIIVVV,Podoplanin,HLA-B*27:05,MHC binding prediction,ELISPOT,1,2,0.5
1391836,FIFYVPFIGL,250.0,259.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1087512,FIGAIIVVV,144.0,152.0,Podoplanin,Podoplanin,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1392797,FILMGLPHA,10.0,18.0,Olfactory receptor 10G8,Olfactory receptor 10G8,,,,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1392798,FILMGLPHV,,,,,neo-epitope,FILMGLPHA,Olfactory receptor 10G8,HLA-A*02:03,MHC binding prediction,ELISA,0,3,0.0
1870784,FINDEIFVEL,165.0,174.0,Histone-lysine N-methyltransferase EZH2,Histone-lysine N-methyltransferase EZH2,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1380441,FIPGQGNNAYVFPRVALGVIAGGIRHI,,,,,neo-epitope,FIPGQGNNAYVFPGVALGVIAGGIRHI,"NADP-dependent malic enzyme, mitochondrial",HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1336681,FISEYCGEI,,,,,neo-epitope,FISEYCGEI,Histone-lysine N-methyltransferase EZH2,HLA-A*02:05,Single allele present,ELISPOT,1,1,1.0
1861317,FISLKILNL,1205.0,1213.0,Baculoviral IAP repeat-containing protein 1,Baculoviral IAP repeat-containing protein 1,,,,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1380488,FKVLCTTPNKYVVIDAAGAVKPQCCVD,,,,,neo-epitope,FKVLCTTPNKYVVVDAAGAVKPQCCVD,Motile sperm domain-containing protein 1,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0
1380489,FKVPSSCPIVTVDEYVDPSGGDRFCLG,,,,,neo-epitope,FKVPSSCPIVTVDGYVDPSGGDRFCLG,Mothers against decapentaplegic homolog 4,HLA-A*24:02,MHC binding prediction,ELISPOT,0,1,0.0
1397284,FLAEHEYGL,,,,,neo-epitope,FLAEHDYGL,Protein virilizer homolog,HLA-A*02:01,Cited reference,ELISA,1,3,1.0
1084399,FLALSILVL,9.0,17.0,calcitonin isoform CT preproprotein [Homo sapiens],Calcitonin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0
1311336,FLAPLFLVLL,,,,,neo-epitope,FLAPLFMVLL,Transmembrane protein 161B,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1397697,FLAPTGVPV,,,,,neo-epitope,FLVPTGVPV,Neurotrimin,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1861320,FLCLKELSV,1101.0,1109.0,Baculoviral IAP repeat-containing protein 1,Baculoviral IAP repeat-containing protein 1,,,,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1861321,FLDREQRESY,,,,,neo-epitope,SLDREQRESY,Protocadherin-1,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1861322,FLEEHKEFL,,,,,neo-epitope,LLEEHKEFL,SMC5-SMC6 complex localization factor protein 2,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1870785,FLFNLNNDFV,665.0,674.0,Histone-lysine N-methyltransferase EZH2,Histone-lysine N-methyltransferase EZH2,,,,HLA-A2,MHC binding prediction,ELISA,0,1,0.0
1861324,FLFQDSKKI,,,,,neo-epitope,FFFQDSKKI,Protogenin,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1334806,FLFYPLDFT,,,,,neo-epitope,FFFYPLDFT,Peroxiredoxin-4,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
1087515,FLGAGLFIYF,241.0,250.0,HLA-DRB1 protein,HLA class II histocompatibility antigen DR beta chain,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1087516,FLGAGLFLYF,,,,,neo-epitope,FLGAGLFIYF,HLA class II histocompatibility antigen DR beta chain,HLA-B*27:05,MHC binding prediction,ELISPOT,1,2,0.5
1312447,FLGDINPQHSW,,,,,neo-epitope,FLGEINPQHSW,"NACHT, LRR and PYD domains-containing protein 1",HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
437314,FLGPWPAAS,22.0,30.0,alpha-2-macroglobulin receptor-associated protein precursor,Alpha-2-macroglobulin receptor-associated protein,,,,HLA-A*02:01,Cited reference,ELISA,1,5,1.0
1391970,FLGYLILGV,11.0,19.0,Kallikrein-4,Kallikrein-4,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0
1312451,FLHQSSVPTL,,,,,neo-epitope,FLHQSPSSSSVPTL,"Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 (Fragment)",HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
858914,FLIYLDVSV,,,,,neo-epitope,FLTYLDVSV,WD repeat-containing protein 46,HLA-A*02:01,T cell assay -Mismatched MHC molecules,ELISA,1,4,1.0
954075,FLKGIGWIPI,1443.0,1452.0,Nebulin,Nebulin,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
1392800,FLKHKLPLSL,259.0,268.0,nucleolar complex protein 4 homolog,Nucleolar complex protein 4 homolog,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1392801,FLKHKMPLSL,,,,,neo-epitope,FLKHKLPLSL,Nucleolar complex protein 4 homolog,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1069534,FLLDEAIGL,,,,,neo-epitope,FLLDEANGL,Speckle-type POZ protein,HLA-A*02:01,Single allele present,ELISPOT,1,2,0.5
1310406,FLLDSCTKL,,,,,neo-epitope,SLLDSCTKL,T-complex protein 1 subunit delta,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1312453,FLLLVAAMI,,,,,neo-epitope,FLLLVVAMI,Olfactory receptor 4A5,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1392802,FLLPSGMAL,,,,,neo-epitope,FSLPSGMAL,ATP-binding cassette sub-family A member 2,HLA-C*03:04,MHC binding prediction,ELISA,1,1,1.0
1861328,FLLTDYALS,,,,,neo-epitope,FLLTDYAPS,Potassium voltage-gated channel subfamily C member 3,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
16785,FLNQTDETL,66.0,74.0,Mammaglobin-A precursor,Mammaglobin-A,,,,HLA-A2,Not determined,ELISPOT,1,1,1.0
16854,FLPSPLFFFL,,,,,analog,FPPSPLFFFL,,HLA-A2,Cited reference,ELISA,1,2,1.0
16859,FLPWHRLFL,207.0,215.0,Tyrosinase precursor,Tyrosinase,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666
1069539,FLQEVNVCGV,,,,,neo-epitope,FLQEVNVYGV,"Solute carrier family 27 (Fatty acid transporter), member 3, isoform CRA_d",HLA-A*02:03,MHC binding prediction,ELISPOT,1,1,1.0
1861330,FLQGRTLTL,887.0,895.0,Baculoviral IAP repeat-containing protein 1,Baculoviral IAP repeat-containing protein 1,,,,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
16878,FLRGRAYGL,325.0,333.0,Epstein-Barr nuclear antigen 3,Epstein-Barr nuclear antigen 3,,,,HLA-A*80:01,Cited reference,ELISPOT,1,1,1.0
1596632,FLRGRLDQL,308.0,316.0,Melanoma antigen preferentially expressed in tumors,Melanoma antigen preferentially expressed in tumors,,,,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1863176,FLRNFSLML,29.0,37.0,TCR gamma alternate reading frame protein isoform 1,,,,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1863177,FLRNFSLMV,,,,,analog,FLRNFSLML,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
911002,FLSDHLYLV,,,,,neo-epitope,FLSDHPYLV,Hsp90 co-chaperone Cdc37-like 1,HLA-A*02:01,Single allele present,ELISPOT,1,11,0.6363636363636364
1069544,FLSIILDHL,,,,,neo-epitope,FLIIILDHL,Myotubularin,HLA-A*02:03,MHC binding prediction,ELISPOT,0,1,0.0
1311341,FLTAHSLPL,,,,,neo-epitope,FLTAHRLPL,Protoporphyrinogen oxidase,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
175797,FLTGIGIITV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,MHC binding assay,ELISA,1,8,1.0
1637461,FLTPKKLQCV,165.0,174.0,Prostate-specific antigen precursor,Prostate-specific antigen,,,,HLA-A2,MHC binding assay,ELISA,1,3,0.6666666666666666
858918,FLTYLDVSV,298.0,306.0,WD repeat domain 46,WD repeat-containing protein 46,,,,HLA-A*02:01,Single allele present,ELISA,0,1,0.0
1861331,FLWRKTSKYM,,,,,neo-epitope,FSWRKTSKYM,DmX-like protein 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1870883,FLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
453847,FLYPFLSHL,1045.0,1053.0,EMILIN-2,EMILIN-2,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
1312472,FMASNDEGV,,,,,neo-epitope,FVASNDEGV,Plexin-B2,HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
1400001,FMDSVIFIL,,,,,neo-epitope,FMDSVIFTL,Ras GTPase-activating-like protein IQGAP1,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1336719,FMFEGHDTTT,,,,,neo-epitope,FMFEGHDTTT,Cytochrome P450 4B1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1310409,FMFVNSLLL,,,,,neo-epitope,SMFVNSLLL,WD repeat-containing protein 75,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1861332,FMMPRIVDV,,,,,neo-epitope,FMMPRIVNV,MAX gene-associated protein,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1861333,FMMPRIVDVT,,,,,neo-epitope,FMMPRIVNVT,MAX gene-associated protein,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
858919,FMPDFDLHL,,,,,neo-epitope,SMPDFDLHL,Neuroblast differentiation-associated protein AHNAK,HLA-A*02:01,Cited reference,ELISPOT,1,8,1.0
1392808,FMSTMDVLV,,,,,neo-epitope,FMSTMDALV,Olfactory receptor 7G1,HLA-A*02:03,MHC binding prediction,ELISA,0,1,0.0
1870786,FMVEDETVL,120.0,128.0,Histone-lysine N-methyltransferase EZH2,Histone-lysine N-methyltransferase EZH2,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1861334,FMVPRDPAL,,,,,neo-epitope,FLVPRDPAL,Ubiquitin carboxyl-terminal hydrolase 6,HLA-A*02:02,MHC binding prediction,ELISPOT,0,1,0.0
1861335,FPAAAFPTA,,,,,neo-epitope,SPAAAFPTA,Bromodomain adjacent to zinc finger domain protein 2A,HLA-B*56:01,MHC binding prediction,ELISPOT,0,1,0.0
1861336,FPAAAFPTAS,,,,,neo-epitope,SPAAAFPTAS,Bromodomain adjacent to zinc finger domain protein 2A,HLA-B*56:01,MHC binding prediction,ELISPOT,0,1,0.0
1861337,FPGNQWNPV,,,,,neo-epitope,FPGNRWNPV,Transmembrane protein 260,HLA-B*56:01,MHC binding prediction,ELISPOT,0,1,0.0
1861339,FPKKIQMLA,,,,,neo-epitope,FPKEIQMLA,ATP-dependent RNA helicase DDX3X,HLA-B*56:01,MHC binding prediction,ELISPOT,1,1,1.0
1861340,FPQGLPNEY,,,,,neo-epitope,FPQGLPDEY,,HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0
444026,FPSLREAAL,294.0,302.0,Melanoma-associated antigen 1,Melanoma-associated antigen 1,,,,HLA-B*07:02,MHC binding prediction,ELISPOT,1,2,0.5
1397704,FPSPSKTSLTL,,,,,neo-epitope,FPSPSKTSLPL,Ankyrin repeat and LEM domain-containing protein 2,HLA-C*07:02,MHC binding prediction,ELISPOT,0,1,0.0
1397705,FPVVNSHSL,,,,,neo-epitope,FAVVNSHSL,Solute carrier family 22 member 15,HLA-C*03:04,MHC binding prediction,ELISPOT,0,2,0.0
1397706,FPYPGMTNQ,,,,,neo-epitope,CPYPGMTNQ,Tyrosine-protein kinase Fer,HLA-B*51:01,MHC binding prediction,ELISPOT,0,1,0.0
1309718,FQAQHIAMA,,,,,neo-epitope,FQAQHIAVA,Cyclin-Q,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1312483,FQDDDQTRL,,,,,neo-epitope,FQDDDQTRV,DnaJ homolog subfamily C member 11,HLA-B*39:01,MHC binding prediction,ELISPOT,0,1,0.0
1713734,FQDSVRTT,,,,,neo-epitope,FQDSVRIT,Integrin alpha-1,HLA-A*02:06,Cited reference,ELISPOT,1,2,0.5
566252,FQDYIKSYL,460.0,468.0,Tyrosinase precursor,Tyrosinase,,,,HLA-C*05:01,Cited reference,ELISPOT,1,2,1.0
1141232,FQETHLPI,,,,,neo-epitope,FQETHKNNPI,Calpain-7,HLA-B*39:01,MHC binding prediction,ELISPOT,1,4,0.75
1852966,FQQEIQILK,,,,,neo-epitope,FQREIQILK,Tyrosine-protein kinase JAK3,HLA-A*11:02,Cited reference,ELISA,0,2,0.0
1861345,FQYFRATYPL,,,,,neo-epitope,FEYFRATYPL,"Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase",HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1658492,FRFFATPAL,,,,,neo-epitope,FRFSATPAL,Sodium channel protein type 4 subunit alpha,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1658493,FRFFTRKSL,,,,,neo-epitope,FRFFTRESL,Sodium channel protein,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1852968,FRHSLVVPY,,,,,neo-epitope,FRHSVVVPY,Cellular tumor antigen p53,HLA-C*07:02,Cited reference,ELISA,0,2,0.0
1658505,FRICPIFVF,,,,,neo-epitope,FRIRPIFVF,DNA repair protein-complementing XP-G cells,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1658530,FRMFLTQGF,,,,,neo-epitope,FRMFPTQGF,Histone acetyltransferase KAT2A,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1658543,FRQSLYLKI,,,,,neo-epitope,FRQSSYLKI,,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1861349,FRYLSLQDI,,,,,neo-epitope,FRYLPLQDI,F-box only protein 38,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1861353,FSELPFLLLY,,,,,neo-epitope,FSELPFLPLY,Nuclear receptor-interacting protein 2,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1861356,FSPGAANLF,,,,,neo-epitope,SSPGAANLF,Zinc finger FYVE domain-containing protein 26,HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
1852972,FTAAALAGH,,,,,neo-epitope,FSAAALAGH,Endothelial transcription factor GATA-2,HLA-A*11:02,Cited reference,ELISA,0,2,0.0
1861358,FTAEDLAPK,,,,,neo-epitope,STAEDLAPK,Protein HEG homolog 1,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
1397708,FTDEKVKAY,,,,,neo-epitope,LTDEKVKAY,Phosphodiesterase,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1861359,FTDRRDAFDF,,,,,neo-epitope,FTDRGDAFDF,Adaptin ear-binding coat-associated protein 1,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1713770,FTGQFVSEEV,,,,,neo-epitope,FTGQFVTEEV,Saccharopine dehydrogenase-like oxidoreductase,HLA-A*02:06,Cited reference,ELISPOT,0,2,0.0
1852975,FTLMYEERAV,,,,,neo-epitope,FILMYEERAV,Dual specificity mitogen-activated protein kinase kinase 4,HLA-A*02:01,Cited reference,ELISA,1,2,0.5
1400104,FTLVTILL,,,,,neo-epitope,FTLVTVLL,D-glucuronyl C5-epimerase,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1861364,FTVVGDDYY,,,,,neo-epitope,FTVVGDDYH,Voltage-gated hydrogen channel 1,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1861365,FVAAFVNIHL,,,Cysteine rich with EGF like domains 2,,,,,HLA-A*02:02,MHC binding prediction,ELISPOT,0,1,0.0
1861367,FVADWAGTF,,,,,neo-epitope,FVADRAGTF,"Isocitrate dehydrogenase [NADP], mitochondrial",HLA-A*25:01,MHC binding prediction,ELISPOT,0,1,0.0
465397,FVDEIQGRY,344.0,352.0,Baculoviral IAP repeat-containing protein 2,Baculoviral IAP repeat-containing protein 2,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
18159,FVFLRNFSL,27.0,35.0,TCR gamma alternate reading frame protein isoform 1,,,,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
735828,FVGEFFTDV,144.0,152.0,glypican 3,Glypican-3,,,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1397711,FVSTSDIKSM,,,,,neo-epitope,FVSKSDIKSM,"3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial",HLA-C*03:04,MHC binding prediction,ELISPOT,1,2,0.5
1334821,FVTETPLEG,53.0,61.0,cyclin-dependent kinase inhibitor 1 isoform 1 [Homo sapiens],Cyclin-dependent kinase inhibitor 1,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0
1334822,FVTETPLEV,,,,,neo-epitope,FVTETPLEG,Cyclin-dependent kinase inhibitor 1,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
1400125,FVVPYMIYLL,,,,,neo-epitope,YVVPYMIHLL,Sister chromatid cohesion protein PDS5 homolog A,HLA-C*03:03,T cell assay -MHC subset identification,ELISPOT,1,1,1.0
1312519,FWYTHNLI,,,,,neo-epitope,FWYTHNLF,NADPH oxidase 4,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1141640,FWYTHNLIF,,,,,neo-epitope,FWYTHNLFF,NADPH oxidase 4,HLA-C*14:03,MHC binding prediction,ELISPOT,1,4,0.75
1312520,FWYTHNLIFV,,,,,neo-epitope,FWYTHNLFFV,NADPH oxidase 4,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1312521,FWYTHNLIFVF,,,,,neo-epitope,FWYTHNLFFVF,NADPH oxidase 4,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1074748,FYCRPHFTI,,,,,neo-epitope,FHCRPHFTI,Claudin-7,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
18380,FYDPMFKYHL,565.0,574.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5
1074749,FYGKTILWF,,,,,neo-epitope,FYGKTIPWF,Damage-control phosphatase ARMT1,HLA-A*24:02,Single allele present,ELISA,1,2,0.5
1074750,FYGKTIPWF,161.0,169.0,damage-control phosphatase ARMT1 isoform b [Homo sapiens],Damage-control phosphatase ARMT1,,,,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,2,0.0
1066337,FYNDIILMV,,,,,neo-epitope,FYNDIILTV,WD repeat-containing protein 63,HLA-C*06:02,MHC binding prediction,ELISPOT,1,1,1.0
1392835,FYQSVISNPF,,,,,neo-epitope,FYESVISNPF,Neuroblastoma-amplified sequence,HLA-A*24:02,MHC binding prediction,ELISA,0,1,0.0
1397295,"GALNSVLTL + OTH(G1, A2, L9)",,,,,analog,QLLNSVLTL,Retroelement silencing factor 1,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1087525,GAQSWLWFA,2482.0,2490.0,Teneurin-3,Teneurin-3,,,,HLA-A*02:11,MHC binding prediction,ELISPOT,0,2,0.0
1087526,GAQSWLWFV,,,,,neo-epitope,GAQSWLWFA,Teneurin-3,HLA-A*02:11,MHC binding prediction,ELISPOT,1,4,0.5
1870887,GAYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870888,GCYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1853001,GDFGLATEK,,,,,neo-epitope,GDFGLATVK,RAF proto-oncogene serine/threonine-protein kinase,HLA-A*11:01,Cited reference,ELISA,0,2,0.0
1571494,GDNFRETLKKKKRTLVMFYAPWCPH,,,,,neo-epitope,GDNFRETLKKKKHTLVMFYAPWCPH,Protein disulfide-isomerase A5,HLA-B*57:01,MHC binding prediction,ELISPOT,0,1,0.0
1074905,GDRFCLGQLSNAHRT,,,,,neo-epitope,GDRFCLGQLSNVHRT,Mothers against decapentaplegic homolog 4,HLA-A*02:01,Single allele present,ELISPOT,1,5,0.8
1074906,GDRFCLGQLSNVHRT,359.0,373.0,SMAD4,Mothers against decapentaplegic homolog 4,,,,HLA-A*02:01,Single allele present,ELISPOT,0,1,0.0
1870891,GDYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
742500,GEEDGAGGHSL,,,,,neo-epitope,GEEDGAGGHSP,ATP-dependent DNA helicase Q5,HLA-B*44:02,MHC binding prediction,ELISA,1,1,1.0
1861387,GEHDARVSF,,,,,neo-epitope,GEHDARVPF,Zinc finger SWIM domain-containing protein 4,HLA-B*47:01,MHC binding prediction,ELISPOT,0,1,0.0
1853009,GEQDHTFRV,,,,,neo-epitope,GERDHTFRV,Histone-lysine N-methyltransferase 2C,HLA-B*44:03,Cited reference,ELISA,0,2,0.0
1870894,GEYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1853012,GEYFTHQIR,,,,,neo-epitope,GEYFTLQIR,Cellular tumor antigen p53,HLA-B*40:01,Cited reference,ELISA,0,2,0.0
1870896,GFYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870898,GGYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1075327,GHGHSYTTAEEAAGIGILTV,16.0,35.0,Melanoma antigen recognized by T-cells 1,Melanoma antigen recognized by T-cells 1,,,,HLA-B*18:01,Single allele present,ELISPOT,1,1,1.0
1870899,GHYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
954188,GIGIGSGQL,158.0,166.0,Epsin-3,Epsin-3,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
1713867,GIHKQKEKSR,248.0,257.0,Prostatic acid phosphatase precursor,Prostatic acid phosphatase,,,,HLA-A3,Cited reference,ELISPOT,0,2,0.0
1861425,GIIPPSVQV,,,,,neo-epitope,GKIPPSVQV,14-3-3 protein eta,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
20368,GILTVILGV,31.0,39.0,Melanoma antigen recognized by T-cells 1,Melanoma antigen recognized by T-cells 1,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1861429,GIPENSFNV,,,,,neo-epitope,GIPGNSFNV,Lumican,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1853029,GITYEYRPSK,,,,,neo-epitope,GITYEDRPSK,Interleukin-6 receptor subunit beta,HLA-A*30:01,Cited reference,ELISA,0,2,0.0
1870901,GIYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870906,GKYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870907,GLADGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1392855,GLAPGLPSG,33.0,41.0,XK-related protein 4,XK-related protein 4,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1392856,GLAPGLPSV,,,,,neo-epitope,GLAPGLPSG,XK-related protein 4,HLA-A*02:01,MHC binding prediction,ELISPOT,0,2,0.0
20767,GLAPPQHLIRV,187.0,197.0,Cellular tumor antigen p53,Cellular tumor antigen p53,,,,HLA-A2,Not determined,ELISPOT,1,1,1.0
1870908,GLCDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870909,GLDDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1334848,GLDGAVDMG,,,,,neo-epitope,GLDGAVDMG,Aldehyde dehydrogenase family 16 member A1,HLA-A*02:01,MHC binding assay,ELISPOT,1,4,0.5
1870910,GLEDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1391846,GLEEAQFWLA,21.0,30.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1540503,GLEPTTMV,,,,,neo-epitope,GLEPTTTV,Paired box protein Pax-3,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1870911,GLFDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1870912,GLGDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
954207,GLGIGALVL,61.0,69.0,"Cytochrome c oxidase assembly factor 3 homolog, mitochondrial","Cytochrome c oxidase assembly factor 3 homolog, mitochondrial",,,,HLA-A2,Cited reference,ELISA,1,1,1.0
954208,GLGIGIASM,182.0,190.0,Proton myo-inositol cotransporter,Proton myo-inositol cotransporter,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
1078646,GLGKGTYGV,,,,,neo-epitope,GVGKGTYGV,WD repeat-containing protein 7,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
606734,GLGPGFSSY,,,,,neo-epitope,GLGPGFSGY,Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein,HLA-B*15:01,T cell assay -Biological process measured,ELISPOT,1,2,1.0
1870913,GLHDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
772699,GLHLRLTSL,152.0,160.0,Necdin,Necdin,,,,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1870915,GLIDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870916,GLKDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1397713,GLLDEAKRLLY,,,,,neo-epitope,GLLDEAQRLLY,,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
742501,GLLDEDFYA,,,,,neo-epitope,GPLDEDFYA,UDP-glucose:glycoprotein glucosyltransferase 2,HLA-A*02:01,MHC binding prediction,ELISA,1,1,1.0
1870917,GLLDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1853058,GLLFLHTRTI,,,Serine/threonine-protein kinase 36,,,,,HLA-A2,Cited reference,ELISA,1,4,1.0
1336794,GLLNSIWPL,,,,,neo-epitope,GLLNSTWPL,Protein FAM86C1,HLA-A*02:01,Single allele present,ELISPOT,1,1,1.0
1870918,GLLVHPQWV,,,,,analog,GVLVHPQWV,Prostate-specific antigen,HLA-A*02:01,Cited reference,ELISPOT,1,2,1.0
1870919,GLMDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870920,GLNDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1397714,GLNVPVQSNK,,,,,neo-epitope,GRNVPVQSNK,Probable E3 ubiquitin-protein ligase HERC6,HLA-A*03:01,MHC binding prediction,ELISPOT,0,2,0.0
1870921,GLPDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1861448,GLPGFVAAFV,,,Cysteine rich with EGF like domains 2,,,,,HLA-A*02:02,MHC binding prediction,ELISPOT,0,1,0.0
1861449,GLPWSFLGWL,,,,,neo-epitope,GLPWSFPGWL,Galactocerebrosidase,HLA-A*02:02,MHC binding prediction,ELISPOT,0,1,0.0
1870922,GLQDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1392184,GLQLGVQAV,229.0,237.0,Serine protease hepsin,Serine protease hepsin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1870923,GLRDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870924,GLSDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870925,GLTDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870926,GLVDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870927,GLWDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870928,GLYAGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870929,GLYCGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870930,GLYDAMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870931,GLYDCMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870932,GLYDDMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870933,GLYDEMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870934,GLYDFMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870935,GLYDGAEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1870936,GLYDGCEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870937,GLYDGDEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870938,GLYDGEEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870939,GLYDGFEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870940,GLYDGGEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1870941,GLYDGHEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870942,GLYDGIEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870943,GLYDGKEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870944,GLYDGLEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1870945,GLYDGMAHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870946,GLYDGMCHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870947,GLYDGMDHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870948,GLYDGMEAL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1870949,GLYDGMECL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870950,GLYDGMEDL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870951,GLYDGMEEL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870952,GLYDGMEFL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870953,GLYDGMEGL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1870954,GLYDGMEHA,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1870955,GLYDGMEHC,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870956,GLYDGMEHD,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870957,GLYDGMEHE,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870958,GLYDGMEHF,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870959,GLYDGMEHG,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870960,GLYDGMEHH,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870961,GLYDGMEHI,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870962,GLYDGMEHK,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
189401,GLYDGMEHL,254.0,262.0,melanoma-associated antigen 10 [Homo sapiens],Melanoma-associated antigen 10,,,,HLA-A*02:01,Cited reference,ELISPOT,1,3,1.0
1870963,GLYDGMEHM,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870964,GLYDGMEHN,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870965,GLYDGMEHP,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870966,GLYDGMEHQ,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1870967,GLYDGMEHR,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870968,GLYDGMEHS,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1870969,GLYDGMEHT,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870970,GLYDGMEHV,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870971,GLYDGMEHW,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870972,GLYDGMEHY,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870973,GLYDGMEIL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870974,GLYDGMEKL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870975,GLYDGMELL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870976,GLYDGMEML,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870977,GLYDGMENL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1870978,GLYDGMEPL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1870979,GLYDGMEQL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870980,GLYDGMERL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870981,GLYDGMESL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1870982,GLYDGMETL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1870983,GLYDGMEVL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870984,GLYDGMEWL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870985,GLYDGMEYL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870986,GLYDGMFHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870987,GLYDGMGHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870988,GLYDGMHHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870989,GLYDGMIHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870990,GLYDGMKHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870991,GLYDGMLHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870992,GLYDGMMHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870993,GLYDGMNHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870994,GLYDGMPHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870995,GLYDGMQHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1870996,GLYDGMRHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870997,GLYDGMSHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870998,GLYDGMTHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1870999,GLYDGMVHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1871000,GLYDGMWHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871001,GLYDGMYHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871002,GLYDGNEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871003,GLYDGPEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1871004,GLYDGQEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871005,GLYDGREHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871006,GLYDGSEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871007,GLYDGTEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871008,GLYDGVEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871009,GLYDGWEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871010,GLYDGYEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871011,GLYDHMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1871012,GLYDIMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1871013,GLYDKMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871014,GLYDLMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1871015,GLYDMMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871016,GLYDNMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871017,GLYDPMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1871018,GLYDQMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871019,GLYDRMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871020,GLYDSMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1871021,GLYDTMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1871022,GLYDVMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871023,GLYDWMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871024,GLYDYMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871025,GLYEGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871026,GLYFGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871027,GLYGGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871028,GLYHGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871029,GLYIGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871030,GLYKGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871031,GLYLGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871032,GLYMGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1871033,GLYNGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5
1871034,GLYPGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871035,GLYQGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871036,GLYRGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871037,GLYSGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871038,GLYTGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1853076,GLYVFRNER,,,,,neo-epitope,GLYIFRNER,Breast cancer type 2 susceptibility protein,HLA-A*31:01,Cited reference,ELISA,1,2,0.5
1871039,GLYVGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871040,GLYWGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1871041,GLYYGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1312575,GMLCSFQTPDA,,,,,neo-epitope,GMLCSFQIPDA,DDB1- and CUL4-associated factor 4-like protein 2,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
126153,GMMRWCMPV,131.0,139.0,"peptidase, U32 family",,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1392861,GMNWRPILTI,,,,,neo-epitope,GMNRRPILTI,Cellular tumor antigen p53,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1871042,GMYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1871044,GNYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1861458,GPAPVGTLSF,,,,,neo-epitope,GPAPVGTPSF,Ankyrin repeat and KH domain-containing protein 1,HLA-B*07:02,MHC binding prediction,ELISPOT,0,1,0.0
542448,GPMKEINLAPDSSSVVV,1854.0,1870.0,Fibronectin,Fibronectin,,,,HLA-B*07:02,MHC binding prediction,ELISPOT,0,2,0.0
1099612,GPRLLLPCPM,,,,,neo-epitope,GPRLFLPCPM,Neuron navigator 3,HLA-B*35:01,MHC binding prediction,ELISPOT,0,1,0.0
1312594,GPTFNCLLDM,,,,,neo-epitope,GPTFNYLLDM,DNA topoisomerase 2-alpha,HLA-B*35:01,MHC binding prediction,ELISPOT,0,1,0.0
1309759,GPWGFSHGA,311.0,319.0,Trinucleotide repeat-containing gene 6A protein,Trinucleotide repeat-containing gene 6A protein,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,1,1,1.0
1871045,GPYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
742502,GQFLTPNSH,,,,,neo-epitope,GQFLAPNSH,Transcription factor Dp-2,HLA-B*15:01,MHC binding prediction,ELISA,1,1,1.0
1400317,GQVPYNYI,,,,,neo-epitope,GQVPYNYN,"Spectrin beta chain, non-erythrocytic 1",HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1309760,GQWGFSHGA,,,,,neo-epitope,GPWGFSHGA,Trinucleotide repeat-containing gene 6A protein,HLA-B*27:05,MHC binding prediction,ELISPOT,1,1,1.0
1871047,GQYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1861468,GRANDLVKY,281.0,289.0,Melanoma-associated antigen D2,Melanoma-associated antigen D2,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1861469,GRANDLVKYL,281.0,290.0,Melanoma-associated antigen D2,Melanoma-associated antigen D2,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
844616,GRIAFFLKY,,,,,neo-epitope,GRIAFSLKY,Synaptotagmin-like protein 4,HLA-B*27:05,MHC binding assay,ELISA,1,2,0.5
795803,GRIAFSLKY,358.0,366.0,Synaptotagmin-like protein 4,Synaptotagmin-like protein 4,,,,HLA-B*27:05,MHC binding assay,ELISA,0,1,0.0
1087536,GRKLFGTHF,,,,,neo-epitope,GRKLFGTPF,Terminal uridylyltransferase 4,HLA-B*27:05,MHC binding prediction,ELISPOT,1,3,0.6666666666666666
1087537,GRKLFGTPF,1258.0,1266.0,Terminal uridylyltransferase 4,Terminal uridylyltransferase 4,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,1,2,0.5
1853113,GRMRSLEAL,,,,,neo-epitope,GRMRCLEAL,Serine/threonine-protein kinase mTOR,HLA-B*39:01,Cited reference,ELISA,0,2,0.0
1861475,GRNDDVKCF,299.0,307.0,Baculoviral IAP repeat-containing protein 2,Baculoviral IAP repeat-containing protein 2,,,,HLA-C*07:01,MHC binding prediction,ELISPOT,0,1,0.0
1662627,GRWALHSAF,,,,,neo-epitope,GRWALHSAS,Protein sidekick-2,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1871048,GRYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1861480,GRYPHLLEQL,350.0,359.0,Baculoviral IAP repeat-containing protein 2,Baculoviral IAP repeat-containing protein 2,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1309762,GSILAYLVV,,,,,neo-epitope,ASILAYLVV,P2X purinoceptor,HLA-C*15:02,MHC binding prediction,ELISPOT,1,1,1.0
1312610,GSKRAVTK,,,,,neo-epitope,GSKKAVTK,Histone H2B type 1-C/E/F/G/I,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1853120,GSLHSGTAK,,,,,neo-epitope,GFLHSGTAK,Cellular tumor antigen p53,HLA-A*11:01,Cited reference,ELISA,0,2,0.0
1391853,GSQDSGAPGEAMETLGRAQRCDDSPAP,,,,,neo-epitope,GSQDSGAPGEAMERLGRAQRCDDSPAP,Regulator of nonsense transcripts 3A,HLA-A*33:03,MHC binding prediction,ELISPOT,1,1,1.0
1312613,GSSPFQHLEK,,,,,neo-epitope,GSNPFQHLEK,Coatomer subunit gamma-2,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1853125,GSVSFGTVY,,,,,neo-epitope,GSGSFGTVY,RAF proto-oncogene serine/threonine-protein kinase,HLA-C*14:03,Cited reference,ELISA,0,2,0.0
1871049,GSYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1334571,GTAAIQAHYK,199.0,208.0,Transcription factor SOX-10,Transcription factor SOX-10,,,,HLA-A*03:01,MHC binding prediction,ELISPOT,1,2,0.5
542571,GTDPQLLLY,1612.0,1620.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,3,0.0
1629692,GTIGIFWFV,,,,,neo-epitope,GTIGIFWFL,Sialin,HLA-A2,MHC binding assay,ELISA,1,1,1.0
1397721,GTKKDVDVLK,,,,,neo-epitope,GTKEDVDVLK,Replication termination factor 2,HLA-A*03:01,MHC binding prediction,ELISPOT,1,2,0.5
1397722,GTKPNPHVY,,,,,neo-epitope,GTKPNPQVY,2'-5'-oligoadenylate synthase 3,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1871050,GTYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1594980,GVADVLLYR,,,,,neo-epitope,GVADALLYR,"Cytochrome c oxidase subunit 7A2, mitochondrial",HLA-A*11:01,MHC binding prediction,ELISPOT,1,1,1.0
1861503,GVFDGAASV,,,,,neo-epitope,GAFDGAASV,Slit homolog 3 protein,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1397321,"GVLNSVLTL + OTH(G1, V2, L9)",,,,,analog,QLLNSVLTL,Retroelement silencing factor 1,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1861505,GVPPAVASL,2150.0,2158.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1861507,GVPVSERSL,59.0,67.0,Baculoviral IAP repeat-containing protein 2,Baculoviral IAP repeat-containing protein 2,,,,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1397726,GVSKIIGGNPK,,,,,neo-epitope,GVSKIIGGDPK,WD repeat-containing protein 1,HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
23214,GVYDGEEHSV,231.0,240.0,Melanoma-associated antigen B2,Melanoma-associated antigen B2,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1871052,GVYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1871053,GWYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
23503,GYYDAQKLL,298.0,306.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5
1871054,GYYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1853141,HCFNDVTAI,,,,,neo-epitope,QCFNDVTAI,Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas,HLA-A*32:01,Cited reference,ELISA,0,2,0.0
1861519,HDHFRVLAL,2021.0,2029.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1594985,HDLGRLHSC,,,,,neo-epitope,HDLGRLHPC,"All-trans-retinol 13,14-reductase",HLA-B*37:01,T cell assay -Mismatched MHC molecules,ELISPOT,1,2,1.0
1336862,HEIHIGYL,,,,,neo-epitope,HEILIGYL,CREB-binding protein,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0
1336863,HEIHIGYLEY,,,,,neo-epitope,HEILIGYLEY,CREB-binding protein,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0
1336864,HEIHIGYLEYV,,,,,neo-epitope,HEILIGYLEYV,CREB-binding protein,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0
1336865,HESRTNTAI,,,,,neo-epitope,HESRTNTDI,Myocyte-specific enhancer factor 2B,HLA-B*40:01,Single allele present,ELISPOT,1,2,1.0
1336866,HESRTNTAIL,,,,,neo-epitope,HESRTNTDIL,Myocyte-specific enhancer factor 2B,HLA-B*40:01,Single allele present,ELISPOT,1,3,0.6666666666666666
1070225,HIAKSLFEV,,,,,neo-epitope,HIAKSPFEV,Filamin-A,HLA-A*02:01,Single allele present,ELISPOT,1,3,0.6666666666666666
954321,HIGIGLLSL,1051.0,1059.0,"proteasome (prosome, macropain) activator subunit 4",Proteasome activator complex subunit 4,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
1309769,HIHCLNPPL,472.0,480.0,chromodomain-helicase-DNA-binding protein 4,Chromodomain-helicase-DNA-binding protein 4,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1309770,HIHCVNPPL,,,,,neo-epitope,HIHCLNPPL,Chromodomain-helicase-DNA-binding protein 3,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1397727,HIKIEPVAI,,,,,neo-epitope,HIKTEPVAI,Krueppel-like factor 5,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1309771,HIMPDTAEI,,,,,neo-epitope,HIMPDTPEI,Nebulin,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1861527,HLARHRHLM,,,,,neo-epitope,HPARHRHLM,Testis-expressed protein 2,HLA-A*66:01,MHC binding prediction,ELISPOT,0,2,0.0
1334574,HLEDFLLHI,,,,,neo-epitope,HLEDFLLRI,Gamma-tubulin complex component 6,HLA-A*02:10,MHC binding prediction,ELISPOT,0,1,0.0
1596648,HLIDSNTLQV,,,,,neo-epitope,HLIDPNTLQV,60S ribosomal export protein NMD3,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
844902,HLLLRIQEL,387.0,395.0,Microphthalmia-associated transcription factor,Microphthalmia-associated transcription factor,,,,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1146659,HLLSVEYQI,,,,,neo-epitope,HLLSVGYQI,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1392898,HLNGLLREA,1668.0,1676.0,ranBP2-like and GRIP domain-containing protein 4,RanBP2-like and GRIP domain-containing protein 4,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1392899,HLNGLLREV,,,,,neo-epitope,HLNGLLREA,RanBP2-like and GRIP domain-containing protein 4,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1312650,HLNRAMLHK,,,,,neo-epitope,HLNRATLHK,Tetratricopeptide repeat protein 5,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1861530,HLRAWFVSL,,,,,neo-epitope,HPRAWFVSL,Protein FAM171A2,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1861531,HLYAYHEEL,,,,,neo-epitope,HLYAYHEEP,Activating transcription factor 7-interacting protein 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1871055,HLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1125066,HMTEVVRHC,,,,,neo-epitope,HMTEVVRRC,Cellular tumor antigen p53,HLA-A*02:01,T cell assay -Mismatched MHC molecules,ELISPOT,1,3,1.0
1125065,HMTEVVRHC + AIB(C9),1.0,9.0,"Chain P, peptide from p53 tumor suppressor",,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1861533,HPAPPAPPPA,,,,,neo-epitope,LPAPPAPPPA,Protein PRRC2A,HLA-B*56:01,MHC binding prediction,ELISPOT,0,1,0.0
1853186,HPLCGYHEQV,,,,,neo-epitope,Epidermal growth factor receptor precursor,,HLA-B*07:02,Cited reference,ELISA,0,2,0.0
1312657,HPQASSAVGF,,,,,neo-epitope,HPQAGSAVGF,Voltage-dependent N-type calcium channel subunit alpha,HLA-B*35:01,MHC binding prediction,ELISPOT,0,1,0.0
1861535,HPRAVTGFLW,,,,,neo-epitope,HPRAVTGFSW,DmX-like protein 2,HLA-B*07:02,MHC binding prediction,ELISPOT,0,1,0.0
1861538,HQFHVHPLL,,,,,neo-epitope,HRFHVHPKS,Protocadherin alpha-C1,HLA-B*41:02,MHC binding prediction,ELISPOT,0,1,0.0
742503,HQNPVTGLLL,,,,,neo-epitope,HQNPVTGLLP,"Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform",HLA-B*38:01,MHC binding prediction,ELISA,1,1,1.0
1853192,HRGCSIWPR,,,,,neo-epitope,Proto-oncogene tyrosine-protein kinase receptor Ret,,HLA-A*33:01,Cited reference,ELISA,0,2,0.0
1075374,HRRGSRSYV,190.0,198.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-C*06:02,Single allele present,ELISPOT,1,2,1.0
1664909,HRYFFFVAM,,,,,neo-epitope,HRYSFFVAM,Lysophospholipid acyltransferase 1,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1861541,HRYHLLRLEK,224.0,233.0,"5,6-dihydroxyindole-2-carboxylic acid oxidase","5,6-dihydroxyindole-2-carboxylic acid oxidase",,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1594989,HSCVMASLR,,,,,neo-epitope,HPCVMASLR,"All-trans-retinol 13,14-reductase",HLA-A*68:01,Single allele present,ELISPOT,1,1,1.0
1853193,HSHFWDNSK,,,,,neo-epitope,RSHFWDNSK,Exostosin-1,HLA-A*31:01,Cited reference,ELISA,0,2,0.0
1397731,HSKPEDTDAW,,,,,neo-epitope,HSKPEDTDTW,,HLA-B*57:01,MHC binding prediction,ELISPOT,0,1,0.0
1397733,HSPFTATSL,,,,,neo-epitope,HAPFTATSL,Putative HERC2-like protein 3,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1312667,HSRNTHLGK,,,,,neo-epitope,HSRNRHLGK,Activity-dependent neuroprotector homeobox protein 2,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1312668,HSRNTHLGKK,,,,,neo-epitope,HSRNRHLGKK,Activity-dependent neuroprotector homeobox protein 2,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1312669,HSRNTHLGKKK,,,,,neo-epitope,HSRNRHLGKKK,Activity-dependent neuroprotector homeobox protein 2,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1312670,HSSKKVMRTK,,,,,neo-epitope,HSNKKVMRTK,Inactive carboxypeptidase-like protein X2,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1400690,HSVSSAFKK,,,,,neo-epitope,HSVSSAFKN,Formin-2,HLA-A*03:01,MHC binding prediction,ELISPOT,1,1,1.0
1397734,HSYSELCTW,,,,,neo-epitope,DSYSELCTW,Transcription initiation factor TFIID subunit 2,HLA-B*57:01,MHC binding prediction,ELISPOT,0,1,0.0
1392912,HTFNCRMFMK,,,,,neo-epitope,HTFNCRMLMK,Nuclear receptor coactivator 3,HLA-A*11:01,MHC binding prediction,ELISA,0,1,0.0
1574044,HTGEKPYRCKVCGTAFTWHSQLARH,,,,,neo-epitope,HTGEKPYRCKVCDTAFTWHSQLARH,,HLA-A*32:01,MHC binding prediction,ELISPOT,1,2,0.5
1861552,HTHYDYVSAL,,,,,neo-epitope,HTHYDHVSAL,Protein CASC1,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
1861553,HTLGAASSF,,,,,neo-epitope,HTLGAASPF,SET-binding protein,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
1861554,HTLGAASSFM,,,,,neo-epitope,HTLGAASPFM,SET-binding protein,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
1391858,HVCAVFIFYV,245.0,254.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,0,1,0.0
1101093,HVKITDFGR,,,,,neo-epitope,HVKITDFGL,Receptor tyrosine-protein kinase erbB-2,HLA-A*31:01,Cited reference,ELISA,1,4,0.5
1101094,HVKITDFGRAK,,,,,neo-epitope,HVKITDFGLAK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,1,3,0.6666666666666666
1392920,HVYYFFSKR,,,,,neo-epitope,HVYYFFPKR,Guanylate cyclase soluble subunit alpha-1,HLA-A*31:01,MHC binding prediction,ELISA,0,1,0.0
1066368,HYHLANDIYF,,,,,neo-epitope,RYHLANDIYF,Zinc finger MYND domain-containing protein 12,HLA-A*24:02,MHC binding prediction,ELISPOT,0,1,0.0
1714010,HYRKWIKDTI,248.0,257.0,Prostate-specific antigen precursor,Prostate-specific antigen,,,,HLA-A24,Cited reference,ELISA,1,7,0.7142857142857143
1312681,HYTAQIILAL,,,,,neo-epitope,HSTAQIILAL,Olfactory receptor 4C11,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1711657,HYTNASDGL,208.0,216.0,Tyrosine-protein kinase Lck,Tyrosine-protein kinase Lck,,,,HLA-A*24:02,Cited reference,ELISA,1,8,0.625
1853209,IAAISEQVRF,,,,,neo-epitope,IAAIREQVRF,Membrane-bound transcription factor site-2 protease,HLA-C*03:03,Cited reference,ELISA,0,2,0.0
1397736,IAASRSVVM,,,,,neo-epitope,IAASRSAVM,Uncharacterized protein C1orf198,HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
954407,IAGLGLLTV,178.0,186.0,transmembrane protein 74B isoform 1,Transmembrane protein 74B,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
1309777,IAMAVLYLA,,,,,neo-epitope,IAVAVLYLA,Cyclin-Q,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1861567,IAYAPEPNQK,,,,,neo-epitope,IVYAPEPNQK,Neuropilin-2,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1397737,IEHNIRNAKY,,,,,neo-epitope,IEHNIRNDKY,Protein polybromo-1,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1397738,IEVEVNEI,,,,,neo-epitope,IEGEVNEI,eEF1A lysine and N-terminal methyltransferase,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1397739,IFDLAGGTF,,,,,neo-epitope,IFDLGGGTF,Heat shock cognate 71 kDa protein,HLA-C*02:02,MHC binding prediction,ELISPOT,0,1,0.0
1397740,IFDLAGGTFDV,,,,,neo-epitope,IFDLGGGTFDV,Heat shock cognate 71 kDa protein,HLA-C*02:02,MHC binding prediction,ELISPOT,0,1,0.0
1861585,IFKSIMRQRL,,,,,neo-epitope,ISKSIMRQRL,T-box transcription factor TBX4,HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
1853231,IFQEMFDKHYK,,,,,neo-epitope,IFQEIFDKHYK,"Isocitrate dehydrogenase [NADP], mitochondrial",HLA-A*33:01,Cited reference,ELISA,1,2,0.5
1871062,IFVELVNAL,170.0,178.0,Histone-lysine N-methyltransferase EZH2,Histone-lysine N-methyltransferase EZH2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,1,1.0
1312696,IFWYTHNLIF,,,,,neo-epitope,IFWYTHNLFF,NADPH oxidase 4,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1853234,IGDFGLATEK,,,,,neo-epitope,IGDFGLATVK,RAF proto-oncogene serine/threonine-protein kinase,HLA-A*11:01,Cited reference,ELISA,0,2,0.0
1148341,IHSTAQIIL,152.0,160.0,Olfactory receptor 4C11,Olfactory receptor 4C11,,,,HLA-B*39:01,MHC binding prediction,ELISPOT,1,1,1.0
1148345,IHYTAQIIL,,,,,neo-epitope,IHSTAQIIL,Olfactory receptor 4C11,HLA-B*39:01,MHC binding prediction,ELISPOT,1,4,0.5
1312700,IHYTAQIILAL,,,,,neo-epitope,IHSTAQIILAL,Olfactory receptor 4C11,HLA-B*39:01,MHC binding prediction,ELISPOT,0,1,0.0
710791,IIDDRNREL,11.0,19.0,"peroxiredoxin 6, partial [Homo sapiens]",Peroxiredoxin-6,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
1861600,IIGSVSKEK,,,,,neo-epitope,IIGSVSKEE,Amyloid-like protein 2,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1392943,IISKLYIPK,368.0,376.0,Ankyrin repeat domain-containing protein 36A,Ankyrin repeat domain-containing protein 36A,,,,HLA-A*11:02,MHC binding prediction,ELISPOT,0,1,0.0
1853260,IKLIPGVSTT,,,,,neo-epitope,IKLIPGVSIT,PMS1 protein homolog 1,HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1391861,ILANIYLLV,276.0,284.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,T cell assay -T cell subset identification,ELISA,1,2,1.0
1125072,ILCETCLIV,,,,,neo-epitope,ILCGTCLIV,PH domain leucine-rich repeat-containing protein phosphatase 1,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1125069,ILCETCLIV + AIB(C3),,,,,neo-epitope,ILCGTCLIV,PH domain leucine-rich repeat-containing protein phosphatase 1,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1125070,"ILCETCLIV + AIB(C3, C6)",,,,,neo-epitope,ILCGTCLIV,PH domain leucine-rich repeat-containing protein phosphatase 1,HLA-A*02:01,MHC binding assay,ELISA,0,1,0.0
1125071,ILCETCLIV + AIB(C6),,,,,neo-epitope,ILCGTCLIV,PH domain leucine-rich repeat-containing protein phosphatase 1,HLA-A*02:01,MHC binding assay,ELISA,0,1,0.0
1391862,ILDASKQRHNKLWCQQTDSSLQQPVDD,,,,,neo-epitope,ILDASKQRHNKLWRQQTDSSLQQPVDD,Protein phosphatase Slingshot homolog 1,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
859010,ILDKVLVHL,,,,,neo-epitope,ILDKVLVHP,"ATP-dependent Clp protease proteolytic subunit, mitochondrial",HLA-A*02:01,Single allele present,ELISA,1,2,1.0
969054,ILDTAGKEEY,,,,,neo-epitope,ILDTAGQEEY,GTP-binding protein GEM,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
954454,ILEGIGILAV,815.0,824.0,Anoctamin-3,Anoctamin-3,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
954455,ILEGIGILSV,773.0,782.0,anoctamin-4 isoform 1,Anoctamin,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
1714066,ILEQSGEWWK,90.0,99.0,Tyrosine-protein kinase Lck,Tyrosine-protein kinase Lck,,,,HLA-A33,Cited reference,ELISPOT,1,5,0.6
1067282,ILEYLTAEV,58.0,66.0,Histone H2A.Z,Histone H2A.Z,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
1861611,ILFEEANGRL,,,,,neo-epitope,IPFEEANGRL,Sentrin-specific protease 6,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1714067,ILGELREKV,120.0,128.0,Negative elongation factor A,Negative elongation factor A,,,,HLA-A2,Cited reference,ELISA,1,7,0.7142857142857143
954460,ILLGIGIYAL,61.0,70.0,transmembrane and coiled-coil domain-containing protein 2 [Homo sapiens],Transmembrane and coiled-coil domain-containing protein 2,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
1861614,ILMHGLVSL,,,,,neo-epitope,YLMHGLVSL,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1861618,ILRTLQQIKK,,,,,neo-epitope,VLRTLQQIKK,Phospholipid-transporting ATPase ABCA1,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
859018,ILTGLNYEV,,,,,neo-epitope,ILTGLNYEA,"Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating",HLA-A*02:01,Single allele present,ELISA,1,1,1.0
1391863,ILWDGFTGQRSKVSQEHEKRCWSVDFN,,,,,neo-epitope,ILWDGFTGQRSKVYQEHEKRCWSVDFN,E3 ubiquitin-protein ligase COP1,HLA-B*58:01,MHC binding prediction,ELISPOT,0,1,0.0
1310498,ILWIFSIYL,,,,,neo-epitope,ILWTFSIYL,ER lumen protein-retaining receptor 3,HLA-A*02:01,Single allele present,ELISA,1,2,1.0
1310499,ILWTFSIYL,118.0,126.0,ER lumen protein-retaining receptor 3 isoform a,ER lumen protein-retaining receptor 3,,,,HLA-A*02:01,Single allele present,ELISA,0,1,0.0
1871066,ILYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1087560,IMACVGFFL,7.0,15.0,Killer cell immunoglobulin-like receptor 2DS4,Killer cell immunoglobulin-like receptor 2DS4,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
27469,IMDQVPFSV,,,,,neo-epitope,ITDQVPFSV,Melanocyte protein PMEL,HLA-A*02:01,MHC binding assay,ELISA,1,4,0.75
83735,IMLEGETKL,76.0,84.0,ssDNA-binding phosphoprotein,Protein I3,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1084935,IMQLMPFGSL,,,,,neo-epitope,TQLMPFGCLL,Epidermal growth factor receptor,HLA-A*02:01,MHC binding assay,ELISPOT,0,1,0.0
1309219,IMQTLAGELY,,,,,neo-epitope,IMQTPAGELY,eIF-2-alpha kinase activator GCN1,HLA-A*29:02,T cell assay -Mismatched MHC molecules,ELISA,1,1,1.0
1309220,IMRTYTYEI,,,,,neo-epitope,IMRTYTYEK,Catenin beta-1 (Fragment),HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1309221,IMRTYTYEK,327.0,335.0,Catenin beta-1,Catenin beta-1,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1312741,IMVDGELY,,,,,neo-epitope,VMVDGELY,Semaphorin-4D,HLA-B*15:01,MHC binding prediction,ELISPOT,0,1,0.0
1397742,IMYLTGMVNK,,,,,neo-epitope,IMYLTGMVDK,Eukaryotic peptide chain release factor GTP-binding subunit ERF3A,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1861624,IPAEHINQA,,,,,neo-epitope,IPAVHINQA,"Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 3",HLA-B*56:01,MHC binding prediction,ELISPOT,0,1,0.0
1861626,IPAMHINQA,,,,,neo-epitope,IPAVHINQA,"Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 3",HLA-B*56:01,MHC binding prediction,ELISPOT,0,1,0.0
1397743,IPASVSAPK,,,,,neo-epitope,SPASVSAPK,Insulin receptor substrate 2,HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
1861628,IPAVKLNKL,,,,,neo-epitope,IPAVKLNEL,Uncharacterized protein KIAA1958,HLA-B*07:02,MHC binding prediction,ELISPOT,0,1,0.0
1861629,IPAVKLNKLL,,,,,neo-epitope,IPAVKLNELL,Uncharacterized protein KIAA1958,HLA-B*07:02,MHC binding prediction,ELISPOT,0,1,0.0
1087564,IPINPRRCL,,,,,neo-epitope,TPINPRRCL,Coatomer subunit gamma-2,HLA-B*07:02,MHC binding prediction,ELISPOT,1,2,0.5
1861631,IPLSDNTIF,,,,,neo-epitope,IPLSDNTIS,Protein FAM200A (Fragment),HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0
1312765,IPVAIKTSP,,,,,neo-epitope,IPVAIKELREATSP,Epidermal growth factor receptor,HLA-B*35:01,Cited reference,ELISA,0,2,0.0
1312766,IPVAIKTSPK,,,,,neo-epitope,IPVAIKELREATSPK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,1,4,0.75
1074935,IPVSSHNSL + GLYC(S4),147.0,155.0,Myocyte-specific enhancer factor 2C,Myocyte-specific enhancer factor 2C,,,,HLA-B*07:02,MHC binding assay,ELISPOT,1,1,1.0
1397744,IQDQIQNCI,,,,,neo-epitope,IQDEIQNCI,Ewing's tumor-associated antigen 1,HLA-B*38:01,MHC binding prediction,ELISPOT,0,1,0.0
1861642,ISDRFIGIY,,,,,neo-epitope,ISDRLIGIY,Structural maintenance of chromosomes protein 4,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1853336,ISFENLDTA,,,,,neo-epitope,ISFENVDTA,Gamma-tubulin complex component,HLA-C*06:02,Cited reference,ELISA,0,2,0.0
1861647,ISIQRAQPL,,,,,neo-epitope,LKLQRAQPL,Probable ATP-dependent RNA helicase DHX58,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1309784,ISLNNAVIEL,,,,,neo-epitope,ISSNNAVIEL,Protein kintoun,HLA-C*15:02,MHC binding prediction,ELISPOT,1,1,1.0
1309785,ISSNNAVIEL,589.0,598.0,Protein kintoun,Protein kintoun,,,,HLA-C*15:02,MHC binding prediction,ELISPOT,1,1,1.0
1861650,ISSQPQVPFY,,,,,neo-epitope,ISSQPQVPFH,Dynamin-binding protein,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1397745,ISTFRQCAL,,,,,neo-epitope,ISTFRQCAR,E3 ubiquitin-protein ligase RNF213,HLA-C*16:01,MHC binding prediction,ELISPOT,0,1,0.0
1312778,ISYLMIALM,,,,,neo-epitope,ISYLMIALT,Protein FAM162A,HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
1312779,ISYLMIALMVV,,,,,neo-epitope,ISYLMIALTVV,Protein FAM162A,HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
1334581,ITAEIFMEK,,,,,neo-epitope,ITAETFMEK,Growth arrest-specific protein 2,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1861653,ITAPSLSGK,,,,,neo-epitope,TTAPSLSGK,Catenin beta-1 (Fragment),HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1861656,ITDAHELGV,,,,,neo-epitope,ITAAHELGV,Transmembrane protein 260,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1861657,ITDAHELGVA,,,,,neo-epitope,ITAAHELGVA,Transmembrane protein 260,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
430645,ITDEFVKQKY,416.0,425.0,Melanoma-associated antigen D2,Melanoma-associated antigen D2,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1853345,ITDFGRAKL,,,,,neo-epitope,ITDFGLAKL,Epidermal growth factor receptor,HLA-C*04:01,Cited reference,ELISA,1,4,0.75
28864,ITDQVPFSV,209.0,217.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,7,0.8571428571428571
1397746,ITEEPILMTY,,,,,neo-epitope,IPEEPILMTY,Retinitis pigmentosa 1-like 1 protein,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
28958,ITKKVADLVGF,102.0,112.0,Melanoma-associated antigen 1,Melanoma-associated antigen 1,,,,HLA-B*57:01,MHC binding prediction,ELISPOT,1,2,1.0
1861668,ITQKYDFFFY,,,,,neo-epitope,ITQKYDFSFY,Monocarboxylate transporter 14,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
910592,ITSAIGILPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
910593,ITSAIGVLFV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
910594,ITSAIGVLPI,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
910595,ITSAIGVLPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
910596,ITSGIGVLPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
1853353,ITYEYRPSK,,,,,neo-epitope,ITYEDRPSK,Interleukin-6 receptor subunit beta,HLA-A*30:01,Cited reference,ELISA,0,2,0.0
1853354,ITYEYRPSKA,,,,,neo-epitope,ITYEDRPSKA,Interleukin-6 receptor subunit beta,HLA-A*30:01,Cited reference,ELISA,0,2,0.0
1397747,IVFIATSEF,,,,,neo-epitope,IVFNATSEF,Hom s 1,HLA-B*15:03,MHC binding prediction,ELISPOT,0,1,0.0
1336996,IVMEYLAFL,,,,,neo-epitope,IVMEYLALL,Anoctamin-6,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
29466,IVTDFSVIK,416.0,424.0,EBNA3B (EBNA4A) latent protein,Epstein-Barr nuclear antigen 4,,,,HLA-A11,Cited reference,ELISPOT,0,1,0.0
1383151,IVVSFQEEMKWKENSRPHLFLIGCIGV,,,,,neo-epitope,IVVSFQEEMKWKEDSRPHLFLIGCIGV,Neuron navigator 2,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0
1074762,IYIGVSVPI,,,,,neo-epitope,ISIGVSVPI,5-hydroxytryptamine receptor 2C,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
859044,IYKAPCENW,,,,,neo-epitope,IYKAPSENW,DNA (cytosine-5)-methyltransferase 1,HLA-A*24:02,MHC binding prediction,ELISPOT,1,2,1.0
418245,IYKAPSENW,191.0,199.0,"Chain A, Dna (cytosine-5)-methyltransferase 1",DNA (cytosine-5)-methyltransferase 1,,,,HLA-A*24:02,MHC binding prediction,ELISPOT,0,1,0.0
1861676,IYLHGSTDKL,,,,,neo-epitope,IYPHGSTDKL,Proteasome subunit beta type-7,HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
1074763,IYLLQYVTL,,,,,neo-epitope,IYLLQYATL,Transformation/transcription domain-associated protein (Fragment),HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1397748,IYTSSGQLQLF,,,,,neo-epitope,IYTSSEQLQLF,Cilia- and flagella-associated protein 70,HLA-A*24:02,MHC binding prediction,ELISPOT,0,1,0.0
1074764,IYVRPFSNF,,,,,neo-epitope,IYVWPFTNF,Olfactory receptor 4K3,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1312791,KADAKALL,,,,,neo-epitope,KADAKPLL,Phosphate-regulating neutral endopeptidase PHEX,HLA-C*05:01,MHC binding prediction,ELISPOT,0,1,0.0
1312792,KADAKALLHI,,,,,neo-epitope,KADAKPLLHI,Phosphate-regulating neutral endopeptidase PHEX,HLA-C*05:01,MHC binding prediction,ELISPOT,0,1,0.0
1312793,KADAKALLHIL,,,,,neo-epitope,KADAKPLLHIL,Phosphate-regulating neutral endopeptidase PHEX,HLA-C*05:01,MHC binding prediction,ELISPOT,0,1,0.0
1853371,KAEDLGMLLK,,,,,neo-epitope,KAEDRGMLLK,Transcription activator BRG1,HLA-A*11:01,Cited reference,ELISA,0,2,0.0
1312795,KAGECGLK,,,,,neo-epitope,KAGERGLK,Collagen alpha-1(XVI) chain,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1312797,KAIESFLEK,,,,,neo-epitope,KARESFLEK,SMC5-SMC6 complex localization factor protein 2,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1862892,KAQVSNEDCL,18.0,27.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*24:02,MHC binding prediction,ELISA,1,1,1.0
1853378,KARLPVGAY,,,,,neo-epitope,KALLPVGAY,Aquaporin-12B,HLA-A*03:01,Cited reference,ELISA,1,2,0.5
451342,KASEKIFYV,41.0,49.0,Protein SSX2,Protein SSX2,,,,HLA-A*02:01,Cited reference,ELISPOT,1,2,1.0
1853397,KELLKHPFTL,,,,,neo-epitope,KELLKHPFIL,Dual specificity mitogen-activated protein kinase kinase 4,HLA-A*02:01,Cited reference,ELISA,1,2,0.5
1861696,KEWEDSQLV,,,,,neo-epitope,KECEDSQLV,Probable ATP-dependent RNA helicase DDX60,HLA-B*40:02,MHC binding prediction,ELISPOT,0,1,0.0
1861697,KEWEDSQLVS,,,,,neo-epitope,KECEDSQLVS,Probable ATP-dependent RNA helicase DDX60,HLA-B*40:02,MHC binding prediction,ELISPOT,0,1,0.0
1861698,KEYPVIFKSI,,,,,neo-epitope,KEYPVISKSI,T-box transcription factor TBX4,HLA-B*41:02,MHC binding prediction,ELISPOT,0,1,0.0
1861699,KFGDLTNNF,,,,,neo-epitope,KFGDLTDNF,Double-stranded RNA-specific editase 1,HLA-A*24:02,MHC binding prediction,ELISPOT,0,1,0.0
619431,KHGDVITII,83.0,91.0,"cell proliferation antigen Ki-67, short form - human",Proliferation marker protein Ki-67,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0
31235,KIFGSLAFL,369.0,377.0,HER2 receptor,Receptor protein-tyrosine kinase,,,,HLA-A*02:01,Cited reference,ELISA,1,2,1.0
1312825,KIFIEWLK,,,,,neo-epitope,KIFIEWMK,"Acetyl-coenzyme A synthetase, cytoplasmic",HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
584787,KIFNFYPRK,,,,,neo-epitope,KIFNLYPRK,Dihydropyrimidinase-related protein 1,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
859062,KIFSEVTLK,,,,,neo-epitope,KIFSEVTPK,NAD-dependent protein deacetylase sirtuin-2,HLA-A*03:01,MHC binding prediction,ELISPOT,1,1,1.0
1861714,KIIAYQPYGK,,,,,neo-epitope,EIIAYQPYGK,Protein kinase C beta type,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1861715,KIIGSVSKEK,,,,,neo-epitope,KIIGSVSKEE,Amyloid-like protein 2,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
859065,KILDAVVAQK,,,,,neo-epitope,KILDAVVAQE,116 kDa U5 small nuclear ribonucleoprotein component,HLA-A*03:01,MHC binding prediction,ELISPOT,1,1,1.0
1853435,KIPVAITSPK,,,,,neo-epitope,KIPVAIKELREATSPK,Epidermal growth factor receptor,HLA-A*11:02,Cited reference,ELISA,0,2,0.0
1104681,KITDFGRAK,,,,,neo-epitope,KITDFGLAK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,1,4,1.0
1670615,KIYAAGTFY,,,,,neo-epitope,KIHAAGTFY,,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1861729,KKYDFGTQL,,,,,neo-epitope,KEYDFGTQL,E3 ubiquitin-protein ligase RNF220,HLA-B*47:01,MHC binding prediction,ELISPOT,0,1,0.0
1391865,KLACDDIRV,188.0,196.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1312857,KLCEANQQQQF,,,,,neo-epitope,KLREANQQQQF,"Spectrin alpha chain, non-erythrocytic 1",HLA-B*15:01,MHC binding prediction,ELISPOT,0,1,0.0
31776,KLCPVQLWV,,,,,analog,KTCPVQLWV,Cellular tumor antigen p53,HLA-A2,Not determined,ELISPOT,1,1,1.0
1337051,KLCRTVIAAA,,,,,neo-epitope,ELCRTVIAAA,Proto-oncogene tyrosine-protein kinase receptor Ret,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1861734,KLFESKAEL,,,,,neo-epitope,QLFESKAEL,Histone-lysine N-methyltransferase MECOM,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1861735,KLFESKAELA,,,,,neo-epitope,QLFESKAELA,Histone-lysine N-methyltransferase MECOM,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1397755,KLFHDMNVSY,,,,,neo-epitope,KLFHDMNVNY,"Glutaredoxin-2, mitochondrial",HLA-A*29:02,MHC binding prediction,ELISPOT,0,1,0.0
1334928,KLGDVITII,,,,,neo-epitope,KHGDVITII,Proliferation marker protein Ki-67,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
954646,KLGIGFAKA,830.0,838.0,sodium channel alpha subunit,Sodium channel protein type 4 subunit alpha,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
846039,KLILWRGLK,,,,,neo-epitope,KPILWRGLK,Condensin-2 complex subunit G2,HLA-A*03:01,MHC binding assay,ELISA,1,2,0.5
1853452,KLIPGVSTT,,,,,neo-epitope,KLIPGVSIT,PMS1 protein homolog 1,HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1863998,KLKAIPTTL,,,,,neo-epitope,KLKAIPTTI,PH domain leucine-rich repeat-containing protein phosphatase 1,HLA-A*02:01,MHC binding prediction,ELISA,1,2,0.5
1861741,KLKFVTLVF,,,,,neo-epitope,ELKFVTLVF,Prostatic acid phosphatase,HLA-A*24:02,MHC binding prediction,ELISPOT,1,2,1.0
1714208,KLKHYGPGWV,129.0,138.0,Peptidyl-prolyl cis-trans isomerase B,Peptidyl-prolyl cis-trans isomerase B,,,,HLA-A2,Cited reference,ELISA,1,12,0.5833333333333334
846041,KLKLPIIMK,,,,,neo-epitope,KLKLPMIMK,A-kinase anchor protein 6,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1861744,KLLENFYVT,,,,,neo-epitope,ELLENFYVT,Uncharacterized protein KIAA1958,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1861745,KLLENFYVTV,,,,,neo-epitope,ELLENFYVTV,Uncharacterized protein KIAA1958,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1312863,KLLMSQANV,,,,,neo-epitope,KLVMSQANV,Hom s 2,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
31987,KLLMVLMLA,2.0,10.0,Mammaglobin-A precursor,Mammaglobin-A,,,,HLA-A2,Not determined,ELISPOT,1,1,1.0
1861748,KLNFRLFVI,,,,,neo-epitope,KLNSRLFVI,Cryptochrome-1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1861749,KLNFRLFVIR,,,,,neo-epitope,KLNSRLFVIR,Cryptochrome-1,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
989936,KLQCVDLHV,170.0,178.0,Prostate-specific antigen precursor,Prostate-specific antigen,,,,HLA-A2,MHC binding assay,ELISA,1,2,0.5
1397763,KLSEQILKK,,,,,neo-epitope,KLSQQILKK,Toll-like receptor 5,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1863999,KLSPQQDAGV,,,,,neo-epitope,KLSPQQDAGG,G-protein coupled receptor family C group 5 member D,HLA-A*02:01,MHC binding prediction,ELISA,0,2,0.0
1711658,KLVERLGAA,246.0,254.0,lymphocyte-specific protein tyrosine kinase,Tyrosine-protein kinase Lck,,,,HLA-A2,Cited reference,ELISPOT,1,11,0.7272727272727273
1087578,KLVVVGACGV,,,,,neo-epitope,KLVVVGAGGV,GTP-binding protein GEM,HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1070772,KLVVVGADGV,,,,,neo-epitope,KLVVVGAGGV,GTP-binding protein GEM,HLA-A*02:03,MHC binding prediction,ELISPOT,1,1,1.0
175610,KLVVVGAGGV,5.0,14.0,GTPase KRas,GTP-binding protein GEM,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,3,0.0
958663,KLVVVGAVGV,,,,,neo-epitope,KLVVVGAGGV,GTP-binding protein GEM,HLA-A*02:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666
1871084,KLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1671227,KLYQCNECK,,,,,neo-epitope,KSYQCNECK,,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
954663,KMGIGWKPL,793.0,801.0,Uncharacterized protein C2orf71,Photoreceptor cilium actin regulator,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
1861757,KMIENESPL,,,,,neo-epitope,KMIENESPS,SET-binding protein,HLA-A*02:02,MHC binding prediction,ELISPOT,0,1,0.0
1671258,KMKNFFFTK,,,,,neo-epitope,KMKNFFSTK,4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase 9,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1312873,KMVEAMATGI,,,,,neo-epitope,KMVEAMATEI,Adhesion G-protein coupled receptor G4,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862895,KNITCCDTDL,73.0,82.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*24:02,MHC binding prediction,ELISA,0,1,0.0
1383672,KNKTLVPTIPRETLAPLRQLLLALLQR,,,,,neo-epitope,KNKTLVPTIPRETSAPLRQLLLALLQR,Serine/threonine-protein kinase ULK1,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1383673,KNKTLVPTIPRETSAPLRQLLLALLQR,235.0,261.0,serine/threonine kinase ULK1 [Homo sapiens],Serine/threonine-protein kinase ULK1,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1595039,KPFCVLISL,,,,,neo-epitope,KPFRVLISL,Protein dopey-2,HLA-B*07:02,Cited reference,ELISPOT,1,2,0.5
846158,KPILWRGLK,332.0,340.0,Condensin-2 complex subunit G2,Condensin-2 complex subunit G2,,,,HLA-A*03:01,MHC binding assay,ELISA,0,1,0.0
1853508,KPPKAKPSPTY,,,,,neo-epitope,KPPKAKPASTV,Phosphatidylinositol 3-kinase regulatory subunit beta,HLA-B*07:02,Cited reference,ELISA,0,2,0.0
1595041,KPSDTPRPVM,,,,,neo-epitope,KPPDTPRPVM,Histone-lysine N-methyltransferase 2C,HLA-B*07:02,Cited reference,ELISPOT,1,2,0.5
1861763,KPSPLAPAA,,,,,neo-epitope,KPSPPAPAA,Formin-1,HLA-B*07:02,MHC binding prediction,ELISPOT,0,1,0.0
1861764,KPSPLAPAAL,,,,,neo-epitope,KPSPPAPAAL,Formin-1,HLA-B*07:02,MHC binding prediction,ELISPOT,0,1,0.0
1861765,KQAKVVNPPI,30.0,39.0,alternative protein DHX40 [Homo sapiens],,,,,HLA-B*27:02,MHC binding prediction,ELISPOT,0,2,0.0
1870794,KQCPCYLAV,569.0,577.0,Histone-lysine N-methyltransferase EZH2,Histone-lysine N-methyltransferase EZH2,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1671737,KQFSAMALK,,,,,neo-epitope,KQFPAMALK,Serine/threonine-protein kinase Sgk3,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1714242,KQHGFASI,,,,,neo-epitope,KQHGFASF,Store-operated calcium entry-associated regulatory factor (Fragment),HLA-A*02:06,Cited reference,ELISPOT,1,2,0.5
1861768,KQIASIQEF,,,,,neo-epitope,KQIASIQES,Brefeldin A-inhibited guanine nucleotide-exchange protein 1,HLA-B*47:01,MHC binding prediction,ELISPOT,0,1,0.0
1714247,KQSVSPPV,,,,,neo-epitope,KQSVSPPI,TBC1 domain family member 9B,HLA-A*02:06,Cited reference,ELISPOT,0,2,0.0
1383799,KQWLVWLAL,,,,,neo-epitope,KQWLVWLLL,Protein-cysteine N-palmitoyltransferase HHAT,HLA-A*02:06,MHC binding assay,ELISA,0,1,0.0
1087593,KQWLVWLFL,,,,,neo-epitope,KQWLVWLLL,Protein-cysteine N-palmitoyltransferase HHAT,HLA-A*02:06,MHC binding prediction,ELISPOT,1,5,0.8
1383800,KQWLVWLFL + MCM(W6),,,,,analog,KQWLVWLLL,Protein-cysteine N-palmitoyltransferase HHAT,HLA-A*02:06,MHC binding assay,ELISA,0,1,0.0
1087594,KQWLVWLLL,68.0,76.0,Protein-cysteine N-palmitoyltransferase HHAT,Protein-cysteine N-palmitoyltransferase HHAT,,,,HLA-A*02:06,MHC binding prediction,ELISPOT,1,3,0.6666666666666666
1383801,KQWLVWLLL + MCM(W6),,,,,analog,KQWLVWLLL,Protein-cysteine N-palmitoyltransferase HHAT,HLA-A*02:06,MHC binding assay,ELISA,0,1,0.0
1671871,KRFLHRQPL,,,,,neo-epitope,KRFPHRQPL,"39S ribosomal protein L38, mitochondrial",HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1671892,KRHEVPVPL,,,,,neo-epitope,KRYEVPVPL,"Sucrase-isomaltase, intestinal",HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1334586,KRIPLPPHLC,,,,,neo-epitope,ERIPLPPHLC,Prickle planar cell polarity protein 3,HLA-C*06:02,Single allele present,ELISPOT,1,2,0.5
1861772,KRIYTGEKPY,,,,,neo-epitope,KRIHTGEKPY,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1861773,KRMSVIVRTL,,,,,neo-epitope,KRMSVIVRTP,Phospholipid-transporting ATPase IB,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1671929,KRPIPIKYKAM,,,,,neo-epitope,KRLIPIKYKAM,Myeloid differentiation primary response protein MyD88,HLA-B*07:02,Single allele present,ELISA,1,1,1.0
1671940,KRRLLILGR,,,,,neo-epitope,KRRLLILGG,Claudin-22,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1861775,KRRWSALVI,62.0,70.0,alternative protein DHX40 [Homo sapiens],,,,,HLA-B*27:02,MHC binding prediction,ELISPOT,1,1,1.0
1671963,KRTNVGILK,,,,,neo-epitope,ERTNVGILK,Desmoglein-1,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1853526,KSAVLASNSQF,,,,,neo-epitope,KSAVLVSNSQF,Tubulin delta chain,HLA-B*57:01,Cited reference,ELISA,0,2,0.0
1312904,KSEALKLFL,,,,,neo-epitope,KAEALKLFL,Apolipoprotein B-100,HLA-C*05:01,MHC binding prediction,ELISPOT,0,1,0.0
445973,KSFEDIHHY,88.0,96.0,GTPase KRas,GTP-binding protein GEM,,,,HLA-C*07:01,MHC binding prediction,ELISPOT,0,1,0.0
1861776,KSLANFGGW,,,,,neo-epitope,KSLANSGGW,Coiled-coil domain-containing protein 61,HLA-B*57:01,MHC binding prediction,ELISPOT,0,1,0.0
1125082,KSPNPSTPC,,,,,neo-epitope,KSPNPSTPR,Ribosomal L1 domain-containing protein 1,HLA-C*01:02,Cited reference,ELISA,1,1,1.0
1125081,KSPNPSTPC + AIB(C9),,,,,neo-epitope,KSPNPSTPR,Ribosomal L1 domain-containing protein 1,HLA-C*01:02,Cited reference,ELISA,1,1,1.0
1595047,KSQREFVRR,,,,,neo-epitope,ESQREFVRR,Cytosolic iron-sulfur assembly component 3,HLA-A*31:01,T cell assay -Mismatched MHC molecules,ELISPOT,1,3,0.6666666666666666
1853536,KSSPFTAAA,,,,,neo-epitope,KSSPFSAAA,Endothelial transcription factor GATA-2,HLA-C*15:02,Cited reference,ELISA,0,2,0.0
33623,KTCPVQLWV,139.0,147.0,Cellular tumor antigen p53,Cellular tumor antigen p53,,,,HLA-A2,Not determined,ELISPOT,1,1,1.0
1853540,KTKPVHSSL,,,,,neo-epitope,KTKPVLSSL,Mediator of RNA polymerase II transcription subunit 12,HLA-B*15:27,Cited reference,ELISA,0,2,0.0
1312911,KTLGPIWK,,,,,neo-epitope,KTLGPILK,Interferon-related developmental regulator 1,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1312913,KTNRIALI,,,,,neo-epitope,KTNRIARI,Metabotropic glutamate receptor 2,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1312914,KTNRIALILA,,,,,neo-epitope,KTNRIARILA,Metabotropic glutamate receptor 1,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1312916,KTQIKLHLSPK,,,,,neo-epitope,KTQIKLHLSAK,Coiled-coil domain-containing protein 150,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1312922,KTSPKANKEI,,,,,neo-epitope,KELREATSPKANKEI,Epidermal growth factor receptor,HLA-B*57:01,Cited reference,ELISA,0,2,0.0
1853541,KTSSGLYVFR,,,,,neo-epitope,KTSSGLYIFR,Breast cancer type 2 susceptibility protein,HLA-A*31:01,Cited reference,ELISA,0,2,0.0
33915,KTWGQYWQV,154.0,162.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*02:01,Cited reference,ELISA,1,2,1.0
1383989,KTYNGYWNTPLLPNKSYRIYFQAASRA,,,,,neo-epitope,KTYNGYWNTPLLPYKSYRIYFQAASRA,Receptor-type tyrosine-protein phosphatase mu,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1672464,KTYPCKIFY,,,,,neo-epitope,KTYPCKISY,Protein-glutamine gamma-glutamyltransferase 5,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1853543,KTYQVSYGFR,,,,,neo-epitope,KTYQGSYGFR,Cellular tumor antigen p53,HLA-A*31:01,Cited reference,ELISA,1,2,0.5
1079584,KVDPIGHVY,,,,,neo-epitope,EVDPIGHVY,Melanoma-associated antigen 6 (Fragment),HLA-A*30:02,MHC binding prediction,ELISPOT,1,1,1.0
1852274,KVETYKEQPL,110.0,119.0,Parathyroid hormone-related protein,Parathyroid hormone-related protein,,,,HLA-A*24:02,Single allele present,ELISA,1,2,1.0
1397781,KVFKLGNKV,,,,,neo-epitope,EVFKLGNKV,DNA polymerase,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1334589,KVFRGNKVK,207.0,215.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*11:01,MHC binding prediction,ELISPOT,1,2,0.5
1672567,KVINLSPFK,,,,,neo-epitope,KVINLSPFE,Coiled-coil domain-containing protein 7,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1397782,KVLGKGSFAK,,,,,neo-epitope,KVLGKGGFAK,Serine/threonine-protein kinase PLK,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1672623,KVMTDPSRK,,,,,neo-epitope,KAMTDPSRK,Ubiquitin carboxyl-terminal hydrolase 37,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1861790,KVPIKRSEM,489.0,497.0,Melanoma-associated antigen D1,Melanoma-associated antigen D1,,,,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1397785,KVTGHRWLK,,,,,neo-epitope,EVTGHRWLK,Basigin,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1397786,KVVLPSDVTSY,,,,,neo-epitope,KVVLPSDVTRY,Collagen alpha-1(VII) chain,HLA-A*32:01,MHC binding prediction,ELISPOT,0,1,0.0
859097,KVYEGVWKK,,,,,neo-epitope,EVYEGVWKK,Tyrosine-protein kinase ABL1,HLA-A*03:01,MHC binding assay,ELISPOT,1,6,0.6666666666666666
1853556,KWIHCFNDV,,,,,neo-epitope,KWIQCFNDV,Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas,HLA-A*24:02,Cited reference,ELISA,0,2,0.0
34344,KYADKIYSI,606.0,614.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5
1074767,KYAFITWLV,,,,,neo-epitope,NYAFITWLV,Transmembrane protein 45A,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
34349,KYAGESFPGI,699.0,708.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,1.0
1391872,KYAVAVGSLCALSSSLLGSMFPMPRVI,,,,,neo-epitope,KYAVAVGSLCALSASLLGSMFPMPRVI,High affinity cationic amino acid transporter 1,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1075431,KYDCFLHPF,291.0,299.0,Histone-lysine N-methyltransferase EZH2,Histone-lysine N-methyltransferase EZH2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,1,1.0
1397788,KYINKTIRV,,,,,neo-epitope,KYIDKTIRV,U6 snRNA-associated Sm-like protein LSm7,HLA-A*24:02,MHC binding prediction,ELISPOT,0,1,0.0
1397789,KYINKTIRVKF,,,,,neo-epitope,KYIDKTIRVKF,U6 snRNA-associated Sm-like protein LSm7,HLA-A*24:02,MHC binding prediction,ELISPOT,0,1,0.0
1871089,KYKELTEQQL,243.0,252.0,Histone-lysine N-methyltransferase EZH2,Histone-lysine N-methyltransferase EZH2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,1,1.0
1074768,KYLQCPLKF,,,,,neo-epitope,KYLQCPLEF,Transient receptor potential cation channel subfamily A member 1,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1075435,KYVGIEREM,735.0,743.0,Histone-lysine N-methyltransferase EZH2,Histone-lysine N-methyltransferase EZH2,,,,HLA-A24,Cited reference,ELISPOT,1,3,0.6666666666666666
1861797,LADFRLARLY,,,,,neo-epitope,LADFGLARLY,Cyclin-dependent kinase 13,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1853569,LAECKDSLL,,,,,neo-epitope,LAECKGSLL,Androgen receptor,HLA-C*08:01,Cited reference,ELISA,0,2,0.0
1397798,LAGGTFDV,,,,,neo-epitope,LGGGTFDV,Heat shock cognate 71 kDa protein,HLA-C*02:02,MHC binding prediction,ELISPOT,0,1,0.0
1309843,LASYFFWGL,,,,,neo-epitope,LASHFFWGL,Ethanolamine kinase 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1087605,LDYEGGTVTF,493.0,502.0,Tripartite motif-containing protein 26,Tripartite motif-containing protein 26,,,,HLA-B*15:01,MHC binding prediction,ELISPOT,0,2,0.0
1087606,LDYEWGTVTF,,,,,neo-epitope,LDYEGGTVTF,Tripartite motif-containing protein 26,HLA-B*15:01,Single allele present,ELISPOT,1,2,0.5
1334591,LEEEINRKM,,,,,neo-epitope,LEEEINRRM,Receptor-type tyrosine-protein phosphatase alpha,HLA-B*40:01,MHC binding prediction,ELISPOT,0,1,0.0
1853632,LEFENKQAL,,,,,neo-epitope,SEFENKQAL,Serine-protein kinase ATM,HLA-B*40:01,Cited reference,ELISA,0,2,0.0
1397811,LELKAVHAY,,,,,neo-epitope,LELKAVPAY,V-type proton ATPase 116 kDa subunit a isoform 4,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1384378,LFFNDLEDCDQIHIDDVSSDDNGQDLS,,,,,neo-epitope,LFFNDLEDCDQIHVDDVSSDDNGQDLS,Eyes absent homolog 2,HLA-B*40:02,MHC binding prediction,ELISPOT,1,1,1.0
1397813,LFHDMNVSY,,,,,neo-epitope,LFHDMNVNY,"Glutaredoxin-2, mitochondrial",HLA-A*29:02,MHC binding prediction,ELISPOT,0,1,0.0
1596691,LFHTFYELL,,,,,neo-epitope,LFHTFYDLL,NLR family CARD domain-containing protein 4,HLA-A*24:02,MHC binding prediction,ELISPOT,0,1,0.0
1861839,LFHTFYELLI,,,,,neo-epitope,LFHTFYDLLI,NLR family CARD domain-containing protein 4,HLA-A*24:02,MHC binding prediction,ELISPOT,0,1,0.0
1397814,LFQQGKDLQQY,,,,,neo-epitope,RFQQGKDLQQY,E3 ubiquitin-protein ligase RNF213,HLA-A*29:02,MHC binding prediction,ELISPOT,0,1,0.0
1861840,LFRIKFKEPL,,,,,neo-epitope,LYRIKFKESF,"Cytochrome c oxidase subunit 4 isoform 1, mitochondrial",HLA-B*08:01,MHC binding prediction,ELISPOT,1,1,1.0
1861842,LFSPGAANLF,,,,,neo-epitope,LSSPGAANLF,Zinc finger FYVE domain-containing protein 26,HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
1334973,LFSTAEAAV,304.0,312.0,cyclin-G-associated kinase isoform X15 [Homo sapiens],Cyclin-G-associated kinase,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
1397815,LFVVFQTVY,,,,,neo-epitope,LFVVFLTVY,Olfactory receptor 10J5,HLA-A*29:02,MHC binding prediction,ELISPOT,0,1,0.0
954846,LGIGVITI,,,Immunoglobulin heavy chain,,,,,HLA-A2,Cited reference,ELISA,1,2,1.0
1853672,LGPMGGSLTL,,,,,neo-epitope,LGPMGGGLTL,Histone-lysine N-methyltransferase 2A,HLA-B*51:01,Cited reference,ELISA,0,2,0.0
1853678,LGSLHSGTAK,,,,,neo-epitope,LGFLHSGTAK,Cellular tumor antigen p53,HLA-A*11:01,Cited reference,ELISA,0,2,0.0
1384471,LGTFIWNKALEKKAISHLEEKELKERN,,,,,neo-epitope,LGTFIWNKALEKKGISHLEEKELKERN,,HLA-A*11:02,MHC binding prediction,ELISPOT,0,1,0.0
1312979,LGVVESAK,,,,,neo-epitope,LGVVESGK,Protein capicua homolog,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1391875,LHKNLLVSYVLRNTRQLYLSERYAELY,,,,,neo-epitope,LHKNLLVSYVLRNARQLYLSERYAELY,Immediate early response gene 5-like protein,HLA-A*02:07,MHC binding prediction,ELISPOT,0,1,0.0
1861856,LHSDFVSFLI,,,,,neo-epitope,LHSDFVSSLI,Plexin-A2,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1853691,LIADFLSGLI,,,HCG2044781,,,,,HLA-A2,Cited reference,ELISA,1,4,0.75
1714397,LIDDYGVEEV,,,,,neo-epitope,LIDDYGVEEE,Transcriptional activator protein Pur-alpha,HLA-A*02:06,Cited reference,ELISPOT,1,2,0.5
1861858,LIDSNTLQV,,,,,neo-epitope,LIDPNTLQV,60S ribosomal export protein NMD3,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1397820,LIFDLAGGTF,,,,,neo-epitope,LIFDLGGGTF,Heat shock cognate 71 kDa protein,HLA-C*02:02,MHC binding prediction,ELISPOT,0,1,0.0
954851,LIGIGIAPL,883.0,891.0,iron-responsive element-binding protein 2,Iron-responsive element-binding protein 2,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
954852,LIGIGLNLV,721.0,729.0,Spatacsin,Spatacsin,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
1861862,LIMPVPGILL,584.0,593.0,melanocyte protein PMEL isoform 1 preproprotein,Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1066141,LIMQLMPFGCL,100.0,110.0,"Chain A, Epidermal Growth Factor Receptor",Receptor protein-tyrosine kinase,neo-epitope,LITQLMPFGCL,Epidermal growth factor receptor,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0
1861864,LISGPSVGV,,,,,neo-epitope,SISGPSVGV,Nucleoporin NUP35,HLA-A*02:02,MHC binding prediction,ELISPOT,0,1,0.0
36773,LIYDSSLCDL,83.0,92.0,Mammaglobin-A precursor,Mammaglobin-A,,,,HLA-A2,Not determined,ELISPOT,1,1,1.0
1853717,LKHPFTLMY,,,,,neo-epitope,LKHPFILMY,Dual specificity mitogen-activated protein kinase kinase 4,HLA-C*12:02,Cited reference,ELISA,0,2,0.0
1384624,LKTVSKDLRNKRSNLYGIAKVVQREDV,,,,,neo-epitope,LKTVSKDLRNKRSSLYGIAKVVQREDV,DENN domain-containing protein 4C,HLA-A*11:02,MHC binding prediction,ELISPOT,0,1,0.0
1085428,LLAALVQDYL,,,calcitonin,Calcitonin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0
37088,LLAGLVSLL,491.0,499.0,Tyrosinase precursor,Tyrosinase,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1067642,LLALAAGLAV,8.0,17.0,Arylsulfatase A,Arylsulfatase A,,,,HLA-A*02:01,Single allele present,ELISA,1,1,1.0
1861874,LLALLMAGL,5.0,13.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,0.6666666666666666
1862897,LLALLPALGL,,,prostate stem cell antigen,,,,,HLA-A*02:01,Single allele present,ELISA,1,2,1.0
1391878,LLAMAFDRYV,117.0,126.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,0,1,0.0
1334592,LLAPGGNSM,131.0,139.0,Transcription factor SOX-2,Transcription factor SOX-2,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
37113,LLAVLYCLL,2.0,10.0,Tyrosinase precursor,Tyrosinase,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1334593,LLCKMINLSK,,,,,neo-epitope,LLCKMINLS,Plastin-1,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1861876,LLCRRSRAAL,,,,,neo-epitope,LLCRRSRAAS,Protocadherin beta-8,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1862898,LLCYSCKAQV,12.0,21.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,3,1.0
1861878,LLDKFVEWY,,,,,neo-epitope,LLDEFVEWY,DCN1-like protein 4,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1312992,LLDNSTTGTDV,,,,,neo-epitope,LLDNSTRGTDV,Coiled-coil domain-containing protein 144B,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
106609,LLDVAPLSL,393.0,401.0,Heat shock 70 kDa protein 1,Heat shock 70 kDa protein 1A,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1861879,LLENVTLIY,,,,,neo-epitope,LLENVTLIH,Ubiquitin carboxyl-terminal hydrolase 10,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1861880,LLFAPEYGPK,,,,,neo-epitope,LLSAPEYGPK,TBC1 domain family member 14,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
37257,LLFGYPVYV,11.0,19.0,transcriptional activator Tax,,,,,HLA-A*02:01,Cited reference,ELISPOT,1,3,1.0
1861884,LLFQRFFVI,,,,,neo-epitope,LLFQRFSVI,"Probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase",HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1309852,LLGCVMYTLL,,,,,neo-epitope,SLGCVMYTLL,Serine/threonine-protein kinase PLK3,HLA-A*02:11,MHC binding prediction,ELISPOT,1,2,0.5
1853757,LLGGNSFEV,,,,,neo-epitope,LLGRNSFEV,Cellular tumor antigen p53,HLA-A*02:06,Cited reference,ELISA,0,2,0.0
954862,LLGIGILVL,23.0,31.0,Bone marrow stromal antigen 2,Bone marrow stromal antigen 2,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
954863,LLGIGIYAL,62.0,70.0,transmembrane and coiled-coil domain-containing protein 2 [Homo sapiens],Transmembrane and coiled-coil domain-containing protein 2,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
37364,LLGRNSFEV,264.0,272.0,Cellular tumor antigen p53,Cellular tumor antigen p53,,,,HLA-A2,Not determined,ELISPOT,1,1,1.0
1107872,LLHETDSAV,4.0,12.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*02:01,MHC binding assay,ELISA,1,3,0.6666666666666666
1596699,LLHTELERF,,,,,neo-epitope,LLHTELERS,Dephospho-CoA kinase domain-containing protein,HLA-B*15:01,MHC binding prediction,ELISPOT,0,1,0.0
1071270,LLHTELERFL,,,,,neo-epitope,LLHTELERSL,Dephospho-CoA kinase domain-containing protein,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1631395,LLIAHFLGV,,,,,neo-epitope,VLIAHFLGV,GPI ethanolamine phosphate transferase 3,HLA-A2,MHC binding assay,ELISA,1,1,1.0
1391879,LLILKTVLGL,221.0,230.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1675895,LLINRGFSK,,,,,neo-epitope,LLIDRGFSK,FRAS1-related extracellular matrix protein 1,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1071271,LLKAELVAGL,,,,,neo-epitope,LLKAVLVAGL,ATP-dependent RNA helicase DHX29,HLA-A*02:03,MHC binding prediction,ELISPOT,1,1,1.0
1853770,LLKHPFTLM,,,,,neo-epitope,LLKHPFILM,Dual specificity mitogen-activated protein kinase kinase 4,HLA-A*30:01,Cited reference,ELISA,1,2,0.5
1334597,LLLCGVQAV,,,,,neo-epitope,LLLCGVLAV,Cilia- and flagella-associated protein 70,HLA-A*02:10,MHC binding prediction,ELISPOT,0,1,0.0
1401543,LLLCIPGL,,,,,neo-epitope,LLLCNPGL,"Glycogen phosphorylase, brain form",HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1397843,LLLEVVWHL,,,,,neo-epitope,LLLEAVWHL,Fanconi anemia group A protein,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
954864,LLLGIGILVL,22.0,31.0,Bone marrow stromal antigen 2,Bone marrow stromal antigen 2,,,,HLA-A2,Cited reference,ELISA,1,1,1.0
106610,LLLLDVAPL,391.0,399.0,Heat shock 70 kDa protein 1,Heat shock 70 kDa protein 1A,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
37528,LLLLTVLTV,12.0,20.0,Mucin-1 precursor,,,,,HLA-A2,Not determined,ELISPOT,1,1,1.0
506786,LLLSAEPVPA,19.0,28.0,B-cell antigen receptor complex-associated protein beta chain isoform 1 precursor,B-cell antigen receptor complex-associated protein beta chain,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
1861892,LLLWGPGQL,115.0,123.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
1577808,LLMREVPLRCTISLWDTYQSEPDGF,,,,,neo-epitope,LLMREVPLRCTIRLWDTYQSEPDGF,TBC1 domain family member 22A,HLA-A*01:01,MHC binding prediction,ELISPOT,1,2,0.5
1313003,LLMSQANV,,,,,neo-epitope,LVMSQANV,"Nascent polypeptide-associated complex subunit alpha, muscle-specific form",HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1861893,LLPALGLLL,100.0,108.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,2,0.5
1861894,LLPALSPGL,,,,,neo-epitope,LLPALSPGS,Syntaxin-5,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1074770,LLPPVYLTF,,,,,neo-epitope,PLPPVYLTF,Interleukin-13 receptor subunit alpha-2,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1714430,LLQAEAPRL,302.0,310.0,Squamous cell carcinoma antigen recognized by T-cells 3,Squamous cell carcinoma antigen recognized by T-cells 3,,,,HLA-A2,Cited reference,ELISPOT,1,3,1.0
1871101,LLQERGVAYI,441.0,450.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
1391880,LLQMFAIHSL,100.0,109.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1861895,LLRKHQLIYL,,,,,neo-epitope,LLRKHQLIHL,,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1313011,LLVAAMIGGFV,,,,,neo-epitope,LLVVAMIGGFV,Olfactory receptor 4A5,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1393130,LLVRNSFEV,,,,,neo-epitope,LLGRNSFEV,Cellular tumor antigen p53,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
446263,LLWDYVYQL,148.0,156.0,transcription factor ETV7 isoform 5 [Homo sapiens],Transcription factor ETV7,,,,HLA-A*02:01,MHC binding assay,ELISA,0,1,0.0
1310602,LLWDYVYQLL,148.0,157.0,transcription factor ETV7 isoform 5 [Homo sapiens],Transcription factor ETV7,,,,HLA-A*02:01,MHC binding assay,ELISA,0,1,0.0
37954,LLWSFQTSA,9.0,17.0,Tyrosinase precursor,Tyrosinase,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1871103,LLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1401631,LLYQELLPL,,,,,neo-epitope,LLYQEFLPL,Transformation/transcription domain-associated protein (Fragment),HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
106611,LMGDKSENV,380.0,388.0,Heat shock 70 kDa protein 1,Heat shock 70 kDa protein 1A,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
38060,LMLGEFLKL,,,,,analog,LTLGEFLKL,Baculoviral IAP repeat-containing protein 5,HLA-A*02:01,Not determined,ELISPOT,1,1,1.0
1074771,LMMSLSALF,,,,,neo-epitope,LMMSLPALF,Sodium channel protein type 5 subunit alpha,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1393134,LMRDHMPPV,,,,,neo-epitope,LMRDHVPPV,Sodium-independent sulfate anion transporter,HLA-A*02:03,MHC binding prediction,ELISA,1,1,1.0
38148,LMVLMLAAL,4.0,12.0,Mammaglobin-A precursor,Mammaglobin-A,,,,HLA-A2,Not determined,ELISPOT,1,1,1.0
1861907,LPAIMFFVSA,,,,,neo-epitope,LPAIMFSVSA,Secretory carrier-associated membrane protein 4,HLA-B*56:01,MHC binding prediction,ELISPOT,0,1,0.0
1853870,LPEPDKMLVAV,,,,,neo-epitope,LPEQDKMLVAV,High affinity nerve growth factor receptor,HLA-B*51:01,Cited reference,ELISA,0,2,0.0
1313054,LPMETPLVI,,,,,neo-epitope,LPMETPLVV,Serpin A12,HLA-B*35:01,MHC binding prediction,ELISPOT,0,1,0.0
1861913,LPNEYAFVT,,,,,neo-epitope,LPDEYAFVT,,HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0
1861914,LPNEYAFVTT,,,,,neo-epitope,LPDEYAFVTT,,HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0
1861917,LPSFRPPTAL,,,,,neo-epitope,LPSLRPPTQP,Brevican core protein,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1075469,LPVPGVLLKEFTVSGNILTI,116.0,135.0,Cancer/testis antigen 1,Cancer/testis antigen 1,,,,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0
1861920,LPVTRKNMPL,,,,,neo-epitope,LPVTRKNMPP,E3 ubiquitin-protein ligase DTX4,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1393148,LPWLSAHEL,,,,,neo-epitope,LPSLSAHEL,FERM domain-containing protein 8,HLA-B*35:01,MHC binding prediction,ELISA,0,1,0.0
1334601,LQFEYTFEI,,,,,neo-epitope,LQFEYPFEI,T-cell surface glycoprotein CD1a,HLA-A*02:10,MHC binding prediction,ELISPOT,0,1,0.0
1080391,LQIEEEYQV,236.0,244.0,L protein,,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1085523,LQPYYGFSNQEVIEMVRKRQ,690.0,709.0,Inactive tyrosine-protein kinase transmembrane receptor ROR1,Inactive tyrosine-protein kinase transmembrane receptor ROR1,,,,HLA-A2,MHC binding prediction,ELISPOT,1,2,1.0
1861929,LQRIHHMAA,,,,,neo-epitope,PQRIHHMAA,AF4/FMR2 family member 2,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1861930,LRAAFFGKCF,,,,,neo-epitope,LRAASFGKCF,Vacuolar protein sorting-associated protein 16 homolog,HLA-B*27:05,MHC binding prediction,ELISPOT,1,1,1.0
1861932,LRFNLIANQH,,,,,neo-epitope,LRFNLTANQH,A disintegrin and metalloproteinase with thrombospondin motifs 7,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1677414,LRFSIIEEF,,,,,neo-epitope,LRFSTIEEF,"Chromosome 18 open reading frame 37, isoform CRA_a",HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1861933,LRFSISNLSM,257.0,266.0,Baculoviral IAP repeat-containing protein 2,Baculoviral IAP repeat-containing protein 2,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1853910,LRILKVTEFK,,,,,neo-epitope,LRILKETEFK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,1,2,0.5
1677448,LRILRIKLR,,,,,neo-epitope,LRILRMKLR,Lipase member H,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1861936,LRLNHPAQL,,,,,neo-epitope,LRLNPPAQL,Microtubule-associated protein 1S,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1861937,LRMRGTIFR,,,,,neo-epitope,LRMRGTISR,40S ribosomal protein SA (Fragment),HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1397860,LRNSGGEVF,,,,,neo-epitope,LRDSGGEAF,OTU domain-containing protein 7B,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
716582,LRPGIHHSL,400.0,408.0,Melanoma-associated antigen D2,Melanoma-associated antigen D2,,,,HLA-C*07:01,MHC binding prediction,ELISPOT,0,1,0.0
1335005,LRSEGSPLV,1147.0,1155.0,proto-oncogene [Homo sapiens],Hepatocyte growth factor receptor,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,4,0.75
1401933,LRTKVYAEL,,,,,neo-epitope,LRTKVHAEL,T-complex protein 1 subunit zeta,HLA-B*27:05,MHC binding prediction,ELISPOT,1,1,1.0
1066399,LSDSRPRHL,,,,,neo-epitope,LGDSRPRHL,Disks large-associated protein 4,HLA-C*05:01,MHC binding prediction,ELISPOT,0,1,0.0
568114,LSEKLERI,155.0,162.0,15 kDa selenoprotein,Selenoprotein F,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
1861943,LSEVVLFRY,,,,,neo-epitope,LSEVVLSRY,,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1313094,LSSSVPRK,,,,,neo-epitope,LSSSVPSQ,Cellular tumor antigen p53,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1861952,LTDIDLQLQF,46.0,55.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1397871,LTEKVSLLK,,,,,neo-epitope,LTEKVSLLE,Protein bicaudal D homolog 2,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1067709,LTLLGTLWGA,17.0,26.0,Protocadherin gamma-A6,Protocadherin gamma-A6,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
910612,LTSAIGVLPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
1853980,LTSTVQLIM,,,,,neo-epitope,LTSTVQLIT,Epidermal growth factor receptor,HLA-B*35:01,Cited reference,ELISA,1,5,0.6
1334605,LTVETLTKV,,,,,neo-epitope,LTMETLTKV,Ral GTPase-activating protein subunit alpha-1,HLA-A*02:10,MHC binding prediction,ELISPOT,0,1,0.0
1861964,LVEFLLLKY,148.0,156.0,Melanoma-associated antigen C2,Melanoma-associated antigen C2,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1397890,LVGPAQLSHW,,,,,neo-epitope,LVGPAQPSHW,Plectin,HLA-B*57:01,MHC binding prediction,ELISPOT,0,1,0.0
40382,LVHFLLLKY,116.0,124.0,Melanoma-associated antigen 3,Melanoma-associated antigen 3,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1871120,LVLAGGFFL,26.0,34.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
1578916,LVRAVQFTETFLMERDKQSKWSGIP,,,,,neo-epitope,LVRAVQFTETFLTERDKQSKWSGIP,Short transient receptor potential channel 4-associated protein,HLA-B*44:03,MHC binding prediction,ELISPOT,1,2,0.5
1853999,LVRRSRTYSL,,,,,neo-epitope,LVRRSRTDSL,Insulin receptor substrate 2,HLA-B*07:02,Cited reference,ELISA,0,2,0.0
1334606,LVRRTLLHA,26.0,34.0,IQ domain-containing protein F5,IQ domain-containing protein F5,,,,HLA-C*15:02,Single allele present,ELISPOT,1,1,1.0
1334607,LVRRTLLHV,,,,,neo-epitope,LVRRTLLHA,IQ domain-containing protein F5,HLA-C*15:02,Single allele present,ELISPOT,1,2,0.5
1397900,LVVVGASGVGK,,,,,neo-epitope,LVVVGAGGVGK,GTP-binding protein GEM,HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
1397901,LVYGPLGAGK,,,,,neo-epitope,LVYGPSGAGK,Replication factor C subunit 3,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1385288,LYASGTTPVPQLPLLLMALLGLCMLVL,,,,,neo-epitope,LYASGTTPVPQLPLLLMALLGLCTLVL,Acid sphingomyelinase-like phosphodiesterase 3b,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1714544,LYAWEPSFL,503.0,511.0,Canalicular multispecific organic anion transporter 2,Canalicular multispecific organic anion transporter 2,,,,HLA-A24,Cited reference,ELISPOT,1,3,0.6666666666666666
1714545,LYCESVHNF,213.0,221.0,Prostatic acid phosphatase precursor,Prostatic acid phosphatase,,,,HLA-A24,Cited reference,ELISPOT,1,7,0.7142857142857143
1074773,LYNAGLFLW,,,,,neo-epitope,LYHAGLFLW,Tetratricopeptide repeat protein 21B,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
40868,LYNFTQIPHL,74.0,83.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5
1402151,LYNGMEHLI,,,,,neo-epitope,LYDGMEHLI,Melanoma-associated antigen 10,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0
753263,LYPEFIASI,,,,,neo-epitope,LYPELIASI,Probable C-mannosyltransferase DPY19L4,HLA-A*24:02,Single allele present,ELISPOT,1,3,1.0
753264,LYPELIASI,139.0,147.0,Probable C-mannosyltransferase DPY19L4,Probable C-mannosyltransferase DPY19L4,,,,HLA-A*24:02,Single allele present,ELISPOT,0,2,0.0
40944,LYSDPADYF,227.0,235.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,0,2,0.0
1074774,LYWHVSHDF,,,,,neo-epitope,LYRHVSHDF,F-box only protein 46,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1074775,LYYEYWSNF,,,,,neo-epitope,LYYEYWSTF,Proto-oncogene Mas,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1393178,MAASLPPTL,,,,,neo-epitope,MAASFPPTL,V(D)J recombination-activating protein 1,HLA-C*12:02,MHC binding prediction,ELISA,0,1,0.0
1861982,MAGPKGFQY,,,,,neo-epitope,MAGPEGFQY,Phosphatidylinositol 3-kinase regulatory subunit beta,HLA-B*35:01,MHC binding prediction,ELISPOT,0,1,0.0
1313135,MALNSEALSV,,,,,neo-epitope,MALNS,Transmembrane protease serine 2 (Fragment),HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1313136,MALTASTVPL,,,,,neo-epitope,MALTASPVPL,Metal transporter CNNM2,HLA-C*03:03,MHC binding prediction,ELISPOT,0,1,0.0
1393181,MASGDHSAY,,,,,neo-epitope,MASGDYSAY,Forkhead box protein B1,HLA-B*35:01,MHC binding prediction,ELISA,0,1,0.0
1854029,MASVDNPLM,,,,,neo-epitope,MASVDNPHV,Epidermal growth factor receptor,HLA-B*15:11,Cited reference,ELISA,0,2,0.0
1067740,MCQWGRLWQL,,,WD repeat-containing protein BING4,WD repeat-containing protein 46,,,,HLA-A*02:01,T cell assay -Mismatched MHC molecules,ELISA,1,7,1.0
1385387,MDQALVGMCVNERCFVKIPPKLAYGNE,,,,,neo-epitope,MDQALVGMCVNERRFVKIPPKLAYGNE,Peptidyl-prolyl cis-trans isomerase FKBP9,HLA-A*24:02,MHC binding prediction,ELISPOT,0,1,0.0
1313149,MEAVALVGAW,,,,,neo-epitope,MEALALVGAW,Inactive hydroxysteroid dehydrogenase-like protein 1,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1313150,MEAVALVGAWY,,,,,neo-epitope,MEALALVGAWY,Inactive hydroxysteroid dehydrogenase-like protein 1,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
139171,MEIFIEVFSHF,1.0,11.0,Minor histocompatibility protein HMSD variant form,Minor histocompatibility protein HMSD variant form,,,,HLA-B*44:03,T cell assay -Mismatched MHC molecules,ELISA,1,2,1.0
1397910,MELKVESF,,,,,neo-epitope,MQLKVESF,"Type II inositol 1,4,5-trisphosphate 5-phosphatase",HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
544090,MEVDPIGHLY,167.0,176.0,Melanoma-associated antigen 3,Melanoma-associated antigen 3,,,,HLA-B*18:01,Cited reference,ELISPOT,1,4,1.0
1385427,MGFDMQTVAQPQGLEPSELLGMLSSGS,,,,,neo-epitope,MGFDMQTVAQPQGLEPSELLGMLSNGS,Palmitoleoyl-protein carboxylesterase NOTUM,HLA-B*40:02,MHC binding prediction,ELISPOT,0,1,0.0
1861998,MHENFTNLL,,,,,neo-epitope,MLENFTNLL,,HLA-B*38:01,MHC binding prediction,ELISPOT,0,1,0.0
41745,MIMQGGFSV,694.0,702.0,Proto-oncogene DBL,Proto-oncogene DBL,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1862002,MINLRRLLL,259.0,267.0,Melanoma antigen preferentially expressed in tumors,Melanoma antigen preferentially expressed in tumors,,,,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1862005,MLAEKTVQV,,,,,neo-epitope,MPAEKTVQV,Phospholipase B-like 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1337343,MLAEQLKQA,,,,,neo-epitope,KLAEQLKQA,Neuroblastoma breakpoint family member 9,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
41953,MLGTHTMEV,178.0,186.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1334611,MLICCCCTL,,,,,neo-epitope,LICCCCTL,Solute carrier family 12 member 4,HLA-A*02:10,MHC binding prediction,ELISPOT,1,1,1.0
753265,MLIGIPVYV,,,,,neo-epitope,MVIGIPVYV,E3 ubiquitin-protein ligase RNF19B,HLA-A*02:01,Single allele present,ELISPOT,1,1,1.0
1397918,MLMKNISTK,,,,,neo-epitope,MLMENISTK,Tyrosine-protein phosphatase non-receptor type 6,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1862008,MLQYKKKAAV,,,,,neo-epitope,MLQYKKKAAA,Protein phosphatase 1 regulatory subunit 21,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1337355,MLREEIAML,,,,,neo-epitope,MLREEIAKL,POTE ankyrin domain family member B2,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1385518,MLSLDFLDDVLRMNKRQLYYQVLNFGM,,,,,neo-epitope,MLSLDFLDDVRRMNKRQLYYQVLNFGM,Signal peptidase complex catalytic subunit SEC11A,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1385519,MLSLDFLDDVRRMNKRQLYYQVLNFGM,1.0,27.0,signal peptidase complex catalytic subunit SEC11A isoform 2 [Homo sapiens],Signal peptidase complex catalytic subunit SEC11A,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1871124,MLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1854086,MMMWDCWHA,,,,,neo-epitope,MMMRDCWHA,Fibroblast growth factor receptor 2,HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1854087,MMMWDCWHAV,,,,,neo-epitope,MMMRDCWHAV,Fibroblast growth factor receptor 2,HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1635981,MMNDQLMFL,663.0,671.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A2,Cited reference,ELISA,0,1,0.0
1397933,MMPPLPGI,,,,,neo-epitope,MMPPQPGI,BUB3-interacting and GLEBS motif-containing protein ZNF207,HLA-B*51:01,MHC binding prediction,ELISPOT,0,1,0.0
1854092,MMWDCWHAV,,,,,neo-epitope,MMRDCWHAV,Fibroblast growth factor receptor 2,HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1862011,MNDHALHILY,,,,,neo-epitope,MNDHAPHILY,Protocadherin alpha-C2,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1854098,MNLRPILTI,,,,,neo-epitope,MNRRPILTI,Cellular tumor antigen p53,HLA-B*52:01,Cited reference,ELISA,0,2,0.0
1854099,MNLRPILTII,,,,,neo-epitope,MNRRPILTII,Cellular tumor antigen p53,HLA-B*52:01,Cited reference,ELISA,0,2,0.0
1862014,MPAWRTRGA,,,,,neo-epitope,LPAWRTR,GHRH receptor splice variant 1,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1862015,MPAWRTRGAI,,,,,neo-epitope,LPAWRTR,GHRH receptor splice variant 1,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1862016,MPFTTVSELM,,,,,neo-epitope,MPFTTVSELV,Mediator of RNA polymerase II transcription subunit 24 (Fragment),HLA-B*35:01,MHC binding prediction,ELISPOT,0,1,0.0
1332820,MPIEPGDIGC,,,,,neo-epitope,MPIEPGDIGY,Bombesin receptor-activated protein C6orf89,HLA-B*35:01,MHC binding assay,ELISPOT,1,1,1.0
1393200,MPSHCNTQY,,,,,neo-epitope,MPSRCNTQY,MIF4G domain-containing protein,HLA-B*35:01,MHC binding prediction,ELISA,0,1,0.0
42387,MQLIYDSSL,81.0,89.0,Mammaglobin-A precursor,Mammaglobin-A,,,,HLA-A2,Not determined,ELISPOT,0,1,0.0
1854110,MQLMPFGCL,,,,,neo-epitope,TQLMPFGCL,Epidermal growth factor receptor,HLA-A*02:06,Cited reference,ELISA,0,2,0.0
859210,MQLMPFGCLL,102.0,111.0,"Chain A, Epidermal Growth Factor Receptor",Receptor protein-tyrosine kinase,neo-epitope,TQLMPFGCLL,Epidermal growth factor receptor,HLA-A*02:01,MHC binding assay,ELISPOT,1,4,1.0
1085695,MQLMPFGSLL,,,,,neo-epitope,TQLMPFGCLL,Epidermal growth factor receptor,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,0.6666666666666666
1595127,MRMNQGVCC,,,,,neo-epitope,MRMSQGVCC,Liprin-alpha-4,HLA-B*39:06,T cell assay -Mismatched MHC molecules,ELISPOT,1,2,1.0
1862022,MRNSFAHSL,131.0,139.0,Baculoviral IAP repeat-containing protein 2,Baculoviral IAP repeat-containing protein 2,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,2,0.0
1385632,MTEYKLVVVGAAGVGKSALTIQLIQNH,,,,,neo-epitope,MTEYKLVVVGAGGVGKSALTIQLIQNH,GTP-binding protein GEM,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1550656,MTEYKLVVVGADGVGKSALTIQLI,,,,,neo-epitope,MTEYKLVVVGAGGVGKSALTIQLIQ,GTP-binding protein GEM,HLA-C*08:02,MHC binding assay,ELISPOT,1,1,1.0
1110884,MTEYKLVVVGADGVGKSALTIQLIQNH,,,,,neo-epitope,MTEYKLVVVGAGGVGKSALTIQLIQNH,GTP-binding protein GEM,HLA-A*02:06,MHC binding prediction,ELISPOT,1,1,1.0
1862030,MTFSSTKDYV,,,,,neo-epitope,MTFSSTKDLC,Coiled-coil domain-containing protein 66,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862031,MTISHVWLGL,,,,,neo-epitope,MAISHVW,Endophilin-B2,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
1862032,MTITSRGTTV,,,,,neo-epitope,MTITPRGTTV,Oviduct-specific glycoprotein,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
910618,MTSAIGILPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,2,1.0
910619,MTSAIGVLPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
1862036,MVEEQLIRY,1424.0,1432.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
753266,MVIGIPVYV,180.0,188.0,RNF19B protein,E3 ubiquitin-protein ligase RNF19B,,,,HLA-A*02:01,Single allele present,ELISPOT,1,1,1.0
1860851,MWVPVVFLTL,1.0,10.0,Prostate-specific antigen precursor,Prostate-specific antigen,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5
43277,NAPPAYEKL,99.0,107.0,Melanoma antigen recognized by T-cells 1,Melanoma antigen recognized by T-cells 1,,,,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1385778,NDLEESPKGGLDIPKSLENTVTSAINK,,,,,neo-epitope,NDLEESPKGGLDILKSLENTVTSAINK,Teashirt homolog 3,HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0
1397955,NETPVAVLTI,,,,,neo-epitope,NETPVAGLTI,"Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2",HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1862050,NEVSEVTVF,,,,,neo-epitope,NEVPEVTVF,"HLA class II histocompatibility antigen, DQ alpha 2 chain",HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1862052,NEYAFVTTF,,,,,neo-epitope,DEYAFVTTF,,HLA-B*41:02,MHC binding prediction,ELISPOT,0,1,0.0
1862053,NFPGSQKVL,89.0,97.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1862056,NHDETSFLL,,,,,neo-epitope,NHDETSSLL,DNA polymerase theta,HLA-B*38:01,MHC binding prediction,ELISPOT,0,1,0.0
1862061,NINDRIKEL,361.0,369.0,Transcription factor E3,Transcription factor E3,,,,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1334612,NISEDVIFF,,,,,neo-epitope,NISEDVIFS,Importin-8,HLA-A*25:01,Single allele present,ELISPOT,1,2,0.5
1334613,NISEDVIFS,349.0,357.0,Importin-8,Importin-8,,,,HLA-A*25:01,Single allele present,ELISPOT,0,1,0.0
1085741,NKSQKPYKI,904.0,912.0,Inactive tyrosine-protein kinase transmembrane receptor ROR1,Inactive tyrosine-protein kinase transmembrane receptor ROR1,,,,HLA-A2,MHC binding prediction,ELISPOT,1,2,1.0
1313214,NLIFVFYM,,,,,neo-epitope,NLFFVFYM,NADPH oxidase 4,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1313215,NLIFVFYML,,,,,neo-epitope,NLFFVFYML,NADPH oxidase 4,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1854156,NLLGGNSFEVR,,,,,neo-epitope,NLLGRNSFEVR,Cellular tumor antigen p53,HLA-A*33:01,Cited reference,ELISA,0,2,0.0
1854158,NLNKHRRYK,,,,,neo-epitope,NLNKHRRYE,Protein sidekick-2,HLA-A*11:01,Cited reference,ELISA,0,2,0.0
1862067,NLPNIKREL,284.0,292.0,Microphthalmia-associated transcription factor,Microphthalmia-associated transcription factor,,,,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1309890,NLQREEYTV,,,,,neo-epitope,NLEREEYTV,TRIO and F-actin-binding protein,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
834063,NLVPAVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
133254,NLVPCVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338545,NLVPDVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338546,NLVPEVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338547,NLVPFVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
133255,NLVPGVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1338548,NLVPHVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
44919,NLVPIVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
964195,NLVPKVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
1338549,NLVPLVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,0,1,0.0
44920,NLVPMVATV,495.0,503.0,tegument protein pp65 [Human betaherpesvirus 5],65 kDa phosphoprotein,,,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1338550,NLVPNVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1338551,NLVPPVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
135858,NLVPQVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1338552,NLVPRVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
135859,NLVPSVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
135860,NLVPTVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
135861,NLVPVVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1338553,NLVPWVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1338554,NLVPYVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1402572,NLYAEPPV,,,,,neo-epitope,NLYAEPAV,Ribose-phosphate pyrophosphokinase,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1871130,NLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1854172,NPLMCRLLGI,,,,,neo-epitope,NPHVCRLLGI,Epidermal growth factor receptor,HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1862085,NRMALFQQL,464.0,472.0,Baculoviral IAP repeat-containing protein 2,Baculoviral IAP repeat-containing protein 2,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1596735,NSKKKWFLF,,,,,neo-epitope,NSKKKWFFF,Protogenin,HLA-A*24:02,MHC binding prediction,ELISPOT,0,1,0.0
1582973,NTLEQEQEALVNHLWKRMDKLEAEK,,,,,neo-epitope,NTLEQEQEALVNRLWKRMDKLEAEK,Coiled-coil domain-containing protein 6,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
719156,NTPVVKSAL,392.0,400.0,Baculoviral IAP repeat-containing protein 2,Baculoviral IAP repeat-containing protein 2,,,,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1337428,NTVILETLK,,,,,neo-epitope,NTDILETLK,Myocyte-specific enhancer factor 2B,HLA-A*11:02,Single allele present,ELISPOT,1,1,1.0
1397958,NVDMRTISF,,,,,neo-epitope,KVDMRTISF,Erythrocyte band 7 integral membrane protein,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1862094,NVELRRNVL,,,,,neo-epitope,NVELPRNVL,Nuclear receptor coactivator 6,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1714926,NVLHFFNAPL,501.0,510.0,Heterogeneous nuclear ribonucleoprotein L,Heterogeneous nuclear ribonucleoprotein L (Fragment),,,,HLA-A2,Cited reference,ELISPOT,1,2,0.5
1397959,NVLIFDLA,,,,,neo-epitope,NVLIFDLG,Heat shock cognate 71 kDa protein,HLA-A*32:01,MHC binding prediction,ELISPOT,0,1,0.0
1854202,NVLJFFNAPL + INDIST(J4),,,,,analog,NVLHFFNAPL,Heterogeneous nuclear ribonucleoprotein L (Fragment),HLA-A2,Cited reference,ELISA,1,4,1.0
1862097,NVLSSLVLV,,,,,neo-epitope,NVLPSLVLV,Deoxyribonuclease-1-like 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
46581,NYARTEDFF,178.0,186.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5
1854206,NYICNSSCM,,,,,neo-epitope,NYMCNSSCM,Cellular tumor antigen p53,HLA-C*07:02,Cited reference,ELISA,0,2,0.0
1386508,NYMCNSSCMGGMNWRPILTIITLEDSS,,,,,neo-epitope,NYMCNSSCMGGMNRRPILTIITLEDSS,Cellular tumor antigen p53,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0
1714953,NYSVRYRPGL,1293.0,1302.0,Canalicular multispecific organic anion transporter 2,Canalicular multispecific organic anion transporter 2,,,,HLA-A24,Cited reference,ELISPOT,0,3,0.0
859256,PFDTRQMLFY,1543.0,1552.0,E3 ubiquitin-protein ligase TRIP12,E3 ubiquitin-protein ligase TRIP12,,,,HLA-A*02:01,Single allele present,ELISA,0,1,0.0
1862126,PLLPALSPGL,,,,,neo-epitope,PLLPALSPGS,Syntaxin-5,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1392357,PLTEYIQPV,268.0,276.0,Serine protease hepsin,Serine protease hepsin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1871139,PLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1583602,PSAYYEAALLQLWVTEACTYRPSAQ,,,,,neo-epitope,PSAYYEAALLQLRVTEACTYRPSAQ,Laminin subunit alpha-5,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
859283,PSDTRQMLFY,,,,,neo-epitope,PFDTRQMLFY,E3 ubiquitin-protein ligase TRIP12,HLA-A*01:01,Single allele present,ELISA,1,3,1.0
1583617,PSPQAEKRLPKLHLEIIDKDSKTRR,,,,,neo-epitope,PSPQAEKRLPKLRLEIIDKDSKTRR,Caseinolytic peptidase B protein homolog (Fragment),HLA-A*32:01,MHC binding prediction,ELISPOT,0,1,0.0
1334615,PVKNLPQM,537.0,544.0,"Beta-1,4-N-acetylgalactosaminyltransferase 3","Beta-1,4-N-acetylgalactosaminyltransferase 3",,,,HLA-B*51:01,Single allele present,ELISPOT,1,1,1.0
1334616,PVKNLPQV,,,,,neo-epitope,PVKNLPQM,"Beta-1,4-N-acetylgalactosaminyltransferase 3",HLA-B*51:01,Single allele present,ELISPOT,1,2,0.5
1074777,PYISGPLRF,,,,,neo-epitope,PYISGPLGF,Anion exchange transporter,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1862142,PYKDFIATL,183.0,191.0,Prostatic acid phosphatase precursor,Prostatic acid phosphatase,,,,HLA-A*24:02,MHC binding assay,ELISA,0,2,0.0
1397964,QASGNHHVW,,,,,neo-epitope,QASGNHYVW,Oxysterol-binding protein (Fragment),HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1397965,QAVAAVQKL,,,,,neo-epitope,QAVAAVQKM,Probable ATP-dependent RNA helicase DHX58,HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
1125095,QCEEVARVL,,,,,neo-epitope,QCEEVARAL,Galactokinase,HLA-B*35:03,Cited reference,ELISA,1,1,1.0
1125094,QCEEVARVL + AIB(C2),,,,,neo-epitope,QCEEVARAL,Galactokinase,HLA-B*35:03,Cited reference,ELISA,1,1,1.0
1397966,QDVSVQVER,,,,,neo-epitope,QDVSVQVEM,Ankyrin repeat domain-containing protein 20B,HLA-A*68:01,MHC binding prediction,ELISPOT,1,2,0.5
1391907,QDVWMRSRADNKPYLSFSEPENAVSEI,,,,,neo-epitope,QDVWMRSRADNKPCLSFSEPENAVSEI,Sorting nexin-16,HLA-B*58:01,MHC binding prediction,ELISPOT,1,1,1.0
1854400,QEECLWMAV,,,,,neo-epitope,QEECLGMAV,Tyrosine-protein kinase JAK2,HLA-B*40:02,Cited reference,ELISA,1,2,0.5
1397967,QEFAPLGTV,,,,,neo-epitope,QEFAPLGTG,Mannose-1-phosphate guanyltransferase alpha,HLA-B*49:01,MHC binding prediction,ELISPOT,0,1,0.0
1854402,QEIQILKAL,,,,,neo-epitope,REIQILKAL,Tyrosine-protein kinase JAK3,HLA-B*40:01,Cited reference,ELISA,0,2,0.0
1862158,QGLPNEYAF,,,,,neo-epitope,QGLPDEYAF,,HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
1715107,QIIHTYSNTV,,,,,neo-epitope,QIIHTDSNTV,BTB/POZ domain-containing protein 2,HLA-A*02:06,Cited reference,ELISPOT,1,2,0.5
1313342,QIKLHLSPK,,,,,neo-epitope,QIKLHLSAK,Coiled-coil domain-containing protein 150,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1854425,QINITAVAHV,,,,,neo-epitope,QINITAVAQV,Integrin alpha-8,HLA-A*02:06,Cited reference,ELISA,0,2,0.0
902812,QIRPIFSNR,734.0,742.0,Squamous cell carcinoma antigen recognized by T-cells 3,Squamous cell carcinoma antigen recognized by T-cells 3,,,,HLA-A3,Cited reference,ELISPOT,1,5,0.6
1688151,QKRPIPIKYKAM,,,,,neo-epitope,QKRLIPIKYKAM,Myeloid differentiation primary response protein MyD88,HLA-B*07:02,Single allele present,ELISA,1,1,1.0
1854429,QKTYQVSYGFR,,,,,neo-epitope,QKTYQGSYGFR,Cellular tumor antigen p53,HLA-A*31:01,Cited reference,ELISA,1,2,0.5
857795,QLCDVMFYL,,,,,neo-epitope,QLRDVMFYL,BRCA1-associated protein,HLA-A*02:01,MHC binding prediction,ELISA,1,4,1.0
1862170,QLFARARPM,,,,,neo-epitope,RLFARARPM,ATP5MF-PTCD1 readthrough,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1862171,QLGEQCWTA,34.0,42.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,2,1.0
1854449,QLIMQLMPF,,,,,neo-epitope,QLITQLMPF,Epidermal growth factor receptor,HLA-A*02:06,Cited reference,ELISA,0,2,0.0
180706,QLLNSVLTL,248.0,256.0,uncharacterized protein KIAA1551,Retroelement silencing factor 1,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1864045,QLQKANVLL,,,,,neo-epitope,QLQKANVRL,Villin-like protein,HLA-A*02:01,MHC binding prediction,ELISA,1,2,0.5
1391909,QLRENFQEKRQWLFKYQSLLRMFLSYC,,,,,neo-epitope,QLRENFQEKRQWLLKYQSLLRMFLSYC,DmX-like protein 1,HLA-B*15:02,MHC binding prediction,ELISPOT,1,1,1.0
1367390,QLWQFLLEL,295.0,303.0,transcriptional regulator ERG isoform 2 [Homo sapiens],Erythroblast transformation-specific transcription factor ERG variant 10,,,,HLA-A*02:01,T cell assay -T cell subset identification,ELISPOT,1,2,1.0
1854459,QLWVDSTPL,,,,,neo-epitope,QLWVDSTPP,Cellular tumor antigen p53,HLA-B*39:01,Cited reference,ELISA,0,2,0.0
1871144,QLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1397972,QMKNPILEL,,,,,neo-epitope,QMKNPILER,Syntaxin-binding protein 1,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1391971,QMVEASLSV,95.0,103.0,Kallikrein-4,Kallikrein-4,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0
51809,QPEWFRNVL,145.0,153.0,Polymerase basic protein 1,RNA-directed RNA polymerase catalytic subunit,,,,HLA-B*07:02,Cited reference,ELISPOT,1,1,1.0
1862181,QPPALSPSY,,,,,neo-epitope,QPPAPSPSY,Zinc finger MIZ domain-containing protein 2,HLA-B*35:01,MHC binding prediction,ELISPOT,0,1,0.0
1113688,QPSGIILDY,,,,,neo-epitope,QPNGIILDY,Ephrin type-B receptor 1,HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0
1397973,QPSGVPTSL,,,,,neo-epitope,QPSGVPTSG,Activating transcription factor 7-interacting protein 1,HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
1387330,QQDDQEVTALEEIICSSSSISFENGNS,,,,,neo-epitope,QQDDQEVTALEEINCSSSSISFENGNS,Zinc finger protein 654,HLA-B*40:02,MHC binding prediction,ELISPOT,0,1,0.0
1854472,QQEIQILKAL,,,,,neo-epitope,QREIQILKAL,Tyrosine-protein kinase JAK3,HLA-B*40:01,Cited reference,ELISA,0,2,0.0
1313376,QQLDTAIRLTL,,,,,neo-epitope,EQLDTAIRLTL,ATP-binding cassette sub-family D member 2,HLA-B*39:01,MHC binding prediction,ELISPOT,0,1,0.0
1334618,QQMGLLTRV,,,,,neo-epitope,QQMGLL,Histone-lysine N-methyltransferase 2D,HLA-A*02:10,MHC binding prediction,ELISPOT,0,1,0.0
1397974,QQQQVVTNK,,,,,neo-epitope,QQQQVGTNK,Prolow-density lipoprotein receptor-related protein 1,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1862186,QRIYTGEKPF,,,,,neo-epitope,QRIHTGEKPF,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1862187,QRLFPGPSY,7.0,15.0,Baculoviral IAP repeat-containing protein 2,Baculoviral IAP repeat-containing protein 2,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1862188,QRLMLRKVAL,,,,,neo-epitope,QRLMLRRVAL,Toll-like receptor 3,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1862191,QSDETDQFLV,,,,,neo-epitope,QSDKTDQFLV,Nucleolar protein 11,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1556360,QSLFWSIFV,,,,,neo-epitope,QSLFWSIFG,Short transient receptor potential channel 4,HLA-A*69:01,MHC binding prediction,ELISPOT,1,1,1.0
1387417,QSVSLRSKTTIREWPSSAIYPSDSFRQ,,,,,neo-epitope,QSVSLRSKTTIRERPSSAIYPSDSFRQ,Rho guanine nucleotide exchange factor 2,HLA-B*13:01,MHC binding prediction,ELISPOT,0,1,0.0
1397975,QTAAAVGVLK,,,,,neo-epitope,QTTAAVGVLK,Lysine-specific demethylase RSBN1L,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1391910,QTDVGGSGLSRLDISVIFEALATGCTS,,,,,neo-epitope,QTDVGGSGLSRLDTSVIFEALATGCTS,"Isobutyryl-CoA dehydrogenase, mitochondrial",HLA-A*02:01,Single allele present,ELISPOT,1,2,0.5
1397976,QTKPASLLY,,,,,neo-epitope,YTKGASLLY,Receptor expression-enhancing protein,HLA-A*26:01,MHC binding prediction,ELISPOT,0,1,0.0
1309261,QTNPVTLQY,,,,,neo-epitope,QTDPVTLQY,Helicase with zinc finger domain 2,HLA-A*29:02,T cell assay -Mismatched MHC molecules,ELISA,1,2,1.0
1862197,QTRKNKKLAL,,,,,neo-epitope,QTRKNKKLAP,Histone-lysine N-methyltransferase 2A,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1313390,QTRLKGSLK,,,,,neo-epitope,QTRVKGSLK,DnaJ homolog subfamily C member 11,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
910623,QTSAIGILPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
910624,QTSAIGVLPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
1862198,QTSIQSPSLY,,,,,neo-epitope,QTSIQSPSSY,Tumor protein 63,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1854493,QVVKGDPPL,,,,,neo-epitope,QVVKGDPPQ,Dual specificity mitogen-activated protein kinase kinase 4,HLA-C*03:03,Cited reference,ELISA,0,2,0.0
1393319,QVWKPSFCFK,920.0,929.0,Synaptopodin,Synaptopodin,,,,HLA-A*11:02,MHC binding prediction,ELISPOT,0,1,0.0
1393320,QVWNPSFCFK,,,,,neo-epitope,QVWKPSFCFK,Synaptopodin,HLA-A*11:02,MHC binding prediction,ELISPOT,0,2,0.0
1074781,QWINLFLQF,,,,,neo-epitope,QWINLFLRF,Calpain-9,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
52886,QYDPVAALF,331.0,339.0,pp65,65 kDa phosphoprotein,,,,HLA-A*24:02,Cited reference,ELISA,1,1,1.0
1397977,QYMDSSLVKI,,,,,neo-epitope,QYMDSSLVKS,"Cell division cycle 2, G1 to S and G2 to M, isoform CRA_a",HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
53036,QYSWFVNGTF,268.0,277.0,Carcinoembryonic antigen-related cell adhesion molecule 5 precursor,Carcinoembryonic antigen-related cell adhesion molecule 5,,,,HLA-A*24:02,Not determined,ELISPOT,1,1,1.0
1862207,RAFYILMEK,,,,,neo-epitope,RASYILMEK,Glutathione synthetase,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1854500,RAILLGAEEK,,,,,neo-epitope,LAKLLGAEEK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,0,2,0.0
1114008,RAKLLGAEEK,,,,,neo-epitope,LAKLLGAEEK,Receptor protein-tyrosine kinase,HLA-A*31:01,MHC binding prediction,ELISPOT,1,1,1.0
1862208,RANDLVKYL,282.0,290.0,Melanoma-associated antigen D2,Melanoma-associated antigen D2,,,,HLA-C*07:01,MHC binding prediction,ELISPOT,0,1,0.0
1862210,RAPISRAQL,1848.0,1856.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1854506,RASKARLPV,,,,,neo-epitope,RASKALLPV,Aquaporin-12B,HLA-B*08:01,Cited reference,ELISA,0,2,0.0
1397978,RATIVPEL,,,,,neo-epitope,RATIDPEL,Muskelin,HLA-C*03:04,MHC binding prediction,ELISPOT,0,2,0.0
1114056,RATVAPRSL,,,,,neo-epitope,serine/threonine-protein kinase STK11 [Homo sapiens],,HLA-C*03:03,MHC binding prediction,ELISPOT,1,1,1.0
1852331,RAVSEHQLL,36.0,44.0,Parathyroid hormone-related protein,Parathyroid hormone-related protein,,,,HLA-A*24:02,Single allele present,ELISA,1,2,1.0
1854510,RDFQQEIQIL,,,,,neo-epitope,RDFQREIQIL,Tyrosine-protein kinase JAK3,HLA-A*24:02,Cited reference,ELISA,0,2,0.0
1862215,RDLRPPGLLR,,,,,neo-epitope,RDLRPPGPLR,Transmembrane protein 145,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1334620,REEKIHDLAL,,,,,neo-epitope,EEKIHDLAL,Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2,HLA-B*40:01,MHC binding prediction,ELISPOT,1,1,1.0
1862217,REELLAATL,,,,,neo-epitope,RGELLAATL,KICSTOR complex protein kaptin,HLA-B*40:02,MHC binding prediction,ELISPOT,0,1,0.0
1862218,REFDKIELA,,,,,neo-epitope,REFDEIELA,"Glutamate receptor ionotropic, NMDA 2B",HLA-B*41:02,MHC binding prediction,ELISPOT,0,1,0.0
1862219,REFDKIELAY,,,,,neo-epitope,REFDEIELAY,"Glutamate receptor ionotropic, NMDA 2B",HLA-B*41:02,MHC binding prediction,ELISPOT,1,1,1.0
1862224,REIVVKTEM,,,,,neo-epitope,GEIVVKTEM,Lysozyme C,HLA-B*47:01,MHC binding prediction,ELISPOT,0,1,0.0
1862226,RESFDPSAFM,,,,,neo-epitope,RESFDPSAFL,Ubiquitin carboxyl-terminal hydrolase 6,HLA-B*40:02,MHC binding prediction,ELISPOT,0,1,0.0
1862227,RFANPRDSF,,,,,neo-epitope,LFANPRDSF,"Atypical kinase COQ8A, mitochondrial",HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
1074782,RFHTPMYFF,,,,,neo-epitope,KFHTPMYFF,Olfactory receptor 5D14,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1854513,RFKDIFQEM,,,,,neo-epitope,RFKDIFQEI,Isocitrate dehydrogenase [NADP] cytoplasmic,HLA-C*14:02,Cited reference,ELISA,0,2,0.0
1596760,RFLEYLPLRF,,,,,neo-epitope,RSLEYLPLRF,Dephospho-CoA kinase domain-containing protein,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0
1585522,RFPLRNAEMAKVLEISSVPASDRMV,,,,,neo-epitope,RFPLRNAEMAKVSEISSVPASDRMV,Sacsin,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1313421,RFQQLDTAI,,,,,neo-epitope,RFEQLDTAI,ATP-binding cassette sub-family D member 2,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1313422,RFQQLDTAIRL,,,,,neo-epitope,RFEQLDTAIRL,ATP-binding cassette sub-family D member 2,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1862232,RGLLDSAQRK,,,,,neo-epitope,LGLLDSAQRK,,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1075620,RGPESRLLEFYLAMPFATPM,81.0,100.0,Cancer/testis antigen 1,Cancer/testis antigen 1,,,,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0
1313432,RGRNSATSADK,,,,,neo-epitope,RGRNSATSADE,Serine/threonine-protein kinase MARK2,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
742510,RHDLPPYRVYL,,,,,neo-epitope,RHDLPPYRVHL,Cell cycle and apoptosis regulator protein 2,HLA-B*38:01,MHC binding prediction,ELISA,1,1,1.0
1690341,RIAGKALKK,,,,,neo-epitope,RIAGKAPKK,Rho guanine nucleotide exchange factor 17,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1313435,RIALILAGSK,,,,,neo-epitope,RIARILAGSK,Metabotropic glutamate receptor 1,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1854524,RIIYDRKFL,51.0,59.0,Eukaryotic translation initiation factor 4E-binding protein 1,Eukaryotic translation initiation factor 4E-binding protein 1,,,,HLA-A2,Cited reference,ELISA,1,4,0.75
1854528,RILKVTEFK,,,,,neo-epitope,RILKETEFK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,1,2,0.5
1854529,RILKVTEFKK,,,,,neo-epitope,RILKETEFKK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,0,2,0.0
1862242,RIRAVGLLTV,52.0,61.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
54313,RIWSWLLGA,473.0,481.0,Tyrosinase precursor,Tyrosinase,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1862244,RIYTGEKPFK,,,,,neo-epitope,RIHTGEKPFK,,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1313444,RIYVGGKINHI,,,,,neo-epitope,RIYVGGKINRI,Solute carrier family 12 member 1,HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
1862245,RKLNFRLFVI,,,,,neo-epitope,RKLNSRLFVI,Cryptochrome-1,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
742511,RKTVRARSRTPSCRSRSHTPSRRRR,,,,,neo-epitope,RKTVRARSRTPSRRSRSHTPSRRRR,Protein SON,HLA-B*07:02,Single allele present,ELISA,1,2,1.0
1397980,RLADAEKLFQL,,,,,neo-epitope,RLADAERLFQL,Puratrophin-1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1715264,RLAEYQAYI,309.0,317.0,Squamous cell carcinoma antigen recognized by T-cells 3,Squamous cell carcinoma antigen recognized by T-cells 3,,,,HLA-A2,Cited reference,ELISA,1,6,0.5
956443,RLARLALVL,17.0,25.0,Trophoblast glycoprotein,Trophoblast glycoprotein,,,,HLA-A*02:01,MHC binding assay,ELISA,1,4,1.0
1310769,RLDAVLMEV,,,,,neo-epitope,RPDAVLMEV,E3 ubiquitin-protein ligase MYLIP,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1854538,RLDPRMSTLQK,,,,,neo-epitope,SH3 and PX domain-containing protein 2A,,HLA-A*11:01,Cited reference,ELISA,1,2,0.5
1690645,RLFLGLAIK,,,,,neo-epitope,RLFPGLAIK,Kinesin-like protein KIF2C,HLA-A*03:01,MHC binding assay,ELISA,1,2,0.5
217981,RLFPGLAIK,10.0,18.0,Kinesin-like protein KIF2C,Kinesin-like protein KIF2C,,,,HLA-A*03:01,MHC binding assay,ELISA,0,1,0.0
1397982,RLFTPISAGY,,,,,neo-epitope,RLFTPISGGY,Cytochrome P450 26B1,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1862252,RLISGPSVGV,,,,,neo-epitope,RSISGPSVGV,Nucleoporin NUP35,HLA-A*02:02,MHC binding prediction,ELISPOT,0,1,0.0
1690684,RLKCPFYGK,,,,,neo-epitope,RLKCPFHGK,UV-stimulated scaffold protein A,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1075627,RLLEFYLAMPFATPMEAELA,86.0,105.0,Cancer/testis antigen 1,Cancer/testis antigen 1,,,,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0
1690716,RLMFFRPIK,,,,,neo-epitope,RLMSFRPIK,Beta-crystallin B1,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1862254,RLMLRKVAL,,,,,neo-epitope,RLMLRRVAL,Toll-like receptor 3,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862255,RLMLRKVALK,,,,,neo-epitope,RLMLRRVALK,Toll-like receptor 3,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
232216,RLPRIFCSC,639.0,647.0,melanocyte protein PMEL isoform 3 preproprotein [Homo sapiens],Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1125099,RLPRIFCSC + AIB(C7),639.0,647.0,melanocyte protein PMEL isoform 3 preproprotein [Homo sapiens],Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1125100,"RLPRIFCSC + AIB(C7, C9)",639.0,647.0,melanocyte protein PMEL isoform 3 preproprotein [Homo sapiens],Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1125101,RLPRIFCSC + AIB(C9),639.0,647.0,melanocyte protein PMEL isoform 3 preproprotein [Homo sapiens],Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1854553,RLPVGAYEV,,,,,neo-epitope,LLPVGAYEV,Aquaporin-12B,HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1711663,RLQEWCSVI,43.0,51.0,Transmembrane protein 189,Plasmanylethanolamine desaturase,,,,HLA-A2,Cited reference,ELISPOT,1,7,0.8571428571428571
1854556,RLQEWCSVIL + UNK(C6),43.0,52.0,Transmembrane protein 189,Plasmanylethanolamine desaturase,,,,HLA-A2,Cited reference,ELISA,1,4,1.0
1393358,RLRKRNEYR,,,,,neo-epitope,RLRKGNEYR,E3 ubiquitin-protein ligase TRIM68,HLA-A*31:01,MHC binding prediction,ELISA,1,1,1.0
1854560,RLSISFENL,,,,,neo-epitope,RLSISFENV,Gamma-tubulin complex component,HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1854564,RLSSSSSSK,,,,,neo-epitope,RLSSSSSSE,Bromodomain-containing protein 3,HLA-A*11:01,Cited reference,ELISA,0,2,0.0
1871154,RLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1690803,RLYKLILWR,,,,,neo-epitope,RLYKPILWR,Condensin-2 complex subunit G2,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1690841,RMLRRRAQK,,,,,neo-epitope,RMLRRRAQE,Anoctamin-7,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
54934,RMPEAAPPV,65.0,73.0,Cellular tumor antigen p53,Cellular tumor antigen p53,,,,HLA-A2,Not determined,ELISPOT,1,1,1.0
1391972,RMPTVLQCV,160.0,168.0,Kallikrein-4,Kallikrein-4,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0
1387789,RMSTIRMKASGKRKLLEEKLNDQLEEQ,,,,,neo-epitope,RMSTIRMKASGKRQLLEEKLNDQLEEQ,Nesprin-1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862267,RPAARGSRV,,,,,neo-epitope,RPAARGSPR,Coiled-coil domain-containing protein 80,HLA-B*56:01,MHC binding prediction,ELISPOT,0,1,0.0
1313469,RPCPGDTTEV,,,,,neo-epitope,RPCPGDTTQV,Hemicentin-1,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1310770,RPDAVLMEV,7.0,15.0,E3 ubiquitin-protein ligase MYLIP isoform X1 [Homo sapiens],E3 ubiquitin-protein ligase MYLIP,,,,HLA-A*02:01,Single allele present,ELISA,0,1,0.0
1595203,RPHHDQRSL,,,,,neo-epitope,RPHHDQRSS,Tau-tubulin kinase 2,HLA-B*07:02,Single allele present,ELISPOT,1,2,0.5
859339,RPHVPESAF,,,,,neo-epitope,GPHVPESAF,E3 ubiquitin-protein ligase UBR4,HLA-B*07:02,Single allele present,ELISPOT,1,1,1.0
1691013,RPIPIKYKA,,,,,neo-epitope,RLIPIKYKA,Myeloid differentiation primary response protein MyD88,HLA-B*07:02,Single allele present,ELISA,1,1,1.0
1691014,RPIPIKYKAM,,,,,neo-epitope,RLIPIKYKAM,Myeloid differentiation primary response protein MyD88,HLA-B*07:02,Single allele present,ELISA,1,5,0.6
55252,RPPIFIRRL,379.0,387.0,EBNA3A nuclear protein,Epstein-Barr nuclear antigen 3,,,,HLA-B*07:02,Cited reference,ELISPOT,1,1,1.0
458440,RPPITQSSL,382.0,390.0,RNA-binding protein 27,RNA-binding protein 27,,,,HLA-B*07:02,MHC binding assay,ELISPOT,1,1,1.0
1075034,"RPPITQSSL + GLYC(R1, T5)",382.0,390.0,RNA-binding protein 27,RNA-binding protein 27,,,,HLA-B*07:02,MHC binding assay,ELISPOT,1,1,1.0
1075035,RPPITQSSL + GLYC(T5),382.0,390.0,RNA-binding protein 27,RNA-binding protein 27,,,,HLA-B*07:02,MHC binding assay,ELISPOT,1,1,1.0
1075033,RPPITQSSL + METH(R1),382.0,390.0,RNA-binding protein 27,RNA-binding protein 27,,,,HLA-B*07:02,MHC binding assay,ELISPOT,1,1,1.0
1337717,RPRCLCTAV,,,,,neo-epitope,RPRCLRTAV,CREB-binding protein,HLA-B*07:02,Single allele present,ELISPOT,1,2,0.5
1393386,RQLEFLQPL,278.0,286.0,Carbohydrate sulfotransferase 3,Carbohydrate sulfotransferase 3,,,,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1854589,RRASKARLP,,,,,neo-epitope,RRASKALLP,Aquaporin-12B,HLA-C*06:02,Cited reference,ELISA,0,2,0.0
588970,RRASRGPIAF,215.0,224.0,Melanoma-associated antigen D2,Melanoma-associated antigen D2,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1691170,RRFSSLYSF,,,,,neo-epitope,RGFSSLYSF,Beta-tectorin,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1691178,RRHCRSYNR,,,,,neo-epitope,RRHCRSYDR,E3 ubiquitin-protein ligase RNF216,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1862287,RRHVLEVEK,,,,,neo-epitope,RRRVLEVEK,G patch domain-containing protein 8,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1862288,RRIYTGERPY,,,,,neo-epitope,RRIHTGERPY,Replication initiator 1,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1691197,RRLLILGRI,,,,,neo-epitope,RRLLILGGI,Claudin-22,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1862289,RRLLVRRNIF,115.0,124.0,Tyrosinase precursor,Tyrosinase,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1862290,RRNDDKSILM,,,,,neo-epitope,RRNDDKSISD,Probable ATP-dependent RNA helicase DHX40,HLA-B*27:02,MHC binding prediction,ELISPOT,0,1,0.0
1862291,RRNGYRALM,50.0,58.0,Melanoma antigen recognized by T-cells 1,Melanoma antigen recognized by T-cells 1,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1862292,RRNLLDLSK,130.0,138.0,"5,6-dihydroxyindole-2-carboxylic acid oxidase","5,6-dihydroxyindole-2-carboxylic acid oxidase",,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1862293,RRNPAGNVAR,312.0,321.0,"5,6-dihydroxyindole-2-carboxylic acid oxidase","5,6-dihydroxyindole-2-carboxylic acid oxidase",,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1691226,RRTQRYFMK,,,,,neo-epitope,RRTQRYFME,Serine/threonine-protein kinase Nek10,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1862296,RRWSALVIG,63.0,71.0,alternative protein DHX40 [Homo sapiens],,,,,HLA-B*27:02,MHC binding prediction,ELISPOT,0,1,0.0
1862297,RRWSALVIGL,63.0,72.0,alternative protein DHX40 [Homo sapiens],,,,,HLA-B*27:02,MHC binding prediction,ELISPOT,0,1,0.0
1862298,RRYNADISTF,416.0,425.0,"5,6-dihydroxyindole-2-carboxylic acid oxidase","5,6-dihydroxyindole-2-carboxylic acid oxidase",,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1313487,RSELNLLV,,,,,neo-epitope,RSELNLLV,"Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 (Fragment)",HLA-C*05:01,MHC binding prediction,ELISPOT,0,1,0.0
1313488,RSKGDIGA,,,,,neo-epitope,RSKGDLGA,Zinc finger protein 366,HLA-C*03:03,MHC binding prediction,ELISPOT,0,1,0.0
1393397,RSLRLHRFR,,,,,neo-epitope,RSLRLHRFT,Taste receptor type 2 member 30,HLA-A*31:01,MHC binding prediction,ELISA,0,1,0.0
1852333,RSVEGLSRRL,25.0,34.0,Parathyroid hormone-related protein,Parathyroid hormone-related protein,,,,HLA-A*24:02,Single allele present,ELISA,1,2,1.0
1397986,RTAKQNPLTK,,,,,neo-epitope,RTAKQNPLTE,G-protein coupled receptor 183,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1397987,RTAKQNPLTKK,,,,,neo-epitope,RTAKQNPLTEK,G-protein coupled receptor 183,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1862306,RTAPRPGSQK,,,,,neo-epitope,RTAPRPGSQE,Endonuclease V,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1337753,RTAVYHEIHI,,,,,neo-epitope,RTAVYHEILI,CREB-binding protein,HLA-B*57:01,Single allele present,ELISPOT,1,2,1.0
1313496,RTGKAAGLL,,,,,neo-epitope,PTGKAAGLL,DNA helicase B,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1862309,RTNPYSYAM,173.0,181.0,Baculoviral IAP repeat-containing protein 2,Baculoviral IAP repeat-containing protein 2,,,,HLA-C*07:01,MHC binding prediction,ELISPOT,0,1,0.0
1337757,RTNTAILETL,,,,,neo-epitope,RTNTDILETL,Myocyte-specific enhancer factor 2B,HLA-C*03:04,MHC binding prediction,ELISPOT,1,1,1.0
1337758,RTNTGILETLK,,,,,neo-epitope,RTNTDILETLK,Myocyte-specific enhancer factor 2B,HLA-A*03:02,MHC binding prediction,ELISPOT,1,2,0.5
1337759,RTNTVILETLK,,,,,neo-epitope,RTNTDILETLK,Myocyte-specific enhancer factor 2B,HLA-A*11:02,Single allele present,ELISPOT,1,1,1.0
1632362,RTQDAEFLK,,,,,neo-epitope,PTQDAEFLK,Paraneoplastic antigen-like protein 8A,HLA-A*11:01,Single allele present,ELISA,1,3,0.6666666666666666
1397988,RTQDVSVQVER,,,,,neo-epitope,RTQDVSVQVEM,Ankyrin repeat domain-containing protein 20B,HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
1334624,RTSSTQQDNPK,,,,,neo-epitope,RSSSTQQDNPK,TRIO and F-actin-binding protein,HLA-A*11:01,Single allele present,ELISPOT,1,2,1.0
1334625,RTSSTQQDNPQ,355.0,365.0,TRIO and F-actin-binding protein,TRIO and F-actin-binding protein,,,,HLA-A*11:01,Single allele present,ELISPOT,1,1,1.0
1309278,RVCGPCSTY,,,,,neo-epitope,RVRGPCSTY,Phospholipid scramblase (Fragment),HLA-A*29:02,T cell assay -Mismatched MHC molecules,ELISA,1,1,1.0
1862314,RVFNKYPTLK,,,,,neo-epitope,RVFNKYPTSK,Activating signal cointegrator 1 complex subunit 3,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1337764,RVFRDSWAL,,,,,neo-epitope,RVFGDSWAL,Otogelin-like protein,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
56387,RVRAMAIYK,156.0,164.0,Cellular tumor antigen p53,Cellular tumor antigen p53,,,,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
179897,RVRFFFPSL,289.0,297.0,Melanoma-associated antigen 1,Melanoma-associated antigen 1,,,,HLA-B*07:02,Cited reference,ELISPOT,1,2,1.0
1087716,RVRVMAIYK,,,,,neo-epitope,RVRAMAIYK,Cellular tumor antigen p53,HLA-A*11:01,MHC binding prediction,ELISPOT,1,2,0.5
742513,RVSTLRVSL,,,,,neo-epitope,RVSTLRVSP,Guanine nucleotide-binding protein subunit beta-5,HLA-B*07:02,MHC binding prediction,ELISA,1,1,1.0
1337790,RVYISYLDCI,,,,,neo-epitope,RVYISYLDSI,CREB-binding protein,HLA-A*30:01,Single allele present,ELISPOT,1,2,1.0
767706,RYCNLEGPPI,133.0,142.0,"LY6K protein, partial [Homo sapiens]",Lymphocyte antigen 6K,,,,HLA-A*24:02,Cited reference,ELISPOT,1,1,1.0
1862322,RYGIRGFSTI,,,,,neo-epitope,RYGIRGFPTI,Protein disulfide-isomerase A6,HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
545022,RYGSFSVTL,479.0,487.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-C*07:01,Single allele present,ELISPOT,1,2,1.0
1715353,RYLTQETNKV,102.0,111.0,Parathyroid hormone-related protein,Parathyroid hormone-related protein,,,,HLA-A24,Cited reference,ELISPOT,1,5,0.8
1074784,RYPRYLYKL,,,,,neo-epitope,MYIRYLYKL,Dedicator of cytokinesis protein 2,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1391913,RYPWARLYSTSQTAVDSGEVKTFLALA,,,,,neo-epitope,RYPWARLYSTSQTTVDSGEVKTFLALA,"Ubiquinone biosynthesis O-methyltransferase, mitochondrial",HLA-A*02:06,MHC binding prediction,ELISPOT,1,1,1.0
1074785,RYSVFFQLL,,,,,neo-epitope,RYSVFFQSL,26S proteasome non-ATPase regulatory subunit 6,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1397989,RYVLHVVAA,,,,,neo-epitope,RYVLHVVAP,Protein mono-ADP-ribosyltransferase PARP14 (Fragment),HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
1066452,RYYVGHKAKF,,,,,neo-epitope,RYYVGHKGKF,Protein mago nashi homolog,HLA-A*24:02,Single allele present,ELISA,1,6,0.5
1066453,RYYVGHKGKF,10.0,19.0,Protein mago nashi homolog 2,Protein mago nashi homolog,,,,HLA-A*24:02,Single allele present,ELISA,0,3,0.0
56721,SACDVSVRV,464.0,472.0,Solute carrier family 45 member 3,Solute carrier family 45 member 3,,,,HLA-C*05:01,Not determined,ELISPOT,1,2,1.0
56722,SACDVSVRVV,464.0,473.0,Solute carrier family 45 member 3,Solute carrier family 45 member 3,,,,HLA-C*05:01,Not determined,ELISPOT,1,2,1.0
1313521,SADGGGLS,,,,,neo-epitope,SADRGGLS,Probable G-protein-coupled receptor 179,HLA-C*05:01,MHC binding prediction,ELISPOT,0,1,0.0
1334627,SADVEFCLSL,315.0,324.0,Tyrosinase precursor,Tyrosinase,,,,HLA-B*44:03,MHC binding prediction,ELISPOT,1,2,0.5
110702,SAFRCFIVY,55.0,63.0,E5 protein,,,,,HLA-B*15:01,Single allele present,ELISA,1,2,1.0
1391914,SAPFLASAVSAQPLLPDQCPALCECSE,,,,,neo-epitope,SAPFLASAVSAQPPLPDQCPALCECSE,Trophoblast glycoprotein,HLA-A*02:06,MHC binding prediction,ELISPOT,1,1,1.0
1397990,SASLHPATV,,,,,neo-epitope,SASLRPATV,Kinesin-like protein,HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
1125133,SCMGGMNWR,,,,,neo-epitope,SCMGGMNRR,Cellular tumor antigen p53,HLA-A*68:01,Cited reference,ELISA,1,1,1.0
1125132,SCMGGMNWR + AIB(C2),,,,,neo-epitope,SCMGGMNRR,Cellular tumor antigen p53,HLA-A*68:01,Cited reference,ELISA,1,1,1.0
1125137,SCSRAVPQV,,,,,neo-epitope,SCSRAIPQV,Cytoplasmic FMR1-interacting protein 1,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1125136,SCSRAVPQV + AIB(C2),,,,,neo-epitope,SCSRAIPQV,Cytoplasmic FMR1-interacting protein 1,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1334628,SEHGFGPSL,,,,,neo-epitope,SEHGFGP,Mitochondrial peptide methionine sulfoxide reductase,HLA-B*40:01,MHC binding prediction,ELISPOT,1,1,1.0
1334629,SEIISFKSL,,,,,neo-epitope,SEIISFKSM,Fasciculation and elongation protein zeta-1,HLA-B*40:01,MHC binding prediction,ELISPOT,1,1,1.0
1854630,SEITKQEKDF,,,,,neo-epitope,SEITEQEKDF,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",HLA-B*44:03,Cited reference,ELISA,0,2,0.0
57494,SEIWRDIDF,192.0,200.0,Tyrosinase precursor,Tyrosinase,,,,HLA-B*44:03,MHC binding prediction,ELISPOT,1,2,0.5
1862343,SELMKVSAM,,,,,neo-epitope,SELVKVSAM,Mediator of RNA polymerase II transcription subunit 24 (Fragment),HLA-B*41:02,MHC binding prediction,ELISPOT,0,1,0.0
1313541,SELRKTLGPIW,,,,,neo-epitope,KTLGPIL,Interferon-related developmental regulator 1,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1393418,SEMEELPSV,238.0,246.0,Variable charge X-linked protein 3B,,,,,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1075663,SESIKKKVL,307.0,315.0,Melanoma-associated antigen C2,Melanoma-associated antigen C2,,,,HLA-B*44:03,MHC binding prediction,ELISPOT,0,2,0.0
1852340,SFPGIYDAL,704.0,712.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,0,2,0.0
1862348,SFSSAPMPQI,,,,,neo-epitope,SFSSASMPQI,Protein PRRC2C,HLA-A*24:02,MHC binding prediction,ELISPOT,0,1,0.0
1075049,SGGDRFCLGQLSNVHRTEAIERARLH,357.0,382.0,SMAD4,Mothers against decapentaplegic homolog 4,,,,HLA-A*02:01,Single allele present,ELISPOT,0,1,0.0
1854641,SGLYVFRNER,,,,,neo-epitope,SGLYIFRNER,Breast cancer type 2 susceptibility protein,HLA-A*31:01,Cited reference,ELISA,0,2,0.0
859441,SHETVIIEL,,,,,neo-epitope,SHETVTIEL,Small nuclear ribonucleoprotein Sm D1,HLA-B*38:01,MHC binding prediction,ELISPOT,1,1,1.0
1391920,SIEDHCSIAQQRNLAQYFKKVLGDTLL,,,,,neo-epitope,SIEDHCSIAQQRNMAQYFKKVLGDTLL,"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1",HLA-A*02:01,Single allele present,ELISPOT,1,2,0.5
1313558,SIGDYYTCAR,,,,,neo-epitope,SIGDYYACAR,Solute carrier family 23 member 1,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1862371,SIKEITNFK,,,,,neo-epitope,SIKEITNLK,Early endosome antigen 1,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
848849,SIKKKVLEF,309.0,317.0,Melanoma-associated antigen C2,Melanoma-associated antigen C2,,,,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1087722,SILEQMHRK,,,,,neo-epitope,SILEQMRRK,Septin-9,HLA-A*11:01,Single allele present,ELISPOT,1,4,0.5
1087723,SILEQMRRK,283.0,291.0,Septin-9,Septin-9,,,,HLA-A*11:01,MHC binding prediction,ELISPOT,0,2,0.0
1862372,SILMHGLVSL,,,,,neo-epitope,PYLMHGLVSL,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1404434,SISCHVFCL,,,,,neo-epitope,SISCHVLCL,Protein mono-ADP-ribosyltransferase PARP10,HLA-A*02:06,MHC binding prediction,ELISPOT,1,2,1.0
1854664,SISFENLDTA,,,,,neo-epitope,SISFENVDTA,Gamma-tubulin complex component,HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1388660,SKRARELQGFLDGLKKGQEQVLGDLSM,,,,,neo-epitope,SKRARELQGFLDGVKKGQEQVLGDLSM,Negative elongation factor B,HLA-B*27:04,MHC binding prediction,ELISPOT,1,1,1.0
545215,SLADTNSLAVV,570.0,580.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1862379,SLANFGGWV,,,,,neo-epitope,SLANSGGWV,Coiled-coil domain-containing protein 61,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862381,SLDTAKVRL,,,,,neo-epitope,PLDTAKVRL,Mitochondrial uncoupling protein 3,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1854680,SLEFENKQAL,,,,,neo-epitope,SSEFENKQAL,Serine-protein kinase ATM,HLA-B*40:01,Cited reference,ELISA,0,2,0.0
1334631,SLFWQTAMV,,,,,neo-epitope,SLFWLTAMV,Immunoglobulin-like domain-containing receptor 2,HLA-A*02:10,MHC binding prediction,ELISPOT,0,1,0.0
1309962,SLGCVMYTLL,245.0,254.0,Serine/threonine-protein kinase PLK3,Serine/threonine-protein kinase PLK3,,,,HLA-A*02:11,MHC binding prediction,ELISPOT,0,1,0.0
1391923,SLHEPMYIFL,56.0,65.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1862385,SLHKGSLYPR,,,,,neo-epitope,PLHKGSLYPR,Caspase recruitment domain-containing protein 16,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1313587,SLIHYTAQI,,,,,neo-epitope,SLIHSTAQI,Olfactory receptor 4C11,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862387,SLKKSFNFF,,,,,neo-epitope,SLKKSFDFF,Sterile alpha motif domain-containing protein 9 (Fragment),HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1313591,SLKQKKKP,,,,,neo-epitope,SLKQKKKR,E3 ubiquitin-protein ligase TRIM23,HLA-B*15:01,MHC binding prediction,ELISPOT,0,1,0.0
448341,SLLDSCTKL,115.0,123.0,T-complex protein 1 subunit delta isoform a,T-complex protein 1 subunit delta,,,,HLA-A*02:01,MHC binding assay,ELISA,0,1,0.0
1391924,SLLISFSYLL,213.0,222.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
59278,SLLMWITQC,157.0,165.0,NY-ESO-1 protein,Cancer/testis antigen 1,,,,HLA-A*02:01,Cited reference,ELISPOT,1,25,0.96
59277,SLLMWITQC + AIB(C9),99.0,107.0,"CTAG2 protein, partial [Homo sapiens]",Cancer/testis antigen 1,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
59283,SLLMWITQV,,,,,analog,SLLMWITQC,Cancer/testis antigen 1,HLA-A*02:01,Not determined,ELISA,1,7,1.0
1397423,"SLLNSVLTL + OTH(S1, L9)",,,,,analog,QLLNSVLTL,Retroelement silencing factor 1,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1632701,SLLPHKHVV,,,,,neo-epitope,SLLPPKHVV,,HLA-A2,MHC binding assay,ELISA,1,1,1.0
1862389,SLLRAAFFGK,,,,,neo-epitope,SLLRAASFGK,Vacuolar protein sorting-associated protein 16 homolog,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1392429,SLLSGDWVL,191.0,199.0,Serine protease hepsin,Serine protease hepsin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1393434,SLLTDCNPA,168.0,176.0,ubiquitin-conjugating enzyme E2 E3,Ubiquitin-conjugating enzyme E2 E3,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1694342,SLLTPPSTK,,,,,neo-epitope,SLLTPPPTK,Sodium/myo-inositol cotransporter,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
237363,SLLTSSKGQLQK,369.0,380.0,Perilipin-2,Perilipin-2,,,,HLA-A*03:01,Cited reference,ELISPOT,0,1,0.0
1337844,SLMDKVSNGI,,,,,neo-epitope,SLMDKVPNGI,Cullin-5,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1309582,SLMEQIPHL,,,Cytoskeleton-associated protein 2,,,,,HLA-A*02:01,MHC binding prediction,ELISA,1,1,1.0
1393438,SLPMKNFPV,,,,,neo-epitope,SLPTKNFPV,IQ domain-containing protein E,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
59401,SLPPPGTRV,,,,,analog,STPPPGTRV,Cellular tumor antigen p53,HLA-A2,Not determined,ELISPOT,1,1,1.0
1862392,SLPSNVLSSL,,,,,neo-epitope,SLPSNVLPSL,Deoxyribonuclease-1-like 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1393439,SLPTKNFPV,687.0,695.0,IQ domain-containing protein E,IQ domain-containing protein E,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1694416,SLQPRGSFK,,,,,neo-epitope,PLQPRGSFK,FH2 domain-containing protein 1,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1862394,SLQRLMLRKV,,,,,neo-epitope,SLQRLMLRRV,Toll-like receptor 3,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1086545,SLSASPVSN,772.0,780.0,Inactive tyrosine-protein kinase transmembrane receptor ROR1,Inactive tyrosine-protein kinase transmembrane receptor ROR1,,,,HLA-A2,MHC binding prediction,ELISPOT,1,2,1.0
1074628,SLSKILDTV,904.0,912.0,breast cancer antigen NY-BR-1,Ankyrin repeat domain-containing protein 30A,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1715618,SLSLGFLFL,13.0,21.0,Prostatic acid phosphatase precursor,Prostatic acid phosphatase,,,,HLA-A*02:01,Cited reference,ELISA,0,1,0.0
1337854,SLVLQPLLPV,,,,,neo-epitope,SLVLQPLLPA,ALS2 C-terminal-like protein,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1871162,SLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1542524,SLYDLDIEA,,,,,neo-epitope,SSYDLDIEA,Protocadherin beta-15,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1694566,SLYLKIHLK,,,,,neo-epitope,SSYLKIHLK,,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1087726,SMACVGFFL,,,,,neo-epitope,IMACVGFFL,Killer cell immunoglobulin-like receptor 2DS4,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1310812,SMFVNSLLL,527.0,535.0,WD repeat-containing protein 75 isoform X1 [Homo sapiens],WD repeat-containing protein 75,,,,HLA-A*02:01,MHC binding assay,ELISA,0,1,0.0
1313618,SMIPKAIESF,,,,,neo-epitope,SMIPKARESF,SMC5-SMC6 complex localization factor protein 2,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1313619,SMIPKAIESFL,,,,,neo-epitope,SMIPKARESFL,SMC5-SMC6 complex localization factor protein 2,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1337858,SMIQIITGQL,,,,,neo-epitope,SMVQIITGQL,Protein FAM83B,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
128111,SMPDFDLHL,2580.0,2588.0,Neuroblast differentiation-associated protein AHNAK,Neuroblast differentiation-associated protein AHNAK,,,,HLA-A*02:01,Single allele present,ELISA,0,1,0.0
1313624,SMSPVLHTENK,,,,,neo-epitope,SMSPVLHTQNK,Nuclear pore membrane glycoprotein 210,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1334632,SMYLPGAEV,275.0,283.0,Transcription factor SOX-2,Transcription factor SOX-2,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1397999,SPFTATSL,,,,,neo-epitope,APFTATSL,Putative HERC2-like protein 3,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1862406,SPHLARHRHL,,,,,neo-epitope,SPHPARHRHL,Testis-expressed protein 2,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1862410,SPLYSVKSL,,,,,neo-epitope,SPLYSVKSF,ATP-dependent RNA helicase DDX19B,HLA-B*07:02,MHC binding prediction,ELISPOT,0,1,0.0
1398001,SPSKTSLTL,,,,,neo-epitope,SPSKTSLPL,Ankyrin repeat and LEM domain-containing protein 2,HLA-B*07:02,MHC binding prediction,ELISPOT,0,1,0.0
1391928,SPTKEAPPGLNDDGQIPASQESVATSV,,,,,neo-epitope,SPTKEAPPGLNDDAQIPASQESVATSV,Structure-specific endonuclease subunit SLX4,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862412,SPVLRSHSF,,,,,neo-epitope,SPVSRSHSF,Mitogen-activated protein kinase kinase kinase kinase 4,HLA-B*35:01,MHC binding prediction,ELISPOT,0,1,0.0
1862414,SPVTFPAAA,,,,,neo-epitope,SPVTSPAAA,Bromodomain adjacent to zinc finger domain protein 2A,HLA-B*56:01,MHC binding prediction,ELISPOT,0,1,0.0
1854756,SPWATSSHL,,,,,neo-epitope,Proto-oncogene tyrosine-protein kinase receptor Ret,,HLA-B*07:02,Cited reference,ELISA,0,2,0.0
1862416,SQFARVPGY,,,,,neo-epitope,SQFARVPGF,Protein PAT1 homolog 1,HLA-B*27:02,MHC binding prediction,ELISPOT,0,1,0.0
1862417,SQFARVPGYV,,,,,neo-epitope,SQFARVPGFV,Protein PAT1 homolog 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1393465,SQMEELPSV,,,,,neo-epitope,SEMEELPSV,,HLA-A*02:06,MHC binding prediction,ELISPOT,0,2,0.0
1862422,SQYEQKVRL,,,,,neo-epitope,SQYEQKVRP,Interferon-induced GTP-binding protein Mx2,HLA-B*47:01,MHC binding prediction,ELISPOT,0,1,0.0
680892,SRILLRQQL,55.0,63.0,Microphthalmia-associated transcription factor,Microphthalmia-associated transcription factor,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1862425,SRLLVRPTSF,,,,,neo-epitope,SRLLVRPTSS,Triple functional domain protein,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1862428,SRSNFDSTL,268.0,276.0,"5,6-dihydroxyindole-2-carboxylic acid oxidase","5,6-dihydroxyindole-2-carboxylic acid oxidase",,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1337923,SRTNTAILETL,,,,,neo-epitope,SRTNTDILETL,Myocyte-specific enhancer factor 2B,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0
1337924,SRTNTAILEV,,,,,neo-epitope,SRTNTDILEV,Myocyte-specific enhancer factor 2B,HLA-C*06:02,MHC binding prediction,ELISPOT,1,1,1.0
1695413,SRVILFSPL,,,,,neo-epitope,SRVILFNPL,Stonin-2,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1391929,SRYFHIPIGNLPEYISTFGSDLFFARH,,,,,neo-epitope,SRYFHIPIGNLPEDISTFGSDLFFARH,DNA polymerase epsilon catalytic subunit A,HLA-B*15:02,MHC binding prediction,ELISPOT,0,1,0.0
1398002,SSAAAPFPL,,,,,neo-epitope,SSAAAPFPH,Ran-binding protein 9,HLA-C*03:04,MHC binding prediction,ELISPOT,1,2,0.5
1854770,SSADHPGASK,,,,,neo-epitope,SSAEHPGASK,Microphthalmia-associated transcription factor,HLA-A*11:01,Cited reference,ELISA,0,2,0.0
1854773,SSCMGGMNLR,,,,,neo-epitope,SSCMGGMNRR,Cellular tumor antigen p53,HLA-A*11:01,Cited reference,ELISA,0,2,0.0
1334636,SSEDDGFFLGE,556.0,566.0,Prickle-like protein 3,Prickle planar cell polarity protein 3,,,,HLA-A*11:01,Single allele present,ELISPOT,1,1,1.0
1334637,SSEDDGFFLGK,,,,,neo-epitope,SSEDDGFFLGE,Prickle planar cell polarity protein 3,HLA-A*11:01,Single allele present,ELISPOT,1,2,0.5
1334638,SSEIISFKSL,,,,,neo-epitope,SSEIISFKSM,Fasciculation and elongation protein zeta-1,HLA-B*40:01,MHC binding prediction,ELISPOT,1,1,1.0
1862432,SSHDHFRVL,2019.0,2027.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-C*07:01,MHC binding prediction,ELISPOT,0,1,0.0
1313673,SSKKVMRTK,,,,,neo-epitope,SNKKVMRTK,Inactive carboxypeptidase-like protein X2,HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1313676,SSLSSPQPQL,,,,,neo-epitope,ASLSSPQPQL,CREB-regulated transcription coactivator 2 (Fragment),HLA-A*30:01,MHC binding prediction,ELISPOT,0,1,0.0
1393475,SSMESRLLK,,,,,neo-epitope,SSMESLLLK,HEAT repeat-containing protein 3,HLA-A*11:01,MHC binding prediction,ELISA,0,1,0.0
1075703,SSPGCQPPA,529.0,537.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-B*07:02,MHC binding prediction,ELISPOT,0,2,0.0
1391932,SSQHASRGGQSDDYEDEGVPASYHTVS,,,,,neo-epitope,SSQHASRGGQSDDDEDEGVPASYHTVS,Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1,HLA-B*15:01,MHC binding prediction,ELISPOT,1,1,1.0
1862436,SSQPQVPFY,,,,,neo-epitope,SSQPQVPFH,Dynamin-binding protein,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1862438,SSRTRHYVTL,,,,,neo-epitope,SSRTRHHVTL,E3 ubiquitin-protein ligase RLIM,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1398003,SSTSNRSSTW,,,,,neo-epitope,SSTSNRSSTR,Phosphoinositide 3-kinase adapter protein 1,HLA-B*57:01,MHC binding prediction,ELISPOT,0,1,0.0
1313686,SSWHNADDDR,,,,,neo-epitope,SSWRNADDDR,Eukaryotic translation initiation factor 3 subunit A,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1595249,SSYTGFANK,,,,,neo-epitope,SNYTGFANK,Kinesin-like protein KIF26B,HLA-A*11:01,Single allele present,ELISPOT,1,6,0.5
427487,STDPQHHAY,745.0,753.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,2,0.0
432412,STEEARFLTY,182.0,191.0,Baculoviral IAP repeat-containing protein 2,Baculoviral IAP repeat-containing protein 2,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1075707,STESITGSLGPLLDGTATLR,446.0,465.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0
1313691,STIKEALSVV,3.0,12.0,transcriptional regulator ERG isoform 1 [Homo sapiens],Transcriptional regulator ERG,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1854796,STPLPGTRVR,,,,,neo-epitope,STPPPGTRVR,Cellular tumor antigen p53,HLA-A*11:01,Cited reference,ELISA,1,2,0.5
61831,STPPPGATRV,,,Cellular tumor antigen p53,Cellular tumor antigen p53,,,,HLA-A2,Not determined,ELISPOT,1,1,1.0
1393483,STRPVLVFER,,,,,neo-epitope,STGPVLVFER,Electrogenic sodium bicarbonate cotransporter 1,HLA-A*31:01,MHC binding prediction,ELISA,0,1,0.0
1862449,STTKRRWSAL,59.0,68.0,alternative protein DHX40 [Homo sapiens],,,,,HLA-A*25:01,MHC binding prediction,ELISPOT,0,1,0.0
1334640,STVPLDTLK,,,,,neo-epitope,TVPLDTLK,WD repeat-containing protein 36,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1854797,STVQLIMQL,,,,,neo-epitope,STVQLITQL,Epidermal growth factor receptor,HLA-C*15:02,Cited reference,ELISA,1,3,0.6666666666666666
1854798,STYMIQKAV,,,,,neo-epitope,STYMIQIAV,Proto-oncogene tyrosine-protein kinase ROS,HLA-A*32:01,Cited reference,ELISA,0,2,0.0
1862453,SVGDFSQEF,,,,,neo-epitope,SVGDSSQEF,Iporin,HLA-B*15:01,MHC binding prediction,ELISPOT,0,1,0.0
1313703,SVISQLMK,,,,,neo-epitope,SVIRQLMK,Sarcoplasmic/endoplasmic reticulum calcium ATPase 1,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1313704,SVISQLMKK,,,,,neo-epitope,SVIKQLMKK,Sarcoplasmic/endoplasmic reticulum calcium ATPase 2,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1862455,SVIVRTLSGK,,,,,neo-epitope,SVIVRTPSGK,Phospholipid-transporting ATPase IA,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1862456,SVIVRTSSGK,,,,,neo-epitope,SVIVRTPSGK,Phospholipid-transporting ATPase IA,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1398011,SVKPHLCSL,,,,,neo-epitope,SVKPRLCSL,Schlafen family member 11,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
911532,SVLENFTIFL,,,,,neo-epitope,SVLENFTILL,Transcriptional enhancer factor TEF-1,HLA-A*02:01,Single allele present,ELISA,1,1,1.0
1398012,SVLLPENYITK,,,,,neo-epitope,SGLLPENYITK,Ubiquitin-associated and SH3 domain-containing protein B,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1068341,SVLWLGALGL,50.0,59.0,Uncharacterized protein C20orf141,Uncharacterized protein C20orf141,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1398014,SVQAPVPPK,,,,,neo-epitope,SLQAPVPPK,Cytosolic endo-beta-N-acetylglucosaminidase,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1398015,SVSDISEYR,,,,,neo-epitope,SVSDISQYR,Epidermal growth factor receptor kinase substrate 8,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1398016,SVSDISEYRV,,,,,neo-epitope,SVSDISQYRV,Epidermal growth factor receptor kinase substrate 8,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1854807,SVSFGTVYK,,,,,neo-epitope,SGSFGTVYK,RAF proto-oncogene serine/threonine-protein kinase,HLA-A*33:03,Cited reference,ELISA,0,2,0.0
1862463,SVYGIVVMNR,,,,,neo-epitope,SVYGTVVMNR,Plexin-C1,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
742514,SWISDIRAGTAPLCRNHIKSSCSLI,,,,,neo-epitope,SWISDIRAGTAPSCRNHIKSSCSLI,Coronin-7,HLA-B*51:01,Single allele present,ELISA,1,1,1.0
1074793,SYEKIYLDF,,,,,neo-epitope,SYEKIHLDF,Platelet-derived growth factor receptor alpha,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1074794,SYGVRFNSF,,,,,neo-epitope,SYGVRFNGF,Gamma-aminobutyric acid receptor subunit theta,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1862468,SYKHEQVYI,96.0,104.0,Prostatic acid phosphatase precursor,Prostatic acid phosphatase,,,,HLA-A*24:02,MHC binding assay,ELISA,0,2,0.0
742515,SYMIMEIEL,,,,,neo-epitope,SSMIMEIEL,F-box only protein 21,HLA-C*14:02,MHC binding prediction,ELISA,1,1,1.0
1862470,SYQLYTHPL,,,,,neo-epitope,SYQLYSHPL,,HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
1862471,SYQRYSHPLF,124.0,133.0,"mucin, partial [Homo sapiens]",,,,,HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
78024,SYTRLFLIL,899.0,907.0,Dermatan-sulfate epimerase precursor,Dermatan-sulfate epimerase,,,,HLA-A*24:02,Cited reference,ELISA,1,2,0.5
1862477,TALPQSILLF,,,,,neo-epitope,TALPRSILLF,Fidgetin,HLA-B*35:01,MHC binding prediction,ELISPOT,0,2,0.0
1862478,TAPIPAEAL,1489.0,1497.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1862479,TAPPYFSPL,878.0,886.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1393500,TAVAGLASY,,,,,neo-epitope,TAVAGLTSY,ADP/ATP translocase 2,HLA-B*35:01,MHC binding prediction,ELISA,0,1,0.0
1854826,TDFGRAILL,,,,,neo-epitope,TDFGLAKLL,Epidermal growth factor receptor,HLA-B*50:01,Cited reference,ELISA,0,2,0.0
1854827,TDFGRAKLL,,,,,neo-epitope,TDFGLAKLL,Epidermal growth factor receptor,HLA-B*37:01,Cited reference,ELISA,0,6,0.0
1862490,TEATFFPPL,,,,,neo-epitope,TGATFFPPL,Bromodomain adjacent to zinc finger domain protein 2B,HLA-B*40:02,MHC binding prediction,ELISPOT,0,1,0.0
1862491,TEATFFPPLL,,,,,neo-epitope,TGATFFPPLL,Bromodomain adjacent to zinc finger domain protein 2B,HLA-B*40:02,MHC binding prediction,ELISPOT,0,1,0.0
1309291,TEDEHFEFY,,,,,neo-epitope,TEDEHFEFH,Targeting protein for Xklp2,HLA-B*44:03,T cell assay -Mismatched MHC molecules,ELISA,1,1,1.0
1862492,TELERFLEY,,,,,neo-epitope,TELERSLEY,Dephospho-CoA kinase domain-containing protein,HLA-B*44:02,MHC binding prediction,ELISPOT,0,1,0.0
1715956,TFDYLRSVL,486.0,494.0,Tyrosine-protein kinase Lck,Tyrosine-protein kinase Lck,,,,HLA-A24,Cited reference,ELISPOT,1,3,0.6666666666666666
1313742,THNLIFVFYML,,,,,neo-epitope,THNLFFVFYML,NADPH oxidase 4,HLA-B*39:01,MHC binding prediction,ELISPOT,0,1,0.0
1075738,THTMEVTVYHRRGSRSYVPL,181.0,200.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-C*06:02,Single allele present,ELISPOT,1,1,1.0
1334644,TIGVDFALK,41.0,49.0,Ras-related protein Rab-38,Ras-related protein Rab-38,,,,HLA-A*25:01,MHC binding prediction,ELISPOT,1,2,0.5
1862510,TIIDNIKEM,,,,,neo-epitope,TIIDNIEEM,C-type lectin domain family 2 member B,HLA-A*66:01,MHC binding prediction,ELISPOT,0,1,0.0
1391936,TIITLEDSSGNLLVRNSFEVRVCACPG,,,,,neo-epitope,TIITLEDSSGNLLGRNSFEVRVCACPG,Cellular tumor antigen p53,HLA-A*33:03,MHC binding prediction,ELISPOT,0,1,0.0
64399,TINPQVSKT,32.0,40.0,Mammaglobin-A precursor,Mammaglobin-A,,,,HLA-A2,Not determined,ELISPOT,1,1,1.0
1393506,TISKLYIPK,,,,,neo-epitope,IISKLYIPK,Ankyrin repeat domain-containing protein 36A,HLA-A*11:02,MHC binding prediction,ELISA,0,2,0.0
1862516,TITAPSLSGK,,,,,neo-epitope,TTTAPSLSGK,Catenin beta-1 (Fragment),HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1854856,TIYVFEIRAR,,,,,neo-epitope,TIYVFQIRAR,Ephrin type-A receptor 3,HLA-A*11:01,Cited reference,ELISA,0,2,0.0
1335269,TLAEDLNLL,,,,,neo-epitope,TSAEDLNLL,DNA damage-binding protein 1,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
545697,TLDEKVAEL,140.0,148.0,Melanoma-associated antigen C2,Melanoma-associated antigen C2,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
859505,TLDWLLQTPK,,,,,neo-epitope,TLGWLLQTPK,GPNMB protein,HLA-A*03:01,MHC binding prediction,ELISPOT,1,1,1.0
1862528,TLFHTFYEL,,,,,neo-epitope,TLFHTFYDL,NLR family CARD domain-containing protein 4,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862529,TLFHTFYELL,,,,,neo-epitope,TLFHTFYDLL,NLR family CARD domain-containing protein 4,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1393511,TLFSALRAL,2604.0,2612.0,Cytoplasmic dynein 1 heavy chain 1,Cytoplasmic dynein 1 heavy chain 1,,,,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1393512,TLFSALWAL,,,,,neo-epitope,TLFSALRAL,Cytoplasmic dynein 1 heavy chain 1,HLA-A*02:06,MHC binding prediction,ELISA,1,2,1.0
1862531,TLIGLPWSFL,,,,,neo-epitope,TLIGLPWSFP,Galactocerebrosidase,HLA-A*02:02,MHC binding prediction,ELISPOT,0,1,0.0
1073443,TLLSQVNKV,,,,,neo-epitope,TPLSQVNKV,Citron Rho-interacting kinase,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1073444,TLMSAMTNL,112.0,120.0,Prostatic acid phosphatase precursor,Prostatic acid phosphatase,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
1337979,TLNLRLSAV,,,,,neo-epitope,TPNLRLSAV,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1313759,TLPQSVSKQSV,,,,,neo-epitope,TLPQSVSKQAV,Leucine-rich repeat and fibronectin type-III domain-containing protein 5,HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
1391938,TLPRVTKIGV,139.0,148.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,0,1,0.0
1398029,TLQELSHAL,,,,,neo-epitope,TRQELSHAL,Pre-mRNA-processing factor 19,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
65064,TLSNVEVFM,73.0,81.0,Mammaglobin-A precursor,Mammaglobin-A,,,,HLA-A2,Not determined,ELISPOT,0,1,0.0
1862537,TLVPDLLSPK,,,,,neo-epitope,PLVPDLLSPK,Methyltransferase N6AMT1,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
742517,TLWCSPIKV,,,,,neo-epitope,TPWCSPIKV,Sushi repeat-containing protein SRPX,HLA-A*02:01,Single allele present,ELISA,1,6,1.0
1596817,TLWEGGLFKL,,,,,neo-epitope,TPWEGGLFKL,SUMO-conjugating enzyme UBC9,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1871173,TLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1309294,TLYSLTLLY,,,,,neo-epitope,TLYSLTPLY,Centromere protein L,HLA-A*29:02,T cell assay -Mismatched MHC molecules,ELISA,1,2,1.0
1699283,TLYSPRGEK,,,,,neo-epitope,TLYSPRGEE,ADAM DEC1,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1086780,TMIGTSSHL,207.0,215.0,Inactive tyrosine-protein kinase transmembrane receptor ROR1,Inactive tyrosine-protein kinase transmembrane receptor ROR1,,,,HLA-A2,MHC binding prediction,ELISPOT,1,2,1.0
449299,TMLARLASA,21.0,29.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5
1542850,TMSLYDLDIEA,,,,,neo-epitope,TMSSYDLDIEA,Protocadherin beta-15,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1862542,TPAAPTAMA,57.0,65.0,dJ579N16.4 [Homo sapiens],,,,,HLA-B*56:01,MHC binding prediction,ELISPOT,0,1,0.0
1862543,TPAHPSQGA,72.0,80.0,dJ579N16.4 [Homo sapiens],,,,,HLA-B*56:01,MHC binding prediction,ELISPOT,0,1,0.0
1862544,TPAHPSQGAV,72.0,81.0,dJ579N16.4 [Homo sapiens],,,,,HLA-B*56:01,MHC binding prediction,ELISPOT,0,1,0.0
1087749,TPINPRRCL,37.0,45.0,Coatomer subunit gamma-2,Coatomer subunit gamma-2,,,,HLA-B*07:02,MHC binding prediction,ELISPOT,0,1,0.0
1854912,TPITMTLPF,,,,,neo-epitope,TPITMTFPF,Olfactory receptor 2T4,HLA-B*07:02,Cited reference,ELISA,0,2,0.0
1854914,TPLPGTRVRA,,,,,neo-epitope,TPPPGTRVRA,Cellular tumor antigen p53,HLA-B*54:01,Cited reference,ELISA,1,2,0.5
1398034,TPLTKDVTL,,,,,neo-epitope,TPLTKDVSL,AP-3 complex subunit beta-1,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1313776,TPLVIKIDKPY,,,,,neo-epitope,TPLVVKIDKPY,Serpin A12,HLA-B*35:01,MHC binding prediction,ELISPOT,0,1,0.0
65748,TPRVTGGGAM,417.0,426.0,tegument protein pp65 [Human betaherpesvirus 5],65 kDa phosphoprotein,,,,HLA-B*07:02,Cited reference,ELISPOT,1,3,1.0
1398036,TPSAAVKLI,,,,,neo-epitope,TPSAAMKLI,StAR-related lipid transfer protein 5,HLA-B*51:01,MHC binding prediction,ELISPOT,0,1,0.0
1338005,TPTDVTARHL,,,,,neo-epitope,TPTDVTAIHL,G1/S-specific cyclin-D3,HLA-B*35:01,Single allele present,ELISPOT,1,1,1.0
1334049,TPTVPSSSF,,,,,neo-epitope,TPTVPSGSF,Alstrom syndrome protein 1,HLA-B*35:01,MHC binding assay,ELISPOT,1,1,1.0
859522,TPWCSPIKV,54.0,62.0,Sushi repeat-containing protein SRPX,Sushi repeat-containing protein SRPX,,,,HLA-A*02:01,Single allele present,ELISA,0,1,0.0
1862558,TQFNAWWHIL,,,,,neo-epitope,TQFHAWWHIL,Alkaline ceramidase (Fragment),HLA-B*38:01,MHC binding prediction,ELISPOT,0,1,0.0
1854921,TQGSAAELI,,,,,neo-epitope,TQGSTAELI,Neurofibromin,HLA-A*24:02,Cited reference,ELISA,0,2,0.0
859524,TQLMPFGCLL,790.0,799.0,Epidermal growth factor receptor precursor,Epidermal growth factor receptor,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0
1086794,TQLMPFGSLL,,,,,neo-epitope,TQLMPFGCLL,Epidermal growth factor receptor,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1862560,TRKNKKLAL,,,,,neo-epitope,TRKNKKLAP,Histone-lysine N-methyltransferase 2A,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1862562,TRNIIKYNL,,,,,neo-epitope,TRNIIKYDL,Olfactomedin-like protein 2B,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1591122,TRRLREQQKTAECDVGDYRCPQDQS,,,,,neo-epitope,TRRLREQQKTAEGDVGDYRCPQDQS,GDNF-inducible zinc finger protein 1,HLA-B*44:03,MHC binding prediction,ELISPOT,0,1,0.0
1862565,TRSEMVKYV,98.0,106.0,Melanoma-associated antigen F1,Melanoma-associated antigen F1,,,,HLA-C*06:02,MHC binding prediction,ELISPOT,0,1,0.0
1335294,TSAEDLNLL,24.0,32.0,Xeroderma Pigmentosum Group E Complementing protein [Homo sapiens],DNA damage-binding protein 1,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
220300,TSALPIIQK,63.0,71.0,Adipose differentiation-related protein,Perilipin-2,,,,HLA-A*03:01,Cited reference,ELISPOT,0,1,0.0
1087759,TSDYLSQSY,,,,,neo-epitope,TSDYVSQSY,Ubiquitin carboxyl-terminal hydrolase 47,HLA-A*01:01,MHC binding prediction,ELISPOT,1,2,0.5
432677,TSDYVSQSY,166.0,174.0,Ubiquitin carboxyl-terminal hydrolase 47,Ubiquitin carboxyl-terminal hydrolase 47,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
729016,TSIANLPKL,,,,,neo-epitope,TSIANLPKL,Acidic leucine-rich nuclear phosphoprotein 32 family member A,HLA-A*02:01,MHC binding assay,ELISPOT,1,4,0.5
1862568,TSIQSPSLY,,,,,neo-epitope,TSIQSPSSY,Tumor protein 63,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1398037,TSIVVSQTL,,,,,neo-epitope,TSIAVSQTL,WD repeat-containing protein 19,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1854935,TSSGLYVFR,,,,,neo-epitope,TSSGLYIFR,Breast cancer type 2 susceptibility protein,HLA-A*31:01,Cited reference,ELISA,0,2,0.0
1862574,TTEGIWKDVY,,,,,neo-epitope,TQGIWKDV,Beta-mannosidase,HLA-B*38:01,MHC binding prediction,ELISPOT,0,1,0.0
1862576,TTLFHTFYEL,,,,,neo-epitope,TTLFHTFYDL,NLR family CARD domain-containing protein 4,HLA-A*24:02,MHC binding prediction,ELISPOT,0,2,0.0
1700801,TTYSPIGEK,,,,,neo-epitope,TTYSPIGGK,Teneurin-1,HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
942779,TVAELVQFL,79.0,87.0,Melanoma-associated antigen F1,Melanoma-associated antigen F1,,,,HLA-C*06:02,MHC binding prediction,ELISPOT,1,1,1.0
1862591,TVLLKKIAF,477.0,485.0,Baculoviral IAP repeat-containing protein 1,Baculoviral IAP repeat-containing protein 1,,,,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1313814,TVTECLNTFCK,,,,,neo-epitope,TVTECLHTFCK,Polycomb group RING finger protein 5,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1074799,TWSTPHFYF,,,,,neo-epitope,TWSTPHSYF,Interleukin-12 subunit beta,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
67308,TYACFVSNL,652.0,660.0,Carcinoembryonic antigen-related cell adhesion molecule 5 precursor,Carcinoembryonic antigen-related cell adhesion molecule 5,,,,HLA-A*24:02,Not determined,ELISPOT,1,1,1.0
1074800,TYGESFHII,,,,,neo-epitope,TYGESFQVI,Protein unc-13 homolog C,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
606965,TYLPSAWNF,,,,,neo-epitope,TYLPSAWNS,PR domain zinc finger protein 10 (Fragment),HLA-A*24:02,T cell assay -Biological process measured,ELISPOT,1,2,1.0
606966,TYLPSAWNFF,,,,,neo-epitope,TYLPSAWNSF,PR domain zinc finger protein 10 (Fragment),HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0
1854953,TYQVSYGFR,,,,,neo-epitope,TYQGSYGFR,Cellular tumor antigen p53,HLA-A*31:01,Cited reference,ELISA,0,2,0.0
67474,TYSVSFDSL,624.0,632.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A24,Cited reference,ELISA,1,7,0.5714285714285714
67475,TYSVSFDSLF,624.0,633.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,1.0
1087764,VADINDHAL,,,,,neo-epitope,VADINDHAP,Protocadherin-16,HLA-C*03:03,MHC binding prediction,ELISPOT,1,3,0.6666666666666666
1087765,VADINDHAP,133.0,141.0,Protocadherin-16,Protocadherin-16,,,,HLA-C*03:03,MHC binding prediction,ELISPOT,0,2,0.0
1398047,VAKGFISRM,,,,,neo-epitope,VAEGFISRM,Macrophage-capping protein (Fragment),HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
1864059,VARLSSKSV,,,,,neo-epitope,VARLSSKSV,Tumor necrosis factor receptor superfamily member 6,HLA-C*03:04,MHC binding prediction,ELISA,1,2,0.5
1086859,VATNGKEVV,132.0,140.0,Inactive tyrosine-protein kinase transmembrane receptor ROR1,Inactive tyrosine-protein kinase transmembrane receptor ROR1,,,,HLA-A2,MHC binding prediction,ELISPOT,1,2,1.0
1313835,VAWHSEVGLPL,,,,,neo-epitope,VAWHSEVGLPV,DDB1- and CUL4-associated factor 12-like protein 1,HLA-C*03:03,MHC binding prediction,ELISPOT,0,1,0.0
1087767,VCRPLHYPLL,131.0,140.0,Olfactory receptor 2T3,Olfactory receptor 2T3,,,,HLA-C*07:02,MHC binding prediction,ELISPOT,0,2,0.0
1854977,VDNPLMCRL,,,,,neo-epitope,VDNPHVCRL,Epidermal growth factor receptor,HLA-B*37:04,Cited reference,ELISA,1,2,0.5
1398051,VEIEQLTY,,,,,neo-epitope,VEIEELTY,Syntaxin-5,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1398052,VENQKHSL,,,,,neo-epitope,VESQKHSL,Caprin-2,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1854988,VETDAAQPAV,,,,,neo-epitope,VETDAAQAAV,Cyclin-dependent kinase 13,HLA-B*40:01,Cited reference,ELISA,0,2,0.0
1334647,VEWLGRCIL,,,,,neo-epitope,EWLGRCIL,Chondroitin sulfate synthase 2,HLA-B*40:01,MHC binding prediction,ELISPOT,1,1,1.0
1398053,VEYPYTSF,,,,,neo-epitope,VEDPYTSF,Cofilin-2,HLA-B*18:01,MHC binding prediction,ELISPOT,0,1,0.0
1852391,VFELANSIVL,584.0,593.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5
1398054,VFKDLSVTL,,,,,neo-epitope,VFEDLSVTL,Renin receptor,HLA-B*38:01,MHC binding prediction,ELISPOT,0,1,0.0
1398055,VGADGVGKSAL,,,,,neo-epitope,VGAGGVGKSAL,GTP-binding protein GEM,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1068511,VIIKPLVWV,215.0,223.0,Serum amyloid P-component,Serum amyloid P-component,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1391946,VILANIYLLV,275.0,284.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,T cell assay -T cell subset identification,ELISA,1,2,1.0
1398058,VIMLNGTKK,,,,,neo-epitope,VIMLNGTKE,Replication termination factor 2,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1716210,VIQNLERGYR,449.0,458.0,Tyrosine-protein kinase Lck,Tyrosine-protein kinase Lck,,,,HLA-A11,Cited reference,ELISPOT,1,5,0.6
1313870,VISQLMKK,,,,,neo-epitope,VIRQLMKK,Sarcoplasmic/endoplasmic reticulum calcium ATPase 1,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1862638,VIVRTLSGK,,,,,neo-epitope,VIVRTPSGK,Phospholipid-transporting ATPase IA,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1855033,VKITDFGRAK,,,,,neo-epitope,VKITDFGLAK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,1,2,0.5
1592156,VKTDSTGTHSLYAMYQDYEIMFHVS,,,,,neo-epitope,VKTDSTGTHSLYTMYQDYEIMFHVS,Signal-induced proliferation-associated 1-like protein 3,HLA-A*32:01,MHC binding prediction,ELISPOT,0,1,0.0
1862947,VLAGGFFLL,27.0,35.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*02:01,MHC binding prediction,ELISA,1,2,1.0
1073891,VLAKKLKFV,,,,,neo-epitope,VLAKELKFV,Prostatic acid phosphatase,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1309304,VLAMAIYKQ,,,,,neo-epitope,VRAMAIYKQ,Cellular tumor antigen p53,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
907518,VLAVFIKAV,10.0,18.0,Immunoglobulin J chain,Immunoglobulin J chain,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0
1862646,VLDHKLEWV,,,,,neo-epitope,VLDHKPEWV,Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862647,VLDKAGSFK,,,,,neo-epitope,VLDKAGSYK,Inactive serine protease PAMR1,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1862648,VLEFEQMNLY,,,,,neo-epitope,VLEFEKMNLY,E3 ubiquitin-protein ligase TRIM17,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1711668,VLEGMEVV,172.0,179.0,Peptidyl-prolyl cis-trans isomerase B,Peptidyl-prolyl cis-trans isomerase B,,,,HLA-A2,Cited reference,ELISA,1,8,0.625
859563,VLENFTIFLV,,,,,neo-epitope,VLENFTILLV,Transcriptional enhancer factor TEF-1,HLA-A*02:01,Single allele present,ELISA,1,1,1.0
1391949,VLGNLTIIYI,41.0,50.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1862948,VLLALLMAGL,4.0,13.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,2,1.0
742518,VLLGVKLFGV,,,,,neo-epitope,VLLGVKLSGV,Collagen alpha-1(XVIII) chain,HLA-A*02:01,Single allele present,ELISA,1,4,1.0
859569,VLLGVKLSGV,534.0,543.0,Collagen alpha-1(XVIII) chain,Collagen alpha-1(XVIII) chain,,,,HLA-A*02:01,Single allele present,ELISA,0,1,0.0
1075780,VLLKEFTVSGNILTIRLTAA,121.0,140.0,Cancer/testis antigen 1,Cancer/testis antigen 1,,,,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0
1086925,VLLQAGSLHA,16.0,25.0,calcitonin isoform CT preproprotein [Homo sapiens],Calcitonin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0
1393557,VLLSICSLL,156.0,164.0,Ubiquitin-conjugating enzyme E2 E2,Ubiquitin-conjugating enzyme E2 E2,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1393558,VLLSICYLL,,,,,neo-epitope,VLLSICSLL,Ubiquitin-conjugating enzyme E2 E2,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1391951,VLLSWKVLDFSGPVPQGTGQPCSCGHW,,,,,neo-epitope,VLLSWKVLDFSGPGPQGTGQPCSCGHW,Breast cancer anti-estrogen resistance protein 1,HLA-A*02:01,Single allele present,ELISPOT,1,2,0.5
1855059,VLMGAVALGA,,,,,neo-epitope,VLTGAVALGA,Bcl-2-like protein 2 (Fragment),HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1855060,VLMGAVALGAL,,,,,neo-epitope,VLTGAVALGAL,Bcl-2-like protein 2 (Fragment),HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1075782,VLNGTVHPV,700.0,708.0,ATP-binding cassette sub-family B member 5,ATP-binding cassette sub-family B member 5,,,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1862652,VLNIVRFLK,,,,,neo-epitope,VLNIVRFLE,Sodium/potassium-transporting ATPase subunit beta-1,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1391952,VLNPIVYGV,287.0,295.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1391977,VLQCVNVSV,164.0,172.0,Kallikrein-4,Kallikrein-4,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0
1862656,VLSSLVLVPL,,,,,neo-epitope,VLPSLVLVPL,Deoxyribonuclease-1-like 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1855071,VLVASRGRAV,40.0,49.0,Prostate-specific antigen precursor,Prostate-specific antigen,,,,HLA-A2,MHC binding assay,ELISA,1,2,0.5
1391978,VLVHPQWVL,59.0,67.0,Kallikrein-4,Kallikrein-4,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0
1310905,VLWDYVYQL,,,,,neo-epitope,LLWDYVYQL,Transcription factor ETV7,HLA-A*02:01,MHC binding assay,ELISA,1,2,1.0
1310906,VLWDYVYQLL,,,,,neo-epitope,LLWDYVYQLL,Transcription factor ETV7,HLA-A*02:01,MHC binding assay,ELISA,1,2,1.0
1393565,VLWHVRYWV,293.0,301.0,Taste receptor type 2 member 46,Taste receptor type 2 member 46,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1393566,VLWHVTYWV,,,,,neo-epitope,VLWHVRYWV,Taste receptor type 2 member 46,HLA-A*02:01,MHC binding prediction,ELISA,0,2,0.0
1871190,VLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1393567,VLYLHITWV,,,,,neo-epitope,VLYLHITRV,Adenylate cyclase type 1,HLA-A*02:03,MHC binding prediction,ELISA,0,1,0.0
651675,VLYPVPLESY,439.0,448.0,Melanoma antigen preferentially expressed in tumors,Melanoma antigen preferentially expressed in tumors,,,,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1075787,VLYRYGSFSVTLDIVQGIES,476.0,495.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-C*07:01,Single allele present,ELISPOT,1,1,1.0
1313896,VMALTASTVPL,,,,,neo-epitope,VMALTASPVPL,Metal transporter CNNM2,HLA-C*03:03,MHC binding prediction,ELISPOT,0,1,0.0
1855075,VMASVDNPL,,,,,neo-epitope,VMASVDNPH,Epidermal growth factor receptor,HLA-A*02:01,Cited reference,ELISA,0,2,0.0
1082754,VMLEGEQEA,,,,,neo-epitope,VMLEGEQEE,Programmed cell death protein 7,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1082755,VMLEGEQEE,375.0,383.0,Programmed cell death protein 7,Programmed cell death protein 7,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1870825,VMMVNGDHRI,699.0,708.0,Histone-lysine N-methyltransferase EZH2,Histone-lysine N-methyltransferase EZH2,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1398076,VPDQKSKQL,,,,,neo-epitope,VPDQNSKQL,PHD finger protein 3,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1862662,VPKEHPAPPA,,,,,neo-epitope,VPKELPAPPA,Protein PRRC2A,HLA-B*56:01,MHC binding prediction,ELISPOT,0,1,0.0
1075793,VPLDCVLYRYGSFSVTLDIV,471.0,490.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-C*07:01,Single allele present,ELISPOT,1,1,1.0
1405954,VQIISCQY,,,,,neo-epitope,VQIIPCQY,Mediator of RNA polymerase II transcription subunit 13,HLA-A*30:02,T cell assay -MHC subset identification,ELISPOT,1,2,1.0
1862668,VQKVASKIPF,,,,,neo-epitope,VQKVASKIPS,Zinc finger BED domain-containing protein 4,HLA-B*15:01,MHC binding prediction,ELISPOT,0,1,0.0
1083076,VQLEEEYEV,,,,,neo-epitope,VQLEEEYED,Unconventional myosin-XVIIIa,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0
1066254,VQLIMQLMPF,,,,,neo-epitope,VQLITQLMPF,Epidermal growth factor receptor,HLA-A*02:06,Cited reference,ELISA,0,2,0.0
1309307,VRAMAIYKQ,157.0,165.0,Cellular tumor antigen p53,Cellular tumor antigen p53,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1862676,VRTLLSQVNK,,,,,neo-epitope,VRTPLSQVNK,Citron Rho-interacting kinase,HLA-B*27:05,MHC binding prediction,ELISPOT,1,1,1.0
1335345,VSDEGGSPI,,,,,neo-epitope,VSDEGGSPI,Cyclin-G-associated kinase,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
1398081,VSKIIGGNPK,,,,,neo-epitope,VSKIIGGDPK,WD repeat-containing protein 1,HLA-A*68:01,MHC binding prediction,ELISPOT,0,1,0.0
1595342,VSKILPSTW,,,,,neo-epitope,VSKTLPSTW,Clathrin interactor 1,HLA-B*57:01,MHC binding prediction,ELISPOT,1,2,1.0
1398082,VSKPGLDYEL,,,,,neo-epitope,VSKPGMDYEL,Probable E3 ubiquitin-protein ligase IRF2BPL,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1862684,VSPEPLQAL,364.0,372.0,Melanoma antigen preferentially expressed in tumors,Melanoma antigen preferentially expressed in tumors,,,,HLA-C*01:02,MHC binding prediction,ELISPOT,0,1,0.0
1398085,VSQPVAPSY,,,,,neo-epitope,VPQPVAPSY,Dyslexia-associated protein KIAA0319-like protein,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1862687,VSVGDFSQEF,,,,,neo-epitope,VSVGDSSQEF,Iporin,HLA-B*15:01,MHC binding prediction,ELISPOT,0,1,0.0
1313924,VTECLNTFCK,,,,,neo-epitope,VTECLHTFCK,Polycomb group RING finger protein 5,HLA-A*11:01,MHC binding prediction,ELISPOT,0,1,0.0
1862691,VTEKLQPTY,,,,,neo-epitope,VTEKLQLTY,Integrin alpha-9,HLA-A*01:01,MHC binding prediction,ELISPOT,1,1,1.0
1123008,VTIGPRLLL,,,,,neo-epitope,VTIGPRLFL,Neuron navigator 3,HLA-C*03:03,MHC binding prediction,ELISPOT,1,1,1.0
1592716,VTKEPIPVLPTVRYNMGGIPTNYKG,,,,,neo-epitope,VTKEPIPVLPTVHYNMGGIPTNYKG,"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial",HLA-C*06:02,MHC binding prediction,ELISPOT,0,1,0.0
1398091,VTLDVILER,,,,,neo-epitope,VTLEVILER,Alpha-catulin,HLA-B*57:01,MHC binding prediction,ELISPOT,0,1,0.0
1398093,VTNHAPLSW,,,,,neo-epitope,VTNHAPLSG,Oxysterol-binding protein-related protein 11,HLA-A*32:01,MHC binding prediction,ELISPOT,0,1,0.0
1862699,VTQVLSCLSY,,,,,neo-epitope,VTQVLSRLSY,DNA-directed RNA polymerase III subunit RPC2,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1313929,VTRRHASHQTF,,,,,neo-epitope,VTRRPASHQTF,Protein argonaute-4,HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
1075820,VTVYHRRGSRSYVPLAHSSS,186.0,205.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-C*06:02,Single allele present,ELISPOT,1,1,1.0
1862705,VVDFKKNLEY,,,,,neo-epitope,VVDLKKNLEY,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C",HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1862706,VVFPRAIFSL,9.0,18.0,microphthalmia-associated transcription factor isoform 3 [Homo sapiens],Microphthalmia-associated transcription factor,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1310221,VVGACGVGK,,,,,neo-epitope,VVGAGGVGK,GTP-binding protein GEM,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
71731,VVLASLIYR,609.0,617.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1398103,VVLPSDVTSY,,,,,neo-epitope,VVLPSDVTRY,Collagen alpha-1(VII) chain,HLA-A*32:01,MHC binding prediction,ELISPOT,0,1,0.0
859591,VVLSWAPPV,44.0,52.0,fibronectin type III domain-containing protein 3B isoform X3 [Homo sapiens],Fibronectin type III domain-containing protein 3B,,,,HLA-A*02:01,MHC binding assay,ELISPOT,0,1,0.0
859592,VVMSWAPPV,,,,,neo-epitope,VVLSWAPPV,Fibronectin type III domain-containing protein 3B,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
1855143,VVRHCPHHER,,,,,neo-epitope,VVRRCPHHER,Cellular tumor antigen p53,HLA-A*33:03,Cited reference,ELISA,0,2,0.0
1398107,VVSHPHLVYW,,,,,neo-epitope,VVSHPDLVYW,TBC domain-containing protein kinase-like protein,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1855144,VVTEVFLLA,,,,,neo-epitope,GVTEVFLLA,Olfactory receptor 5L2,HLA-A*02:06,Cited reference,ELISA,0,2,0.0
1310224,VVVGACGVGK,,,,,neo-epitope,VVVGAGGVGK,GTP-binding protein GEM,HLA-A*03:01,MHC binding prediction,ELISPOT,0,1,0.0
1393591,VVVPCEPPEV,,,,,neo-epitope,VVVPYEPPEV,Cellular tumor antigen p53,HLA-A*02:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666
1393592,VVVPYEPPEV,216.0,225.0,Cellular tumor antigen p53,Cellular tumor antigen p53,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666
1311524,VYALIAGATL,,,,,neo-epitope,VCALIAGATL,Protein phosphatase 1F,HLA-A*02:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666
78068,VYDYNCHVDL,109.0,118.0,Squamous cell carcinoma antigen recognized by T-cells 3,Squamous cell carcinoma antigen recognized by T-cells 3,,,,HLA-A24,Cited reference,ELISPOT,1,17,0.5882352941176471
1075826,VYFFLPDHL,,,,,neo-epitope,Melanocyte protein Pmel 17 precursor,,HLA-A*24:02,Cited reference,ELISPOT,1,3,1.0
473138,VYGIRLEHF,56.0,64.0,kinetochore protein Nuf2,Kinetochore protein Nuf2,,,,HLA-A*24:02,Single allele present,ELISPOT,1,2,1.0
1338137,VYHEIHIGYL,,,,,neo-epitope,VYHEILIGYL,CREB-binding protein,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0
606993,VYQYTFPDF,,,,,neo-epitope,VYQYTSPDF,Insulin-induced gene 1 protein,HLA-A*24:02,T cell assay -Biological process measured,ELISPOT,1,2,1.0
606994,VYQYTFPDFL,,,,,neo-epitope,VYQYTSPDFL,Insulin-induced gene 1 protein,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0
1087792,VYRPLHYPLL,,,,,neo-epitope,VCRPLHYPLL,Olfactory receptor 2T3,HLA-C*07:02,MHC binding prediction,ELISPOT,1,3,0.6666666666666666
1313946,WATSSSRVW,,,,,neo-epitope,RATSSSRVW,Tumor necrosis factor ligand superfamily member 14,HLA-B*35:01,MHC binding prediction,ELISPOT,0,1,0.0
1862722,WEDSQLVSHL,,,,,neo-epitope,CEDSQLVSHL,Probable ATP-dependent RNA helicase DDX60,HLA-B*40:02,MHC binding prediction,ELISPOT,0,1,0.0
1391954,WLAFPLCSL,28.0,36.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,T cell assay -T cell subset identification,ELISA,1,2,1.0
1716322,WLEYYNLER,511.0,519.0,Squamous cell carcinoma antigen recognized by T-cells 3,Squamous cell carcinoma antigen recognized by T-cells 3,,,,HLA-A3,Cited reference,ELISPOT,1,2,0.5
1862723,WLIEGDLQV,,,,,neo-epitope,WLIGGDLQV,Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862724,WLIEGDLQVL,,,,,neo-epitope,WLIGGDLQVL,Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
742519,WLIRETQPITK,,,,,neo-epitope,WLIRETQPISK,Xaa-Pro aminopeptidase 1,HLA-A*03:01,MHC binding prediction,ELISA,1,1,1.0
1406177,WLLLCIPGL,,,,,neo-epitope,WLLLCNPGL,"Glycogen phosphorylase, brain form",HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1338145,WLSDASERHPV,,,,,neo-epitope,WLSDASVRHPV,Versican core protein,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1406182,WLTGFLLA,,,,,neo-epitope,WLRGFLLA,Inhibin beta A chain,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1862725,WLVDLLPST,,,,,neo-epitope,RLVDLLPST,Tenascin-R,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1871196,WLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
1862726,WMLAEKTVQV,,,,,neo-epitope,WMPAEKTVQV,Phospholipase B-like 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1398113,WPVLLLNV,,,,,neo-epitope,WPVLLLLL,Matrilin-4,HLA-B*51:01,MHC binding prediction,ELISPOT,0,1,0.0
1393605,WQLEFLQPL,,,,,neo-epitope,RQLEFLQPL,Carbohydrate sulfotransferase 3,HLA-A*02:06,MHC binding prediction,ELISPOT,0,2,0.0
1313966,WRFQQLDTAI,,,,,neo-epitope,WRFEQLDTAI,ATP-binding cassette sub-family D member 2,HLA-B*39:01,MHC binding prediction,ELISPOT,0,1,0.0
1862727,WRNILLLSL,,,,,neo-epitope,WRNILLLPL,Caspase recruitment domain-containing protein 16,HLA-B*27:05,MHC binding prediction,ELISPOT,0,1,0.0
1862728,WRNILLLSLH,,,,,neo-epitope,WRNILLLPLH,Caspase recruitment domain-containing protein 16,HLA-B*27:05,MHC binding prediction,ELISPOT,1,1,1.0
1708078,WRNSFLLRY,,,,,neo-epitope,WRNSSLLRY,Intelectin-1,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1862730,WTNCILHEY,,,,,neo-epitope,WTNRILHEY,Uncharacterized protein (Fragment),HLA-A*66:01,MHC binding prediction,ELISPOT,0,2,0.0
1066512,WTRDSCDFSY,,,,,neo-epitope,RTRDSCDFSY,Uncharacterized protein KIAA1958,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1393608,WVMPEIPAL,762.0,770.0,"hCG2043250, isoform CRA_b",,,,,HLA-A*02:06,MHC binding prediction,ELISPOT,0,1,0.0
1393609,WVMPVIPAL,,,,,neo-epitope,WVMPEIPAL,,HLA-A*02:06,MHC binding prediction,ELISPOT,1,2,1.0
1860897,WVPVVFLTL,2.0,10.0,Prostate-specific antigen precursor,Prostate-specific antigen,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5
1398115,WVVSHPHLV,,,,,neo-epitope,WVVSHPDLV,TBC domain-containing protein kinase-like protein,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1338150,WVYECTVFL,,,,,neo-epitope,WVYEGTVFL,Olfactory receptor 2L8,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1074811,WYLKVINLF,,,,,neo-epitope,WYPKVINLF,"Dynein heavy chain 12, axonemal",HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
1313977,WYTHNLIF,,,,,neo-epitope,WYTHNLFF,NADPH oxidase 4,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1313978,WYTHNLIFVF,,,,,neo-epitope,WYTHNLFFVF,NADPH oxidase 4,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1862737,YDYVSALHPV,,,,,neo-epitope,YDHVSALHPV,Protein CASC1,HLA-B*41:02,MHC binding prediction,ELISPOT,0,1,0.0
1066513,YEGQVISNGF,,,,,neo-epitope,YGGQVISNGF,Adhesion G-protein coupled receptor D1,HLA-B*44:02,MHC binding prediction,ELISPOT,1,1,1.0
1398116,YEHEDVKEA,,,,,neo-epitope,YEDEDVKEA,Cytochrome b-c1 complex subunit 7,HLA-B*49:01,MHC binding prediction,ELISPOT,1,1,1.0
1855185,YEYRPSKAPSF,,,,,neo-epitope,YEDRPSKAPSF,Interleukin-6 receptor subunit beta,HLA-B*13:01,Cited reference,ELISA,0,2,0.0
1310009,YFFWGLWAL,,,,,neo-epitope,HFFWGLWAL,Ethanolamine kinase 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862743,YGIRGFSTI,,,,,neo-epitope,YGIRGFPTI,Protein disulfide-isomerase A6,HLA-A*23:01,MHC binding prediction,ELISPOT,0,1,0.0
1398117,YHGDPMPCL,,,,,neo-epitope,YHGDPMPCP,Complement C1s subcomponent,HLA-B*38:01,MHC binding prediction,ELISPOT,0,1,0.0
742520,YHSIEWAI,,,,,neo-epitope,YHPIEWAI,KIF-binding protein,HLA-B*38:01,MHC binding prediction,ELISA,1,2,1.0
1596835,YIHGRGWAL,,,,,neo-epitope,YIHGGGWAL,Arylacetamide deacetylase-like 1,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1862749,YIMMKTHLL,,,,,neo-epitope,YTMMKTHLL,Interleukin-1 receptor-associated kinase-like 2,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1309319,YKLVVVGAG,4.0,12.0,GTPase NRas,GTP-binding protein GEM,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1309320,YKLVVVGAV,,,,,neo-epitope,YKLVVVGAG,GTP-binding protein GEM,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1338166,YLAINEILGQL,,,,,neo-epitope,YLAINEISGQL,"Inositol 1,4,5-trisphosphate receptor type 1",HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
697034,YLAMPFATPMEAELARRSLA,91.0,110.0,Cancer/testis antigen 1,Cancer/testis antigen 1,,,,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0
74567,YLAPGPVTA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,MHC binding assay,ELISA,0,2,0.0
1310015,YLCLQNNFI,,,,,neo-epitope,YLYLQNNFI,Prolargin,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
754326,YLCSGSSYFV,89.0,98.0,Fragile X mental retardation 1 neighbor protein,Fragile X mental retardation 1 neighbor protein,,,,HLA-A*02:01,MHC binding prediction,ELISA,1,2,1.0
1335375,YLDLKGPKV,,,,,neo-epitope,DLDLKGPKV,Neuroblast differentiation-associated protein AHNAK,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
1335376,YLDTDVILM,,,,,neo-epitope,YPDTDVILM,Transforming protein RhoA,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0
534528,YLEAGPVTA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,Cited reference,ELISA,1,2,1.0
534529,YLEPAPVTA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,MHC binding assay,ELISA,0,2,0.0
534530,YLEPGAVTA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,Cited reference,ELISA,1,2,0.5
534531,YLEPGPATA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,Cited reference,ELISA,1,2,0.5
534532,YLEPGPVAA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,Cited reference,ELISA,1,2,1.0
74638,YLEPGPVTA,280.0,288.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding assay,ELISA,1,7,0.8571428571428571
74641,YLEPGPVTV,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,MHC binding assay,ELISA,1,2,1.0
1633479,YLEYGLHAA,,,,,neo-epitope,YREYGLHAA,Condensin-2 complex subunit D3,HLA-A2,MHC binding assay,ELISA,1,1,1.0
1709837,YLFFIQGYK,,,,,neo-epitope,YLSFIQGYK,"Dynein heavy chain 5, axonemal",HLA-A*03:01,MHC binding assay,ELISPOT,0,1,0.0
1314009,YLFRGRINPEV,,,,,neo-epitope,YLFRGRINTEV,"Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 protein",HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
74682,YLGSYGFRL,,,,,analog,YQGSYGFRL,Cellular tumor antigen p53,HLA-A2,Not determined,ELISPOT,1,1,1.0
1075853,YLHARLREL,462.0,470.0,Melanoma antigen preferentially expressed in tumors,Melanoma antigen preferentially expressed in tumors,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,2,0.0
1391956,YLIAVLGNLT,37.0,46.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,1,1,1.0
1862753,YLLFQNTDL,,,,,neo-epitope,YLLFQDTDL,General transcription factor 3C polypeptide 2,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1391957,YLLILKTVL,220.0,228.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,0,1,0.0
74787,YLLKPVQRI,627.0,635.0,Proto-oncogene DBL,Proto-oncogene DBL,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0
1393622,YLLTDCNPA,,,,,neo-epitope,SLLTDCNPA,Ubiquitin-conjugating enzyme E2 E3,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1087429,YLPGVIAAI,130.0,138.0,Metalloreductase STEAP1,Metalloreductase STEAP1,,,,HLA-A*02:01,Cited reference,ELISA,1,12,0.6666666666666666
1335381,YLQTDVFLV,,,,,neo-epitope,YPQTDVFLV,Cell division control protein 42 homolog (Fragment),HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
1862754,YLRTAKFLEM,,,,,neo-epitope,YLRTAKSLEM,Band 4.1-like protein 4A,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
74915,YLSGANLNL,605.0,613.0,Carcinoembryonic antigen-related cell adhesion molecule 5 precursor,Carcinoembryonic antigen-related cell adhesion molecule 5,,,,HLA-A*02:01,Not determined,ELISPOT,1,1,1.0
857812,YLSNIIPAL,,,,,neo-epitope,YLSKIIPAL,Replication factor C subunit 5,HLA-A*02:01,MHC binding prediction,ELISA,1,4,1.0
1310966,YLTDEDFEF,2179.0,2187.0,archvillin,Supervillin,,,,HLA-A*02:01,MHC binding assay,ELISA,0,1,0.0
1310967,YLTDEDFEFA,2179.0,2188.0,archvillin,Supervillin,,,,HLA-A*02:01,MHC binding assay,ELISA,0,1,0.0
1310968,YLTDKDFEF,,,,,neo-epitope,YLTDEDFEF,Supervillin,HLA-A*02:01,MHC binding assay,ELISA,1,2,1.0
1310969,YLTDKDFEFA,,,,,neo-epitope,YLTDEDFEFA,Supervillin,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0
1871201,YLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0
509159,YLYDRLLRI,79.0,87.0,DNA replication complex GINS protein PSF1,DNA replication complex GINS protein PSF1,,,,HLA-A*02:01,MHC binding prediction,ELISA,1,4,1.0
857813,YLYDRLLRV,,,,,neo-epitope,YLYDRLLRI,DNA replication complex GINS protein PSF1,HLA-A*02:01,MHC binding prediction,ELISA,1,4,1.0
1862756,YMASEVVEV,,,,,neo-epitope,YMAPEVVEV,MAP kinase-interacting serine/threonine-protein kinase 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862757,YMASEVVEVF,,,,,neo-epitope,YMAPEVVEVF,MAP kinase-interacting serine/threonine-protein kinase 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
75043,YMDGTMSQV,,,,,neo-epitope,YMNGTMSQV,Tyrosinase,HLA-A*02:01,Cited reference,ELISPOT,1,2,1.0
1314018,YMEAVALV,,,,,neo-epitope,YMEALALV,Inactive hydroxysteroid dehydrogenase-like protein 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1314019,YMHTDLQAL,,,,,neo-epitope,YMYTDLQAL,Spermatogenesis-associated protein 16,HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
1314020,YMHTDLQALHM,,,,,neo-epitope,YMYTDLQALHM,Spermatogenesis-associated protein 16,HLA-C*12:03,MHC binding prediction,ELISPOT,0,1,0.0
1855225,YMKSLEFENK,,,,,neo-epitope,YMKSSEFENK,Serine-protein kinase ATM,HLA-A*11:01,Cited reference,ELISA,1,2,0.5
1855227,YMMMWDCWHA,,,,,neo-epitope,YMMMRDCWHA,Fibroblast growth factor receptor 2,HLA-A*02:01,Cited reference,ELISA,1,2,0.5
1855228,YMMMWDCWHAV,,,,,neo-epitope,YMMMRDCWHAV,Fibroblast growth factor receptor 2,HLA-A*02:01,Cited reference,ELISA,1,2,0.5
1855229,YMPGGDLVKL,,,,,neo-epitope,YMPGGDLVNL,Rho-associated protein kinase 2,HLA-A*02:06,Cited reference,ELISA,0,2,0.0
1862759,YMYEAPPGA,,,,,neo-epitope,FMYEAPPGA,Corepressor interacting with RBPJ 1,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1393624,YMYLRQLFHI,,,,,neo-epitope,YMYLRQLFRI,Casein kinase I isoform alpha,HLA-A*02:01,MHC binding prediction,ELISA,1,2,1.0
1393625,YMYLRQLFRI,274.0,283.0,Casein kinase I isoform alpha,Casein kinase I isoform alpha,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862760,YNSFSSAPM,,,,,neo-epitope,YNSFSSASM,Protein PRRC2C,HLA-B*15:01,MHC binding prediction,ELISPOT,0,1,0.0
1398120,YNTDDIEFY,,,,,neo-epitope,YTTDDIEFY,Gamma-aminobutyric acid receptor subunit beta-2,HLA-A*29:02,MHC binding prediction,ELISPOT,0,1,0.0
1398121,YPAPQPPVL,,,,,neo-epitope,SPAPQPPVL,TOX high mobility group box family member 2,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
488933,YPDTDVILM,74.0,82.0,transforming protein RhoA isoform 2 [Homo sapiens],Transforming protein RhoA,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
1406323,YPPPPPALL,,,,,neo-epitope,YPPPPPALP,Neural Wiskott-Aldrich syndrome protein,HLA-B*07:02,MHC binding prediction,ELISPOT,1,1,1.0
1335387,YPQTDVFLV,72.0,80.0,cell division control protein 42 homolog isoform 1 precursor [Homo sapiens],Cell division control protein 42 homolog (Fragment),,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5
1862763,YPVIFKSIM,,,,,neo-epitope,YPVISKSIM,T-box transcription factor TBX4,HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0
75493,YQGSYGFRL,103.0,111.0,Cellular tumor antigen p53,Cellular tumor antigen p53,,,,HLA-A2,Not determined,ELISPOT,1,1,1.0
1338189,YQVSCCDWLL,,,,,neo-epitope,HQVSCCDWLL,Synaptojanin-2,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1855245,YQVSYGFRL,,,,,neo-epitope,YQGSYGFRL,Cellular tumor antigen p53,HLA-B*37:01,Cited reference,ELISA,1,2,0.5
607013,YQYTFPDF,,,,,neo-epitope,YQYTSPDF,Insulin-induced gene 1 protein,HLA-B*15:01,MHC binding prediction,ELISPOT,1,1,1.0
607014,YQYTFPDFLY,,,,,neo-epitope,YQYTSPDFLY,Insulin-induced gene 1 protein,HLA-B*15:01,MHC binding prediction,ELISPOT,1,1,1.0
1391622,YRAEVGQNAYLPCFYTPAAPGNLVPVC,26.0,52.0,T cell immunoglobulin mucin-3 [Homo sapiens],Hepatitis A virus cellular receptor 2,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1391623,YRAEVGQNAYLPCVYTPAAPGNLVPVC,,,,,neo-epitope,YRAEVGQNAYLPCFYTPAAPGNLVPVC,Hepatitis A virus cellular receptor 2,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0
1862765,YRALMDKSL,54.0,62.0,Melanoma antigen recognized by T-cells 1,Melanoma antigen recognized by T-cells 1,,,,HLA-C*06:02,MHC binding prediction,ELISPOT,0,1,0.0
1710550,YRHLFKVFR,,,,,neo-epitope,YRHLFKVFG,P2X purinoceptor 1,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1710566,YRIYDIPPK,,,,,neo-epitope,YRVYDIPPK,Cytochrome b-245 heavy chain,HLA-B*27:05,MHC binding assay,ELISPOT,0,1,0.0
1862767,YRNQFPEIL,525.0,533.0,Melanoma-associated antigen E1,Melanoma-associated antigen E1,,,,HLA-C*07:01,MHC binding prediction,ELISPOT,0,1,0.0
1335393,YSARIEENI,272.0,280.0,desmoglein-3 isoform X1 [Homo sapiens],Desmoglein-3,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,4,0.5
546632,YSDHQPSGPYY,402.0,412.0,Transcription factor SOX-10,Transcription factor SOX-10,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,3,0.0
607015,YSKNLNSFF,,,,,neo-epitope,YSKNLNSSF,Protein MMS22-like,HLA-B*15:01,MHC binding prediction,ELISPOT,1,1,1.0
1338191,YSLVPLQIPL,,,,,neo-epitope,YSLVPLQIPL,PRAME family member 5,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1862773,YSSIVANRW,,,,,neo-epitope,YPSIVANRW,Multidrug resistance-associated protein 1,HLA-B*57:01,MHC binding prediction,ELISPOT,0,1,0.0
1855249,YTAPGIVEI,,,,,neo-epitope,DTAPGIVEI,Otoancorin,HLA-C*03:03,Cited reference,ELISA,0,2,0.0
1314050,YTAQIILAL,,,,,neo-epitope,STAQIILAL,Olfactory receptor 4C11,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1398122,YTAVHYAASY,,,,,neo-epitope,YTAVHYAAAY,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1862774,YTAYTAHLY,,,,,neo-epitope,YTAYTAHLH,Protein DENND6B,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
1862775,YTCEKPYYY,,,,,neo-epitope,YTCEEPYYY,Complement C1s subcomponent,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1862776,YTDALVHDLL,,,,,neo-epitope,YTDALVHDPL,2-amino-3-carboxymuconate-6-semialdehyde decarboxylase,HLA-A*01:03,MHC binding prediction,ELISPOT,0,1,0.0
75995,YTDFVGEGL,292.0,300.0,Solute carrier family 45 member 3,Solute carrier family 45 member 3,,,,HLA-C*05:01,Not determined,ELISPOT,1,2,1.0
1398124,YTFEIQGV,,,,,neo-epitope,YTFEIQAV,Ephrin type-B receptor 2,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1398125,YTFEIQGVNGV,,,,,neo-epitope,YTFEIQAVNGV,Ephrin type-B receptor 2,HLA-A*68:02,MHC binding prediction,ELISPOT,0,1,0.0
1314053,YTHNLIFV,,,,,neo-epitope,YTHNLFFV,NADPH oxidase 4,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
1314054,YTHNLIFVF,,,,,neo-epitope,YTHNLFFVF,NADPH oxidase 4,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1314055,YTHNLIFVFYM,,,,,neo-epitope,YTHNLFFVFYM,NADPH oxidase 4,HLA-C*14:03,MHC binding prediction,ELISPOT,0,1,0.0
1075871,YTTAEEAAGIGILTVILGVL,21.0,40.0,Melanoma antigen recognized by T-cells 1,Melanoma antigen recognized by T-cells 1,,,,HLA-B*18:01,Single allele present,ELISPOT,1,1,1.0
1398128,YTTVRALTL,,,,,neo-epitope,YTTVRALTR,BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 2,HLA-B*08:01,MHC binding prediction,ELISPOT,0,1,0.0
1862778,YTWPSGNIY,,,,,neo-epitope,YTWPSGNTY,Junctophilin-1,HLA-A*01:01,MHC binding prediction,ELISPOT,0,1,0.0
1314061,YVAAYQRL,,,,,neo-epitope,YVAAYQQL,Golgin subfamily A member 2,HLA-A*02:01,MHC binding prediction,ELISPOT,0,1,0.0
859644,YVDFREYEYY,,,,,neo-epitope,YVDFREYEY,Receptor-type tyrosine-protein kinase FLT3,HLA-A*01:01,T cell assay -Mismatched MHC molecules,ELISPOT,1,4,0.75
1862780,YVGSPLAAM,,,,,neo-epitope,FVGSPLAAM,Protein PAT1 homolog 1,HLA-A*25:01,MHC binding prediction,ELISPOT,0,1,0.0
1391960,YVPFIGLSMV,253.0,262.0,Olfactory receptor 51E1,Olfactory receptor 51E1,,,,HLA-A2,MHC binding prediction,ELISA,0,1,0.0
1398129,YVSEKDVISAK,,,,,neo-epitope,YVSEKDVTSAK,"Leucine-rich PPR motif-containing protein, mitochondrial",HLA-A*68:01,MHC binding prediction,ELISPOT,0,2,0.0
1851946,YVVPGSPCL,,,,,neo-epitope,SVVPGSPCL,Tensin-1,HLA-C*03:03,MHC binding assay,ELISPOT,1,3,0.6666666666666666
1855254,YYILDKKEHFK,,,,,neo-epitope,YYILEIRKSTS,Proto-oncogene tyrosine-protein kinase ROS,HLA-A*33:01,Cited reference,ELISA,0,2,0.0
474330,YYPPSQIAQL,,,,,neo-epitope,YYPPSQIAQL,Polyadenylate-binding protein 1,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0
607022,YYSKNLNSF,,,,,neo-epitope,YYSKNLNSS,Protein MMS22-like,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0
607023,YYSKNLNSFF,,,,,neo-epitope,YYSKNLNSSF,Protein MMS22-like,HLA-A*24:02,T cell assay -Biological process measured,ELISPOT,1,2,1.0
1074812,YYSPQAQTL,,,,,neo-epitope,YYSPQAQTP,SLAIN motif-containing protein 1,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,1,0.0
